The Important Role of Post-translational Modifications, Neddylation and Acetylation, in Immunity. by Mathewson, Nathan D.
The Important Role of Post-translational Modifications, 
Neddylation and Acetylation, in Immunity 
 
by 
 
Nathan D. Mathewson 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Immunology) 
in The University of Michigan 
2015 
 
 
 
 
 
 
 
 
Doctoral Committee: 
 
 Professor Pavan R. Reddy, Chair 
Associate Professor David Aronoff, Vanderbilt University  
 Professor Bethany Moore 
 Professor Gabriel Nuñez 
Professor Benjamin S. Segal 
 Professor Yi Sun 
  
 
 
 
 
 
 
© Nathan D. Mathewson 
2015 
  
		 	ii	
DEDICATION 
 
For my family. Your support and encouragement 
have inspired and boosted my resolve. 
		 	iii	
ACKNOWLEDGMENTS 
 
This dissertation would not have been possible without the support and mentorship of my 
advisor and mentor, Pavan Reddy. Pavan has always been willing to take time when I 
stop by and interrupt him at his office, a gesture of commitment that I am extremely 
appreciative of. Through his willingness and encouragement to discuss ideas critically, 
Pavan has trained me to think logically, clearly, and directly. He has thus been 
fundamental in molding me into a young scientist and has been the finest mentor I could 
imagine. 
I am also indebted to the members of the Reddy lab, particularly Tomomi Toubai for his 
extensive and patient assistance in teaching me critical cellular techniques. I am also 
thankful for Yaping Sun and his knowledge and help in understanding molecular 
techniques. Julia Wu for being bay-buddies and for assistance in performing experiments. 
Katherine Oravecz-Wilson for managing the lab and Cynthia Zajac for your day to day 
help.
		 	iv	
TABLE OF CONTENTS 
 
DEDICATION...................................................................................................................ii 
ACKNOWLEDGMENTS.................................................................................................iii 
LIST OF FIGURES..........................................................................................................vii 
LIST OF TABLES...........................................................................................................xiv 
LIST OF ABREVIATIONS.............................................................................................xv 
ABSTRACT..................................................................................................................xviii 
 
CHAPTER I 
 INTRODUCTION...................................................................................................1 
  Overview of the Immune System................................................................1 
  Posttranslational modifications.................................................................11 
  Hematopoietic stem cell transplantation...................................................17 
  The role of the microbiome in GVHD......................................................23 
  Statement of purpose.................................................................................32 
 
 
 
 
		 	v	
CHAPTER II 
NEDDYLATION PLAYS AN IMPORTANT ROLE IN THE REGULATION OF 
MURINE AND HUMAN DENDRITIC CELL FUNCTION................................36 
 
Abstract.............................................................................................................36 
 
     Introduction.......................................................................................................37 
 
     Results...............................................................................................................40 
  
    Discussion.........................................................................................................60 
 
     Materials and Methods......................................................................................64 
 
CHAPTER III 
SAG/RBX2 E3 UBIQUITIN LIGASE DIFFERENTIALLY REGULATES 
INFLAMMATORY RESPONSES OF MYELOID CELL SUBSETS................69  
 
Introduction......................................................................................................70 
  
    Results...............................................................................................................73 
  
    Discussion.........................................................................................................87 
 
     Materials and Methods.....................................................................................90 
 
 
CHAPTER IV 
  
SAG/RBX2 DEPENDENT NEDDYLATION REGULATES T CELL 
RESPONSES........................................................................................................94 
 
Abstract............................................................................................................94  
 
Introduction......................................................................................................96 
  
    Results............................................................................................................100 
  
    Discussion......................................................................................................120 
 
     Materials and Methods...................................................................................123 
		 	vi	
CHAPTER V 
 
UNBIASED PROFILING UNCOVERS A CRUCIAL ROLE FOR TARGETED 
GUT MICROBIOME DERIVED METABOLITES IN MODULATING GI 
EPITHELIAL CELL DAMAGE AND MITIGATING GVHD.........................128 
 
Abstract..........................................................................................................128 
 
Introduction....................................................................................................130 
  
    Results.............................................................................................................132 
  
    Discussion.......................................................................................................163 
 
     Materials and Methods...................................................................................166 
 
 
CHAPTER VI 
  
CONCLUSION...................................................................................................175  
 
 
CHAPTER VII 
  
FUTURE DIRECTIONS....................................................................................179 
  
 
REFERENCES...............................................................................................................182
		 	vii	
LIST OF FIGURES 
 
Figure 
Fig 1.1 – Activation of NEDD8 molecule..................................................................14 
Fig 1.2 – Neddylation.................................................................................................15 
Fig 1.3 – Comparison of MLN4924 to AMP.............................................................16  
Fig 1.4 – The intestinal barrier and gut homeostasis..................................................22 
Fig 1.5 – Antigen presenting cells in GVT: to maximize GVT responses, two 
important factors must be considered: antigen presentation and donor T cells.......33 
Fig 2.1 – Neddylation inhibition.................................................................................40 
Fig. 2.2 - Neddylation inhibition attenuates LPS-induced TNF-α and IL-6 release and 
gene expression in BMDC.......................................................................................41 
Fig. 2.3 - Neddylation inhibition in BMDC mitigates release of non-TLR4– 
stimulated cytokines in vitro....................................................................................43 
Fig. 2.4 - Neddylation inhibition mitigates allogeneic T-cell 
proliferation..............................................................................................................45 
Fig. 2.5 - T cell proliferation and Th1 lineage cytokines are decreased following 
stimulation with α-CD3 and α-CD28 functional Ab................................................46 
Fig. 2.6 - Neddylation blockade regulates DC-mediated T-cell 
activation..................................................................................................................47 
Fig. 2.7 - Description of in vivo transplant scheme....................................................48 
		 	viii	
Fig. 2.8 – Neddylation modulates human DC function..............................................49 
Fig. 2.9 – Inhibition of neddylation does not alter phenotype or cell viability in 
BMDC.....................................................................................................................50 
Fig. 2.10 – siRNA-mediated neddylation inhibition..................................................52 
Fig. 2.11 – siRNA-mediated neddylation inhibition inhibits LPS-induced TNF-a 
production................................................................................................................53 
Fig. 2.12 – Neddylation inhibition and dexamethasone differentially affect NF-κB 
translocation in BMDC............................................................................................55 
Fig. 2.13 – Neddylation inhibition affects NF-κB translocation in 
BMDC.....................................................................................................................56 
Fig. 2.14 – Neddylation inhibition prevents IκB degradation in 
BMDC......................................................................................................................57 
Fig. 2.15 – Neddylation inhibition does not perturb the MAPK/ERK 
pathway....................................................................................................................59 
Fig. 3.1 – Characterization of LysM-Cre/Sagfl/fl mice................................................73 
Fig. 3.2 – LysM-Cre+/Sagfl/fl (KO) mice exhibit increased mortality to LPS 
injection....................................................................................................................76 
Fig. 3.3 – LysM-Cre+/Sagfl/fl (KO) mice exhibit increased LPS-induced 
proinflammatory cytokines in the sera.....................................................................76 
Fig. 3.4 – Sag-deficient macrophages release less TNFɑ and IL-6 
in vitro......................................................................................................................77 
Fig. 3.5 – Sag-deficient macrophage viability and BMDM function.........................78 
Fig. 3.6 – Sag-deficient macrophages release less cytokines in vivo.........................80 
		 	ix	
Fig. 3.7 – IκB accumulation in Sag-deficient macrophages.......................................81 
Fig. 3.8 – NF-κB translocation is inhibited in Sag-deficient  
macrophages............................................................................................................82 
Fig. 3.9 – Sag-deficient neutrophils release less TNFɑ and IL-6 in response to 
LPS..........................................................................................................................83 
Fig. 3.10 – NF-κB translocation is not inhibited in Sag-deficient 
neutrophils...............................................................................................................84 
Fig. 3.11 – Sag-deficient neutrophils exhibit increased ROS and decrease NRF2 
transcription factor...................................................................................................85 
Fig. 3.12 – The function of BMDC from SAG-deficient mice are not different from 
SAG-competent mice...............................................................................................86 
Fig. 3.13 – Model of mechanism................................................................................89 
Fig. 4.1 – MLN4924 inhibits neddylation in T cells................................................100 
Fig. 4.2 – MLN4924 does not alter viability of T cells............................................101 
Fig. 4.3 – Neddylation has intrinsic role in T cell function......................................103 
Fig. 4.4 – Inhibiting neddylation decreases T cell cytokines...................................104 
Fig. 4.5 – Inhibiting neddylation decreases T cell proliferation without increasing 
apoptosis................................................................................................................105 
Fig. 4.6 – Phenotype of neddylation inhibited T cells..............................................106 
Fig. 4.7 – Breeding scheme of T cell conditional SAG knockout 
mouse.....................................................................................................................107 
Fig. 4.8 – SAG protein is knocked out in T cells of mice........................................108 
Fig. 4.9 – Thymopoiesis is normal in KO mice.......................................................108 
		 	x	
Fig. 4.10 – Phenotype is not different in KO mouse................................................109 
Fig. 4.11 – Allogeneic stimulation of KO T cells results in less 
proliferation...........................................................................................................110 
Fig. 4.12 – Inhibition of neddylation does not impact NF-κB 
translocation...........................................................................................................111 
Fig. 4.13 – Confocal imaging of MLN4924 impact on NF-κB................................112 
Fig. 4.14 – Microarray of mRNA transcripts in WT and KO T cells.......................113 
Fig. 4.15 – SOCS1 is increased when neddylation is blocked in T 
cells........................................................................................................................114 
Fig. 4.16 – Immunophenotype following allogeneic BMT......................................116 
Fig. 4.17 – Diminished release of cytokines by KO T cells after allogeneic 
BMT.......................................................................................................................117 
Fig. 4.18 – Decreased GVHD and increased survival of recipients of KO donor T 
cells........................................................................................................................118 
Fig. 4.19 – Inhibition of neddylation with MLN4924 decreases GVHD and improves 
survival...................................................................................................................119 
Fig. 5.1 – GC/MS experimental analysis..................................................................132 
Fig. 5.2 – Fatty acid levels on day +7.......................................................................133 
Fig. 5.3 – Heatmap of fatty acid profiles (short and long chain) of all animals 
combined...............................................................................................................134 
Fig. 5.4 – Butyrate levels in the periphery...............................................................135 
Fig. 5.5 – Fatty acids analysis on day +21...............................................................136 
		 	xi	
Fig. 5.6 – Loss of butyrate decreases levels of acetylated histone H4 in 
IECs.......................................................................................................................137 
Fig. 5.7 – Loss of butyrate decreases levels of acetylated histone H4 in 
IECs.......................................................................................................................138 
Fig. 5.8 – Loss of butyrate decreases levels of butyrate transporter, 
SLC5A8.................................................................................................................139 
Fig. 5.9 – Loss of butyrate decreases level of butyrate receptor and 
transporter..............................................................................................................140 
Fig. 5.10 – Inflammatory cytokines decrease expression of butyrate 
transporter..............................................................................................................141 
Fig. 5.11 – Local intragastric administration of butyrate increases acetylated-H4 and 
SLC5A8 in IECs....................................................................................................142 
Fig. 5.12 – Butyrate increases association of acetyl-H4 with 
SLC5A8.................................................................................................................143 
Fig. 5.13 – Intragastric gavage of butyrate decreases GVHD and improves 
survival...................................................................................................................144 
Fig. 5.14 – Intragastric gavage of butyrate improves survival of mMHC- mismatch 
BMT.......................................................................................................................145 
Fig. 5.15 – Butyrate improves IEC junctions...........................................................146 
Fig. 5.16 – Less FITC-dextran traverses IEC barrier in butyrate treated allo-BMT 
recipients................................................................................................................147 
Fig. 5.17 – Fewer activated T cells in butyrate treated allo-BMT 
recipients................................................................................................................148 
		 	xii	
Fig. 5.18 – Intragastric gavage of butyrate does not alter Treg ratio or number of 
donor macrophages in the intestine........................................................................149 
Fig. 5.19 – Improved GVHD score and increased survival were still observed in the 
absence of Tregs....................................................................................................150 
Fig. 5.20 – No difference in splenic T cell HDAC or HAT activity........................151 
Fig. 5.21 – Butyrate protects from irradiation- and allo-induced  
apoptosis................................................................................................................152 
Fig. 5.22 – Butyrate increases organoid size and improves organoid 
junctions.................................................................................................................153 
Fig. 5.23 – Butyrate treatment of IECs decreases pro-apoptotic proteins and increases 
anti-apoptotic proteins...........................................................................................154 
Fig. 5.24 – Butyrate treatment of IECs increases mRNA expression of junctional 
proteins..................................................................................................................155 
Fig. 5.25 – Butyrate treatment of IECs increases acetyl-H4 association with BCL-B 
and JAM................................................................................................................155 
Fig. 5.26 – Intragastric gavage of butyrate increases anti-apoptotic gene expression, in 
vivo........................................................................................................................156 
Fig. 5.27 – Intragastric gavage of butyrate increases junctional protein gene 
expression, in vivo.................................................................................................157 
Fig. 5.28 – Intragastric gavage of 17 strains of Clostridia take hold amongst 
indigenous microbiota...........................................................................................159 
Fig. 5.29 – Intragastric gavage of 17 strains of Clostridia increase butyrate in the 
intestinal tissue......................................................................................................160 
		 	xiii	
Fig. 5.30 – Intragastric gavage of 17 strains of Clostridia decreases GVHD and 
improves survival...................................................................................................161 
Fig. 5.31 – Intragastric gavage of 17 strains of Clostridia decreases GVHD and 
improves survival – MSKCC.................................................................................162 
  
		 	xiv	
LIST OF TABLES 
 
Table 
Table 3.1 – Mouse complete blood count (CBC)....................................................74 
Table 3.2 – Mouse naïve phenotype........................................................................75 
Table 3.3 – Elicited macrophages............................................................................79 
		 	xv	
LIST OF ABREVIATIONS 
 
Abs Antibodies 
Allo-BMT Allogeneic bone marrow transplant 
APC Antigen presenting cell 
ASC Apoptosis-associated speck-like protein containing CARD 
BMDC Bone marrow derived dendritic cells 
BMDM Bone marrow derived macrophage 
CAND1 Cullin-associated and neddylation-dissociated protein 1 
CRL Cullin ring ligase 
CTL Cytotoxic T lymphocyte 
DAMP Danger associated molecular pattern 
G-CSF Granulocyte colony stimulating factor 
GF Germ free 
GI Gastrointestinal 
GVHD Graft versus host disease 
GVT Graft versus tumor 
HAT Histone acetyltransferase 
HDAC Histone deacetylase 
HDACi Histone deacetylase inhibitor 
		 	xvi	
HECT Homologous to the E6AP carboxyl terminus 
HLA Human leukocyte antigen 
HSCs Hematopoietic stem cell 
IkB Inhibitor of kappaB 
KO knockout 
LPS Lipopolysaccharide 
MHC Major histocompatibility complex 
MLR Mixed lymphocyte reaction 
mRNA messenger RNA 
MYD88 Myeloid differentiation primary response gene 88 
NAE NEDD8 activating enzyme 
NEDD8 
Neural precursor cell expressed developmentally down-regulated 
protein 8 
NF-kB Nuclear factor-kappaB 
NLR NOD like receptor 
PAMPS Pathogen associated molecular patterns 
PRRs Pattern recognition receptors 
PTM Posttranslational modification 
Rbx2 RING box protein 2 
RING Really interesting new gene 
SAG Sensitive to apoptosis gene 
SPF Specific pathogen free 
TBI Total body irradiation 
		 	xvii	
TCR T cell receptor 
TH T helper cell 
ThCTL T helper cytoxic lymphocyte 
TLR Toll like receptor 
Tregs T regulatory cell 
TSA Tumor specific antigen 
Ub Ubiquitin 
UBC12 Ubiquitin conjugating enzyme E2M 
VDJ Variable, joining, diversity 
WT Wild type 
		 	xviii	
ABSTRACT 
 
Proteins undergo posttranslational modifications (PTMs) by the attachment of various 
side chains including phosphate, acetate, sumo, ubiquitin, etc. Our lab has previously 
shown that the PTM acetylation is important for immune responses. To that end, 
acetylation of the non-histone protein STAT3 increases the expression of indoleamine 
2,3-dioxygenase (IDO) in dendritic cells resulting in decreased responses in the context 
of allogeneic bone marrow transplant (allo-BMT) leading to attenuated graft versus host 
disease (GVHD). Further, histone deacetylase inhibitors (HDACi) enhance T regulatory 
cells. However, the role of other modifications, such as neddylation, remained unknown. 
Neddylation facilitates the degradation of proteins by the E3 ligase system known as 
cullin RING ligase (CRL) and has been identified to regulate the proliferation and 
survival of liver, breast, and pancreatic cancer cells. Further, the neddylation pathway has 
previously been suggested to regulate the function of NF-κB, a critical transcription 
factor for several immune cell functions. Therefore, we systematically examined the role 
of neddylation in the function of innate (DCs, macrophages, and neutrophils) and 
adaptive (T cells) immune cells. We found that neddylation affects immunity in a cell 
specific manner. It positively regulates NF-κB in DC and macrophage functions where, 
by contrast, it negatively regulates neutrophils and T cells in a non NF-κB manner. Our 
data suggest that the loss of a critical adapter element of the CRL, sensitive to apoptosis 
		 	xix	
gene (SAG), in neutrophils leads to increased reactive oxygen species (ROS) resulting in 
increased inflammatory responses. Examination of T cells revealed that inhibition of the 
neddylation pathway results in less degradation of SOCS proteins attenuating T cell 
functions following allo-stimulation. 
Expanding on the previous observations made in our lab, we further explored the role of 
acetylation in regulating immunopathology, such as graft versus host disease (GVHD). 
We found that the endogenous histone deacetylase inhibitor (HDACi) butyrate – which is 
also a primary energy source of intestinal epithelial cells (IECs) and is derived 
exclusively from the GI microbiota – is critical for the survival of IECs and the negative 
regulation of GVHD severity. Our data show that diminutive levels of butyrate are found 
within the intestinal tissue following allo-BMT. Furthermore, the loss in butyrate leads to 
decreased acetylation of histone-H4, decreased IEC junctional integrity, and increased 
allo-mediated damage – effects that were restored upon local intragastric gavage with 
exogenous butyrate leading to mitigated GVHD pathology and improved mortality. 
Furthermore, rationally altering the microbiota to high butyrate-producing Clostridial 
strains recapitulates the effects of synthetic butyrate by decreasing GVHD severity and 
improving survival. 
Collectively, these data further our knowledge of the roles of PTMs in immunity – 
specifically the heretofore-unknown functions of neddylation in the regulation of immune 
cells and acetylation in the regulation of immune pathology. 
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CHAPTER I 
 
INTRODUCTION 
 
 
Overview of the Immune System 
The collection of cells that protect vertebrates from surrounding pathogenic foreign 
microorganisms is known as the immune system. The specialized cells of the immune 
system are categorized under two main arms of defense and are comprised of innate 
immunity and adaptive immunity1. 
The innate immune system is the host’s first line of cellular mediated defense against 
invading bacteria, fungi, and viruses that express pathogen associated molecular patterns 
(PAMPs). Although a wide array of PAMPs are almost immediately detected by pattern 
recognition receptors (PRRs) encoded in the germ line of innate immune cells leading to 
the elimination of the invading microorganism, the innate immune system does not 
develop a lasting immunity to that pathogen1. 
The second arm of defense – the adaptive immune system – consists of a specific 
immune response driven by the production of pathogen-specific antibodies (Abs) by B 
cells and cellular recognition by cytotoxic T cells. Generation of specific antigen 
receptors consisting of Ab immunoglobulin production by B cells and ɑβ T cell receptors 
(TCR) in T cells, is accomplished through the somatic rearrangement of variable, 
diversity, and joining [V(D)J] regions of the antigen receptor encoding genes2. This 
rearrangement leads to an extremely diverse repertoire of individual TCRs (upwards of 
	 2	
1011 TCRs) with an approximate 3.6x107 distinct T cell clones comprehensively 
increasing the host’s ability to fight infection3,4. Upon T cell recognition of cognate 
antigen, pathogen-specific clonal expansion occurs leading to the elimination of the 
antigen source1. Following antigen clearance, the immune response ceases and the 
majority of the effector cells undergo apoptosis5,6. The remaining effector cells are then 
converted to memory cells resulting in the development of the hallmark lifelong 
immunity known as immunological memory6,7. Immunological memory allows the 
adaptive immune response to be shortened from a time period requiring days upon the 
first pathogenic insult, to only a fraction of the time following reinfection8. 
 
Detection of pathogen 
The epithelium of the skin, gut, and lungs is an important part of host defense against 
invading pathogens, as it is often the first point of contact with the infection1. When a 
pathogen crosses the physical epithelial barrier, the innate immune system composes the 
first line of cell-mediated host defense. As mentioned above, innate immune cells possess 
PRRs to detect invading pathogens. There are several categories of PRRs that exist to 
recognize PAMPs in various cellular surfaces and compartments. One type of PRR is 
known as toll-like receptors (TLRs). Many TLRs have been described and are known to 
recognize various PAMPs. These include TLR4 recognition of lipopolysaccharide (LPS), 
TLR2 of bacterial lipoproteins, TLR5 of flagellin, TLR3 and 7 of RNA, and TLR9 of 
DNA9. The engagement of extracellular TLR receptors requires the adaptor protein 
known as myeloid differentiation primary response protein 88 (MYD88) for downstream 
signaling10,11. 
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While TLRs are both extracellular and intracellular, another type of PRR, known as 
NOD-like receptors (NLR), is found in the intracellular compartment12,13. Indeed, NLRs 
function through the recognition of intracellular PAMPs and danger- associated 
molecular patterns (DAMPs)14. NOD1 and NOD2 are the most well studied members of 
the NLR family and are often viewed as the prototypical NLRs. NOD1 is ubiquitously 
expressed, where NOD2 expression is restricted to innate immune cells and intestinal 
Paneth cells13. Signaling through the NLR has differential functional effects dependent 
upon which class of NLR is stimulated. NLR signaling is critical for the function of the 
inflammasome, a multiprotein complex that plays an important role in inflammatory 
responses. Activation of NOD1 and NOD2 triggers MAPK and NF-κB pathways, where 
activated NLRP1, NLRP3, and NLRC4 act as scaffolding platforms for the formation of 
inflammasomes. A commonality of these three inflammasomes is their association with 
the protein apoptosis-associated speck-like protein containing a CARD (ASC), which 
enables the recruitment of caspase-1. The activation of caspase-1 by the inflammasome is 
required for the processing of IL-1β and IL-18. Although NLRs and TLRs have disparate 
cellular locations, these PRRs can have both non-redundant and complimentary 
functions. For example, when cells have become refractory to TLR agonists, NOD1/2 
signaling is not mitigated highlighting the non-redundant roles for these PRRs. However, 
TLR-mediated NF-κB is required for the production of pro-IL-1β, where NLR activation 
of caspase-1 is required for the cleavage of pro-IL-1β to active IL-1β, leading to its 
secretion.  
 
Amongst the first PRR-expressing cellular responders to pathogen are known as 
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neutrophils. While neutrophils are short-lived compared to another type of innate immune 
cell called macrophages, they are the most numerous and the most important cells that 
compose innate immune responses1. The main function of a neutrophil is phagocytosis 
and efficient destruction of collected material in intracellular vesicles. Neutrophils are 
also an important source of TNFɑ which triggers local containment of infection and 
increases extravasation of immune cells into the infected area1. While neutrophils react 
quickly to pathogen based upon expressed PAMPs, the response is not pathogen specific. 
Several immune cell types, whose function is to generate and present antigen peptide to 
adaptive immune cells for a pathogen specific response, continually sample the physical 
barrier1,15. These surveying cells are known as antigen presenting cells (APCs). 
 
Antigen Presenting Cells 
There are three cell types known to have the capability of presenting antigen to activate T 
cells – DCs, macrophages, and B cells. While all three cell types are indeed professional 
APCs, it is DCs that are the most potent and can collect, process, and present antigen 
from myriad sources1,16. By contrast, macrophages and B cells specialize in presenting 
antigens from intracellular compartments and mainly interact with T cells that have been 
previously primed by DCs1,15. 
 
It is well known that the innate and adaptive immune systems work in concert to provide 
protection from invading pathogens. Dendritic cells serve as a bridge between the two 
arms of the immune system – that is, ingesting pathogen and presenting peptide to T cells 
with appropriate activating cytokines, such as IL-121. When sampling the peripheral 
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environment via phagocytosis, the DC is in an immature state. Maturation of a DC occurs 
by 1) PRR recognition of PAMPs expressed on collected material, 2) the cytokine 
environment present during an inflammatory response, or 3) by mediators released during 
tissue damage1,15. The mature DC state is distinct from immature in that the phagocytic 
nature of the DC is down regulated. Further, DC maturation up-regulates the expression 
of both class I and II major histocompatibility complex (MHC) molecules increasing the 
display of processed peptide on the cell surface. In addition, activated DCs migrate to the 
lymph node and increase co-stimulatory B7 molecules (CD80 and CD86) necessary for T 
cell activation.  
 
Macrophages are found in most tissues, including the lymphoid tissue, and are activated 
through PRRs, similarly to DCs1. Although an important role of these cells is the 
presentation of antigen to primed T cells (T cells previously activated by DCs), a primary 
role of macrophages is the ingestion of microbes and particulate antigens thereby 
preventing their systemic escape into the blood1. Indeed, macrophages constitutively 
scavenge dead or dying cells of the liver sinusoids, the splenic red pulp, and especially 
clear the large numbers of cells of the blood that die daily1,17. Notably, macrophages that 
have engulfed microorganisms, but are unable to destroy them, use their antigen 
presentation capabilities to recruit the adaptive immune system for assistance1. 
 
B cells internalize soluble molecules that bind to their cell surface immunoglobulin. 
Protein components of the antigen are processed and presented via peptide:MHC class II 
complexes1. This allows for the interaction with CD4 T cells and may result in 
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immunoglobulin class switching to better refine Ab responses18. B cells do not 
constitutively express B7 co-stimulatory molecules necessary for the activation of T cells. 
However, PRR stimulation – as also seen in DCs and macrophages – results in these 
molecules expression on the B cell surface1. 
 
T cell Subsets 
Following T cell development in the thymus (discussed below), two principal types of 
naïve T cell migrate into the periphery known as CD4+ and CD8+  – based upon the cells 
surface expression of CD4 and CD8 glycoproteins19. CD4 T cells are either naïve effector 
cells or T regulatory cells (Tregs). Upon stimulation by cognate antigen, naïve CD4 T 
cells differentiate into several effector T cell subsets, often referred to as T helper cells 
(TH) as they provide activation, growth, and survival signals to accessory cells20. CD4 T 
cells must be presented with antigen by MHC class II-expressing APCs which result in 
their differentiation into three main categories of TH cells distinguished as TH1, TH2, and 
TH17 cells that each promote distinct types of responses based upon the form of 
infection1. TH1 cells assist in the eradication of the bacterial invasion of intracellular 
vesicles of macrophages through the release of IFNγ and IL-2. IFNγ instructs the 
macrophage to increase intracellular killing and it also promotes CD8+ T cell function 
(discussed below)1. 
By contrast, TH2 cells produce a wide array of cytokines21, including IL-4, that evoke a 
strong antibody response and recruit eosinophils culminating in a robust reaction to 
parasitic infections. These effector activities of TH2 cells are shared with those indicated 
in allergic responses which increase the production of protective barrier mucus at 
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mucosal sites1. 
TH17 cells are being increasingly associated with inflammatory diseases, are known to 
play a strong role in mucosal immunology, and are also indicated in autoimmune 
diseases1,22. Upon stimulation, TH17 cells release cytokine mediators including IL-17 and 
IL-22, which induce a substantial tissue reaction. The receptor of IL-17 is expressed on 
nearly every cell type of the body promoting the recruitment of neutrophils to the site of 
inflammation22,23. 
 
The function of Tregs in the adaptive immune response is to suppress T effector 
responses. There are two main groups of Tregs, both of which express the transcription 
factor FoxP3. One subset is committed to a regulatory function during development in the 
thymus known as natural Tregs. The other subset, known as induced Tregs, differentiate 
from naïve CD4 T cells into Treg cells in the periphery influenced by local environmental 
conditions24. Treg cells require a source of IL-2 which is detected by the constitutive 
expression of CD25+ on the Treg cell surface1,24. Tregs release an anti-inflammatory 
cytokine known as IL-10 which inhibits the activity of TH1 cells and macrophages25. This 
regulation of immune responses diminishes optimal pathogen clearance but also protects 
from immune-mediated tissue damage. Thus, Tregs and the release of IL-10 cytokine can 
both hinder pathogen clearance and mitigate immunopathology25. 
 
Although CD4 T cells are classically referred to as ‘helper cells’ due to their release of 
cytokines that result in accessory cell activation, CD4 T cells also function as cytoxic-
killing cells (ThCTL). Indeed, ThCTLs have been found in the peripheral blood of 
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humans seropositive for human cytomegalovirus, hepatitis, and human 
immunodeficiency-126-28. Similar to CD8+ cytotoxic T lymphocytes (CTLs, discussed 
below), ThCTLs induce target cell apoptosis through the release of granulocytes29,30 and 
Fas/Fas ligand mediated apoptosis31,32. 
 
CD8 CTLs responding to foreign antigen become potent and specific cytotoxic killers 
known as effectors20. CTLs target cells that are infected with viruses present in the 
cytosol of the invaded cell. Classically, CTLs were once thought to require CD4 TH cells 
for a measureable effector response. A strong primary response is now, however, clearly 
measured in animals that lack CD4+ T cells. Indeed, mice that lack expression of CD4 T 
cells – either by CD4+ T cell depletion, genetic deletion of major MHC class II molcules 
(discussed further below), or mice deficient in CD4 glycoprotein co-receptor – still 
generate CD8+ CTL-mediated killing similar to wild type (WT) mice33-35. However, 
while a primary CTL response is similar in animals that lack CD4+ T cell help, the 
formation of memory CTLs is now understood to require CD4 TH cells, rendering a 
secondary response unattainable in CD4 T cell-deficient animals36,37. These studies have 
given great insight into the hallmark immune memory response required for effective 
immunity. 
 
T cell development 
Adaptive immune cells derive from the pluripotent hematopoietic stem cells (HSCs) of 
the bone marrow1. T cell-progenitors migrate from the bone marrow via the blood to the 
thymus1 and differentiate into new T cells, known as lymphopoiesis. Developing T cells 
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undergo rigorous selection based upon TCR interaction with MHC molecules expressed 
by thymic cells19. When the TCR of the developing T cell is capable of interacting with 
MHC molecules presented in the thymus, that T cell is positively selected (approximately 
10-30% of somatically rearranged TCRs). In the absence of positive selection, the 
developing T cell dies due to neglect19. All possible self-peptide antigens are next 
presented to the positively selected developing T cells in the context of MHC:self-
peptide. If, however, the developing T cell responds strongly to the self-peptide, that T 
cell clone is deleted to ensure an autoimmune attack does not occur upon migration to the 
periphery – a process known as negative selection1,19. 
 
Activation of T cells 
For a T cell to be stimulated and undergo clonal expansion, specialized cell-surface 
peptide-presentation proteins called MHC molecules must present the cells cognate 
antigen. There are two classes of MHC molecules which are termed class I and class II 
molecules1. Class I MHC molecules are expressed by all nucleated cells and present 
antigen-peptide derived from the cytosol of cells to CD8+ T cells38. MHC-I molecules 
consist of two polypeptide chains known as the three subunit ‘ɑ-chain’ which is 
noncovalently associated with a smaller chain termed β2-microglobulin1. The ɑ1 and ɑ2 
subunits compose the peptide binding cleft and the region that interacts with the TCR on 
CD8+ T cells. Genetic inactivation of the β2 subunit blocks MHC-I function effectively 
preventing presentation of class I antigen to T cells enabling studies to explore class I 
dynamics39.  
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Class II MHC molecules are expressed by accessory cells functioning as professional 
APCs – such as DCs, macrophages, and B cells. These APCs sample the extracellular 
environment and present peptide derived from phagocytosed antigen, contained within 
intracellular vesicles, to only CD4+ T cells1. MHC-II molecules are composed of two 
chains, ɑ and β each consisting of two subunits. Although similar in name, the ɑ chain of 
MHC-II is distinct from that found in MHC-I1. The MHC-II peptide binding cleft is 
comprised of the ɑ1 and β1 subunits of the corresponding chains40. 
Importantly, TCRs of both CD4 and CD8 T cells only recognize peptide presented in the 
context of the appropriate MHC-class molecule. Furthermore, the TCR interacts with 
both the antigen-peptide and the MHC molecule1,38,40. 
Upon activation by the MHC complex, new T effector cells fall into three broad 
categories: killing, activation, and regulation1. 
 
Primary activation of naïve T cells requires additional signaling through co-stimulatory 
receptors for the T cell to become fully activated. A consequence of TCR-only 
stimulation results in anergic T cells – that is, T cells that respond very poorly upon 
future interaction with cognate peptide41. The best characterized co-stimulatory 
molecules are known as B7 molecules and interact with the CD28 receptor on T cells1. 
Stimulation through CD28 stabilizes the life of IL-2 messenger RNA (mRNA) transcripts 
allowing for copious amounts of IL-2 protein to be produced. The existence of other co-
stimulatory receptors serve to modify the co-activation signal received by the T cell42. 
For example CTLA-4 receptor bind B7 molecules on an order of 20 times more avidly 
than CD281,43. Rather than stimulate the T cell, CTLA-4 signaling has an inhibitory effect 
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on the T cell and restricts the production of IL-2. Another type of co-stimulation occurs 
through the interaction of inducible co-stimulator (ICOS) on T cells with ICOS ligand 
expressed on APCs. Although ICOS signaling too inhibits IL-2 production – by contrast 
with CTLA-4 – ICOS regulates the expression of other T cell cytokines such as IFN! and 
IL-4 thereby having a strong indication in ‘helper’ roles of the T cell including isotype 
switching in B cells1,44. 
 
Posttranslational modifications 
Posttranslational modifications (PTMs) are a broad array of versatile, reversible chemical 
alterations of newly translated proteins45. PTMs are crucial for a proteins function and 
control its cellular location, lifespan, and activity46. PTMs can occur at any step during 
the life of a protein47 and include (but are not limited to) acetylation, phosphorylation, 
ubiquitylation, and neddylation48-50, which are all critical for an immune response. For 
example, in immunity the most common modus to terminate a signaling event is the 
ubiquitination of a protein leading to subsequent proteolytic degradation via the 
proteasome1. Similarly, phosphorylation of inhibitor-κB (IκB) protein releases the 
transcription factor nuclear factor-κB (NF-κB) allowing its translocation into the nucleus 
initiating the production of inflammatory cytokines, such as TNFɑ and IL-651. 
 
Acetylation 
Acetylation is most often associated with modification of histone proteins, around which 
chromatin is wound52,53, known as nucleosomes. The chromatin structure of a eukaryotic 
cell has a major impact on the level of gene transcription52. Within the cell, DNA exists 
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as nucleosome repeats wherein 146bp of DNA are wound around a histone octamer – 
composed of two of each of the H2A, H2B, H3, and H4 histone proteins52. Dynamics of 
H3 and H4 tail acetylation are the best understood and most commonly studied54. 
The attachment of acetyl groups by histone acetyltransferases (HATs) to the tails of 
histone-solenoids results in an open chromatin conformation, allowing gene expression. 
By contrast, histone deacetylases (HDAC) remove acetyl groups thereby returning the 
chromatin to a closed state and thus inhibiting gene expression52. There are several 
classes of HDAC; Class I (HDACs 1, 2, 3, and 8), Class II (HDACs 4, 5, 6, 7, 9, and 10), 
and Class IV (HDAC 11) are zinc dependent enzymes, whereas Class III HDAC enzymes 
are known as sirtuins and rely on nicotinamide adenine dinucleotide (NAD) and are zinc 
independent55. HDAC enzymes are frequently disregulated in cancer56, thus HDAC 
inhibitors (HDACi) have been shown to have a profound effect on many disease states 
including cancers of the blood55,57,58 through myriad cell death pathways56. While many 
synthetic HDACi have been developed and are currently either approved or in various 
stages of clinical trial53, the commensal microbiota found in the gastrointestinal (GI) tract 
exclusively make an endogenous HDACi, called butyrate (explained in depth later) 59-61. 
 
Acetylation can, however, occur on non-histone proteins, such as STAT348. STAT3 
acetylation promotes the transcription of indoleamine 2,3-deoxygenase (IDO) on DCs 
which promotes the induction of Tregs1. 
 
Ubiquitylation 
Attachment of the small 23 kD ubiquitin (Ub) molecule is most often associated with 
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degradation of a target protein62. Ubiquitylation can, however, serve non proteolytic roles 
such as in the NF-κB pathway1. Nevertheless, attachment of Ub requires three enzymes 
to facilitate the lysine residue modification of the protein substrate. The E1 molecule 
activates Ub in an ATP-dependent manner and transfers the activated Ub molecule to an 
E2 molecule. The E2-Ub conjugate interfaces with an adaptor protein on the E3-ligase 
scaffolding to catalyze target protein mono- or poly-ubiquitylation63,64. There are two 
main classes of E3 ligases – those that contain either a homologous to the E6AP carboxyl 
terminus (HECT) domain or a really interesting new gene (RING) domain65 – with the 
vast majority containing RING finger domains. A major difference between E3 classes is 
that those with a HECT domain form a catalytic intermediate with Ub and, by contrast, 
RING domain E3s do not. Furthermore, RING E3s serve as a scaffold that brings the E2-
Ub conjugate within close proximity of the substrate65. RING finger Ub-ligase family 
members can function as monomers, dimers, or multi-subunit complexes. Multi-subunit 
RING domains are most often cullin RING ligases (CRLs)66.  
CRL function must first be activated by the attachment of a 16 kD Ub-homolog called 
neural precursor cell expressed developmentally downregulated protein 8 (NEDD8) 
through a process known as neddylation67 
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Neddylation 
Similar to Ub molecule activation and transfer, NEDD8 requires an ATP dependent 
specific E1 enzyme known as NEDD8 activating enzyme (NAE) (Fig. 1.1). 
 
Following activation, NAE transfers NEDD8 to an E2 molecule called NEDD8-
conjugating enzyme (UBC12), which in turn transfers NEDD8 to the cullin backbone66,67, 
displacing cullin-associated NEDD8-dissociated protein 1 (CAND1) – a competitive 
inhibitor of cullin protein. The attachment of NEDD molecule to cullin protein allows the 
recruitment of the multi-subunit components composing the CRL complex67 which serves 
as the scaffolding to complete substrate ubiquitylation of a specific subset of proteins68 
(Fig. 1.2). 
 
Fig 1.1 – Activation of NEDD8 molecule. NEDD8 is activated by NEDD8 
activating enzyme (NAE) in an ATP dependent process. Once activated, 
NEDD8 is transferred to the E2 molecule, Ubc12. A small molecule inhibitor, 
MLN4924, prevents the activation of NEDD8 molecule by NAE. MLN4924 is an 
AMP-mimetic with potent and specific inhibitory capabilities. 
	 15	
 
 
There at least seven cullins (CUL1, CUL2, CUL3, CUL4A, CUL4B, CUL5, and CUL7) 
that each facilitate ubiquitylation based on their substrate binding region specificity67,68. 
 
An adaptor molecule – sensitive to apoptosis gene (SAG) / RING-box protein 2 (Rbx2) – 
is a critical component of the CRL5 complex and interfaces with the Ub-E2 conjugate 
(Fig. 1.2)69-71. Initially, SAG was cloned and found to be a redox inducible agent that 
protected cells from apoptosis69. Subsequent studies found SAG to be over expressed in 
human primary tumor tissues and that silencing SAG inhibited the growth of the 
 
Fig 1.2 – Neddylation. Following the activation of NEDD8 (Fig. 1.1), it is 
transferred to cullin protein of the CRL complex. This displaces the inhibitor of 
CRL activity, CAND1. Upon initiation of the CRL by NEDD8, multi-subunit 
components are recruited forming the substrate-binding region. Target proteins 
are next recruited and mono- or poly-ubiquitylated followed by subsequent 
degradation by the proteasome. 
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cancerous cells71. Together these studies suggest that knockdown / knockout of SAG 
protein would block CRL function regulating neddylation72-74. 
 
Recent attempts to find a pharmacological inhibitor of neddylation were met with the 
discovery of MLN4924, a potent and selective inhibitor of NAE75. MLN4924 is an AMP-
mimetic and binds the nucleotide-binding site of NAE (Fig. 1.1)75-77. The differences 
between MLN4924 and AMP are 4-fold as MLN4924 has: 1) a deazapurine base 
substituted with an aminoindane at N6 in place of the adenine base; 2) a carbocycle with 
a 2’-hydroxyl group absent in place of the ribose sugar; 3) a sulphamate in place of the 
phosphate; and 4) contrasts the stereochemistry of AMP with a non-natural anti-
relationship to the deazapurine (Fig. 1.3)75. Although MLN4924 is an AMP-mimetic, it 
does not inhibit other enzymes that utilize ATP due to its binding site specificity75. 
 
 
 
Fig 1.3 – Comparison of MLN4924 to AMP. (A) Chemical structure of 
MLN4924 ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-
pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulphamate. (B) The 
structure of adenosine monophosphate (AMP).  
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Proteins that are polyubiquitinylated are degraded by cellular proteasomes under 
homeostatic conditions and studies have shown that inhibition of the proteasome, results 
in substantially preventing intracellular protein turnover78. However, inhibition of NAE 
with MLN4924 only affects the degradation of proteins whose ubiquitylation is 
performed using the CRL neddylation scaffolding68,75. Indeed, Soucy et. al. found 
MLN4924 treatment of HCT-116 cells inhibited overall protein turnover by just 9%, 
compared to ~50% when cells were treated with the proteasome inhibitor, bortezomib. 
 
Subsequent studies have revealed that global inhibition of neddylation – inhibition of all 
five CRL ligases – with MLN4924 causes radiosensitization of human pancreatic cancer 
cells79 and breast cancer cells80, as well as induces autophagy prior to apoptosis in liver 
cancer cells81. 
 
Thus, neddylation regulates the ubiquitylation and subsequent degradation of a specific 
subset of proteins68. Furthermore, the neddylation pathway can be regulated utilizing the 
small molecule, global inhibitor MLN492450,75,79-81 and by knocking-down or knocking-
out SAG protein69-71. 
 
Hematopoietic stem cell transplantation 
Allogeneic hematopoietic bone marrow transplantation (allo-BMT) is a curative therapy 
by conferring a donor graft versus tumor (GVT) effect for many patients who would 
otherwise succumb to hematological malignant diseases82. Allo-BMT recipients undergo 
a conditioning regimen to prepare for the donor stem cells and post-transplantation 
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therapy83. These steps eradicate any underlying malignancy, ensure that the donor stem 
cells engraft in the recipient bone marrow, and attempt to minimize the incidence and 
severity of immune-mediated graft-versus-host disease (GVHD)83. Conditioning 
regimens typically involve a combination of total body irradiation (TBI) and cytoxic 
chemotherapeutics. Chemotherapeutic use has progressed from using a single-agent 
methotrexate to modern calcineurin-inhibitor based combinations83. Stem cells can either 
be harvested directly from a donor’s bone marrow or – now more commonly – from the 
donor’s peripheral blood by pretreating the patient with granulocyte-colony stimulating 
factor (G-CSF), which effectively induces egress of stem cells from the bone marrow into 
the blood stream84. Soon after the recipient has undergone myeloablative therapy and 
allo-BMT, the patient often experiences a period of severe febrile immunodeficiency 
(leukopenia and lymphopenia) putting the recipient at an increased risk for infection85. 
The recovery of neutrophils is one of the first signs of donor engraftment86. 
 
Graft versus host disease 
Although BMT increases survival of patients with hematological malignancies, 40–50% 
of recipients experience complications or secondary disease associated with BMT known 
as GVHD87. GVHD is a complex disease that is modified by the extent of the 
conditioning regimen, degree of human leukocyte antigen (HLA) mismatch, activation of 
donor cells, and destruction of target tissues88,89.  
 
Conditioning of the host with myeloablative therapy results in damage to host tissues. 
Damaged tissues respond by producing proinflammatory cytokines (TNFα, IL-1β, IL-6) 
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and by increasing the expression of cellular adhesion molecules and chemokines90-93. 
This inflammatory milieu activates host antigen presenting cells (APC) and results in the 
upregulation of MHC antigens and co-stimulatory molecules88. In addition, damage 
conferred on the gastrointestinal tract sets up the milieu for future stimulation of the 
immune cells by PAMPs and metabolic by-products produced by the microbiome. We 
are beginning to understand the impacts of the GI tract microbiome on GVHD. The 
discussion below will therefore primarily focus on the GI microbiome and its impact on 
GVHD and not on the microbiota from other mucosal surfaces.  
 
The Microbiome of the GI Tract  
The body is colonized by commensals including bacteria, fungi, and viruses. The human 
GI tract contains trillions of microorganisms, which is estimated to outnumber human 
cells 10 to 194,95. The gut of a human adult is largely dominated by the phyla 
Bacteroidetes, Firmicutes, Proteobacteria, and Actinobacteria96. While only a small 
fraction of these microorganisms may be pathogenic, it is now appreciated that the 
relationship between the host and the commensal microbiome as a whole impacts several 
aspects of the host biology97,98. Microbiota-associated molecular patterns are directly 
recognized by PRRs. In addition, they secrete a multitude of metabolites that also affect 
host immunity and biology.  
 
Pathogen Recognition Receptors  
Innate immune cells of the host express certain PRRs encoded in the germ-line to detect 
PAMPs associated with microbes99 (discussed in depth above). Recognition of PAMPs 
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through PRRs results in the activation of innate immune cells, such as neutrophils and 
APCs. In addition to cells of hematopoietic origin, such as the innate and adaptive 
immune system, PRRs are also expressed on epithelial and endothelial cells.  
 
The Metabolome  
The microbiota are known to perform key metabolic functions100. The microbiota of the 
gut can metabolize not only material directly ingested by the host but also produce by-
products of its own metabolism. The intestinal metabolome thus consists of products 
from discrete host metabolism, microbial metabolism, and mammalian-microbial co-
metabolism101. The critical impact of microbiota-derived metabolites is being 
increasingly appreciated. Donohoe et al. demonstrates that the microbiota plays a critical 
effect on the energy homeostasis of colonocytes through the generation of short chain 
fatty acids (SCFAs). Recent studies show that colonocytes from germ-free mice are in an 
energy-deprived state demonstrating a decreased ratio of NADH/NAD+, oxidative 
phosphorylation, and levels of ATP which in turn result in autophagy102.  
In addition to the effects of microbial metabolites on non-immune cells, the impact of the 
metabolome on immune cells is now increasingly being understood. Recent studies have 
shown that 17 rationally selected strains of Clostridia, known to produce the SCFA 
butyrate, directly result in the increased presence of regulatory T cells (Tregs) in the gut. 
Tregs play a critical role in maintaining gastrointestinal homeostasis by modulating 
inflammatory responses via the release of the anti-inflammatory molecule IL-10, which 
also directly impact macrophages103-106. Similarly, other groups have utilized a cocktail of 
altered Schaedler flora which too resulted in the de novo generation of colonic Tregs107.  
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With the emerging importance of the effects of microbial metabolites on host biology 
beginning to be appreciated, recent studies have shown diet to play a role in regulating 
rapid changes in the taxonomic composition of the gut microbiome108,109. These findings 
suggest that an appropriate diet conducive to homeostatic microbiota may be an 
important factor when treating comorbidities as the associated metabolome is 
correspondingly altered110,111.  
Together, these data suggest the microbial metabolome could impact GVHD, although 
this hypothesis remains to be formally tested.  
 
Antimicrobial Peptides  
It has long been established that colonization of commensal microflora provides 
protection against invading pathogenic bacteria, referred to as colonization resistance112. 
Further, intestinal epithelial cells (IECs) provide a physical barrier against contaminating 
factors found in the lumen of the gut (Fig. 1.4). IECs are known to produce both 
antimicrobial peptides (AMPs) which inhibit the growth of and kill microorganisms, and 
a polysaccharide-rich mucus layer which functions in a manner similar to biofilms113. 
The biofilm-like mucus promotes various functions of the microbiota including 
metabolism of luminal contents, fortification of host defenses, and resistance to 
hydrodynamic forces due to peristalsis113.  
Defensins and cathelicidins are AMPs that have been identified in many mammals. 
Defensins interact with, and potentially destroy, both Gram-negative and Gram-positive 
bacteria through membrane disruption114,115. Several studies have also described the 
ability of defensins to sequester components of the bacterial cell wall, thus inhibiting its 
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synthesis114,116. These findings emphasize the ability of defensins to mount a multifaceted 
attack on bacterial targets. Cathelicidin (LL-37) is chiefly produced and stored in 
granules of neutrophils; however, it is also an inducible product of epithelial cells, T 
cells, and monocytes117.  Recent studies have demonstrated the rapid release of defensins 
not only neutralizes pathogenic bacteria, but they are also sufficient to initiate and 
amplify an adaptive immune response resulting in both Th1-dependant cellular responses 
and Th2-dependent humoral responses by activation of immature dendritic cells (DC)118.  
 
 
Fig 1.4 – The intestinal barrier and gut homeostasis. The intestinal lumen 
contains by-products of microbial fermentation – both commensal (SCFAs) and 
pathogenic (PAMPs). Host intestinal epithelial cells (IECs) provide a physical 
barrier against contaminating PAMPs and produce cytokines, amino acid 
metabolites (Indoles), and DAMPs that are found in the lumen. Specialized 
IECs, known as Paneth cells, produce antimicrobial peptides (AMPs) that 
selectively inhibit pathogenic bacteria while preserving commensal microbiota 
and provide critical trophic factors for intestinal stem cells. Damage to IEC 
homeostasis results in loss of barrier function and activation of immune cells. 
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Another type of AMP, RegIIIα (RegIIIγ in mice), is a C-type lectin, found primarily in 
the intestine, and is generated by Paneth cells. RegIII is composed of a combination of α-
helical structures and beta sheets119 that binds to peptidoglycan carbohydrates of Gram-
positive bacterial cell walls, in a calcium independent process.  
Studies have shown that RegIIIα adopts a hexameric membrane-permeating pore 
structure to kill bacteria120,121.  
In addition to AMPs, IECs also secrete chemotactic cytokines (chemokines) resulting in 
the recruitment of innate immune cells and produce proinflammatory enzymes such as 
inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) which activate 
neutrophils resulting in their degranulation upon pathogenic stimuli122.  
Thus, in coordination with immune cells, IECs can have a significant influence on both 
the microbiota and homeostasis of the host tissue.  
 
The Role of the Microbiome in GVHD  
Early Experimental Studies  
A role for the microbiome in modulating the severity of GVHD was first identified in the 
early 1960s by the seminal studies of van Bekkum et al. using germ-free recipient mice. 
The authors made the observation that the severity of GVHD was markedly decreased 
when compared to conventional BMT controls123,124. Subsequent studies by the same and 
other groups confirmed and expanded these findings125,126. Further studies by van 
Bekkum et al. isolated colonization resistant microflora which inhibited colonization of 
Escherichia coli, K. pneumoniae, and P. aeruginosa by treating conventionally housed 
mice with antibiotics (streptomycin, neomycin, and pimaricin)127. The colonization 
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resistant microflora were then transferred to germ-free mice prior to BMT resulting in 
decreased GVHD severity, thus indicating that select microorganisms may be beneficial 
in the context of BMT. These studies formed the basis for clinical utilization of antibiotic 
prophylaxis prior to BMT and the establishment of standard practice gut decontamination 
prior to BMT in the clinic, at many transplants centers.  
 
Clinical Studies  
The early experimental studies described above led to initial clinical trials designed to 
determine the role of GI bacterial decontamination in BMT patients. In a study performed 
nearly 30 years ago, patients were divided into 3 groups: administration of oral 
nonabsorbable antibiotics with isolation and decontamination in laminar airflow isolation 
(LAF) rooms, prophylactic granulocyte transfusions from a single family member donor, 
or conventional treatment in single rooms with hand-washing and mask precautions128. 
Following engraftment, significantly fewer infections were observed in patients isolated 
in LAF rooms and acute GVHD occurred much later than control groups. More 
importantly, day 100 overall survival was significantly improved in patients in LAF 
isolation (92 %) compared to groups in conventional treatment (64 %)128. Another study 
in which patients were either treated with meropenem, a broad-spectrum antibiotic, 
starting on the first day of febrile episode, or prophylactically treated beginning the first 
day with <500/mm3 granulocytes, demonstrated fewer febrile episodes in patients 
receiving meropenem prophylaxis. Prophylactic use of meropenem during the period of 
neutropenia favorably affected the morbidity of the BMT procedure suggesting that 
reduced febrile episodes were due to decreased bacterial infections129.  
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Other studies indicate that increased survival in patients treated in LAF rooms resulted in 
less transplant-related mortality (TRM) independent of prophylactic antibiotic use130, 
whereas other studies indicated that there is no benefit to isolation in LAF room 
following BMT131. Several groups have performed additional studies utilizing antibiotic 
prophylaxis prior to BMT or during granulocytopenic period following BMT with 
conflicting results. One such study housed all patients in LAF rooms with one group 
receiving prophylactic systemic antibiotics (PSA). However, overall survival at day 100 
of groups in LAF rooms with PSA was 72.2 % where groups in LAF rooms only was 
70.6 % suggesting no improvement in survival, even though LAF + PSA groups had 
significantly lower incidence of infections132. However, many of these studies have 
sought to answer disparate questions and lacked sufficient power to determine the 
validity of prophylactic antibacterial use on GVHD severity in the patients.  
 
The Impact of the Microbiome of the Host on GVHD: Recent Observations  
Despite early observations as noted above, the role that the host microbiome plays in the 
severity of GVHD was largely unexplored until recent years. Recent studies have made 
significant strides in illuminating alterations in the intestinal microbiota following 
allogeneic BMT in mice and humans133,134. Jenq et al. described observations utilizing 
clinical models of BMT (B10.BR → B6) where recipients were subjected to lethal 
irradiation and received donor BM with or without isolated T cells. A loss of overall 
diversity was seen consisting of an expansion of Lactobacillales with a simultaneous loss 
of Clostridiales in allo-recipients of BM with isolated T cells. Elegant experiments where 
the predominant pre-BMT species of Lactobacillus (L. johnsonii) was reintroduced 
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following gut decontamination and allo-BMT, resulted in improved overall survival 
compared to recipients of allo-BMT receiving only gut decontamination133. Likewise, 
unpublished observations from our laboratory suggest that intragastric introduction of a 
cocktail of 17 rationally selected strains of predominantly Clostridiales103 with salutary 
effects on the GI epithelium, results in decreased GVHD and improved overall survival59.  
Another recent study illuminated the impact of the loss of diversity in the gut further, 
following allo-BMT. The study observed that Paneth cells are targets of GVHD134. 
Paneth cells, located next to intestinal stem cells (ISC) within the crypts of the intestinal 
lumen (Fig. 1.4), are essential regulators of the composition of the intestinal 
microbiota135,136. Further, Paneth cells are known to secrete antimicrobial peptides and α-
defensins which largely function by forming pores in bacterial cell walls137,138. Eriguchi 
et al. revealed that the loss of Paneth cells from GVHD resulted in decreased expression 
of α-defensins. The authors further suggest that α-defensins selectively kill non-
commensal bacteria while preserving commensal microbiota134. The study suggests that 
the decrease in the expression of α-defensins resulted in the loss of microbial diversity (as 
also observed in Jenq et al.) and an overwhelming expansion of E. coli, leading to 
septicemia.  
A recent study demonstrated the importance of bacterial diversity in the intestinal tract on 
mortality outcomes following BMT. The authors collected fecal specimens from patients 
that received allo-BMT, at the time of stem cell engraftment139. Microbial diversity was 
then determined by performing bacterial 16S rRNA gene sequencing. Patients with lower 
bacterial diversity exhibited significantly worse mortality. Overall survival at 3 years was 
36 % for low, 60 % for intermediate, and 67 % for high diversity groups139. These results 
	 27	
suggest that diversity of the intestinal microbiota at time of engraftment may be a 
predictor of mortality in recipients of allo-BMT and thus highlight the consequences of 
dysbiosis of the intestinal flora.  
 
The Impact of the Microbiome of the Donor  
The microbiome is known to play a key role in the development and maturation of T 
cells103,140,141. The influence of the donor microbiota on the donor allograft and its impact 
on GVHD was recently examined142. Using clinically relevant murine models of BMT, 
the authors observed the severity of GVHD induced by T cells harvested from germ-free 
(GF) donors and specific pathogen-free (SPF) donors. Interestingly, there was no 
difference in the frequency of Treg cells in the periphery of the host or levels of lineage-
specific cytokines in the sera such as IFNγ, IL-5, IL-17, or the anti-inflammatory 
cytokine IL-10. Further, clinical observation revealed that GVHD progression and 
severity was similar between recipients of the GF and SPF donor T cells with no 
difference in histopathological scores of the small intestine and liver. In addition, no 
survival benefit was observed in the recipients of donor T cells from GF or SPF donor T 
cells. Furthermore, when SPF donor mice were treated with broad-spectrum antibiotics 
prior to T cell isolation, no difference in survival was determined.  
These data indicate that absence of the effects of the microbiome on T cells may be lost 
once they have been removed from the germ-free environment.  
 
PAMPs and GVHD  
There is mounting evidence that microorganisms and PRRs of the innate immune system 
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play a critical role in the pathogenesis of acute GVHD124,133,143. Products of Gram-
negative bacteria, such as LPS, were suggested to be contributors to the severity and 
progression of GVHD in certain experimental models144-146. Cooke et al. utilized a potent 
antagonist of LPS and observed significantly reduced production of TNFα and intestinal 
damage. While donor T cell responses were unaltered, overall GVHD severity was 
reduced145. However, a recent study utilized a different model system with myeloid 
differentiation primary response gene (88) (MYD88) and TIR-domain-containing 
adapter-inducing interferon-β (TRIF) double knockout cells, thus the donor allograft was 
deficient in all TLR signaling147. The authors demonstrated that loss of TLR signaling did 
not protect from GVHD nor improve overall survival, suggesting that TLR signaling is 
dispensable for GVHD severity.  
Human genetic association studies wherein patients possessing TLR4 polymorphisms, 
who also received grafts from HLA-matched donor siblings, demonstrated an increased 
risk for Gram-negative bacteremia and GVHD severity148.  
In another study, TLR9 deficient recipients of allo-BMT have demonstrated decreased 
systemic GVHD149. The authors observed that APCs isolated from TLR9−/− mice had a 
decreased ability to stimulate allogeneic T cells. Further, utilizing cytosine-
phosphorothioate guanine oligodeoxynucleotides (CpG ODNs), which mimics bacterial 
and viral DNA and stimulates TLR9, Blazar et al. found that CpG treatment enhanced 
allo-T cell responses leading to increased GVHD severity and mortality150. These TLR9 
dependent studies emphasize the importance of TLR signaling for host APC function 
during GVHD151. The analysis of TLR9 gene associated polymorphisms on the clinical 
outcome of 413 donors showed no association of the TLR9 polymorphisms with 
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incidence or severity of GVHD148,151. However, patients with the T1486C mutation 
exhibited significantly improved survival due to reduced TRM and relapse rate.  
The importance of TLRs in neutrophils on the severity of GVHD has recently been 
demonstrated. Neutrophils are the largest human white blood cell population and have 
important roles in cleaving chemokines and the production of reactive oxygen species 
(ROS). During allogeneic immune responses, neutrophils amplify tissue damage caused 
by conditioning regimens152. Schwab et al. utilized clinical models of BMT where donor 
neutrophils were TLR2, TLR3, TLR4, TLR7, and TLR9 deficient. GVHD severity was 
significantly reduced suggesting that TLR signaling is important for neutrophil-mediated 
inflammation in the context of allo-BMT.  
The role of NLRs in GVHD has been examined in several recent studies. NOD2 
deficiency in recipients of experimental BMT resulted in increased GVHD of both MHC-
mismatched and MHC-matched models153,154 corresponding with enhanced activation and 
proliferation of donor T cells, due to increased activation status of DCs.  
The presence of certain cytokines, such as IL-1β, was suggested to predict the outcome 
and severity of GVHD91. IL-1β is one such proinflammatory cytokine that is released 
following NLR stimulation. A study examining the genotypes of 133 patients undergoing 
BMT from (HLA)-matched donor siblings demonstrated a strong correlation between 
genetic variants of NLRP2 and NLRP3 genes and the clinical outcome and severity of 
GVHD155.  
Immune-mediated tissue destruction, which is often found in acute GVHD, is a result of 
cellular damage or response to DAMPs. Although critical for the function of the cell, 
extracellular ATP released from a damaged cell is subsequently internalized and serves as 
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a strong activating signal of NLRP3156. In response to accumulated ATP and NLRP3 
stimulation, APCs increased expression of co-stimulatory molecules which resulted in 
enhanced proinflammatory signals and expansion of donor T cells with a reduction of 
Treg cells and increased GVHD severity157.  
Siglec-G recognition of non-infectious DAMPs regulates innate immune responses158. A 
recent study examined the role of Siglec-G expression on host APCs, specifically on 
hematopoietic cells, and its ability to negatively regulate GVHD in multiple clinically 
relevant murine models159. The authors demonstrate that recipients deficient in Siglec-G 
exhibit significantly increased GVHD severity and mortality, in a CD24 dependent 
manner. Upon administration of CD24 fusion protein to WT recipients of allo-BMT, 
improved overall survival is observed. However, administration of CD24 fusion protein 
to recipients deficient in Siglec-G did not improve survival, suggesting that Siglec 
signaling is required for the effects of CD24159.  
These data suggest that the Siglec-G–CD24 axis controls the severity of GVHD and that 
enhancing this interaction may represent a method of mitigating clinical GVHD.  
 
The Metabolome and GVHD  
Many recent studies have made strides to identify the taxonomic composition and activity 
of the host microbiome103,111,133. However, few publications examine the role of 
microbial metabolites (e.g., SCFAs) in the homeostasis of host physiology. While it is 
increasingly evident that alterations in the microbiome correlate with many disease 
states160-162, the mechanism through which these alterations confer their effects is poorly 
understood.  
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The most studied microbial metabolites are SCFAs, of which butyrate, acetate, and 
propionate are the most abundant. As described earlier in this review, SCFAs are 
produced by microbial fermentation of complex polysaccharides in the gut and are 
subsequently absorbed by the intestinal epithelium100. Butyrate is utilized as a major 
energy source for IECs and is a known histone deacetylase inhibitor (iHDAC)163. Thus, 
microbial metabolites may play an important role in maintaining the health of the 
physical barrier of the gut epithelium as well as protecting the host from the influences of 
PAMPs and DAMPs.  
SCFAs may have a particularly important role in the protection of the host from GVHD. 
Unpublished observations from our lab demonstrate that there is a significantly decreased 
concentration of butyrate found in the tissue of the GI tract following allo-BMT. In 
addition, this coincides with a substantial and significant decrease in the acetylation state 
of histones in IECs of allo-BMT recipients. When butyrate was supplemented via 
intragastric gavage, it increased histone acetylation in IECs and significantly improved 
junction integrity mitigating GVHD severity59.  
 
AMPs and GVHD  
AMPs, produced by Paneth cells, have been shown to be a critical “first line of defense” 
of the innate immune system among epithelial barriers164,165. As discussed above, a recent 
study observed a loss of α-defensins in the gut due to a GVHD-mediated decrease of 
Paneth cells134. Furthermore, non-commensal bacteria were selectively targeted and 
killed by α-defensins, while commensal microbiota were preserved. Equally, several 
studies have observed that the composition of the intestinal microbiome is directly 
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influenced by alterations in the expression of AMPs166,167.  
Another recent study by Ferrara et al. identified the AMP RegIIIα as a biomarker found 
in the plasma indicative of acute GVHD in the lower GI tract. The authors found RegIIIα 
to be 3-fold higher at GI GVHD onset in a large cohort of patients, compared to control 
cohorts168.  
The effects of the microbiome on GVHD, and that of GVHD on the microbiome, are now 
being increasingly appreciated. The differential role that the microbiota plays in the 
host133,134 and the donor142 and the effects of polymorphisms of PRRs on GVHD severity 
highlight the complex interactions between the microbiome and GVHD that remain to be 
meticulously examined. Further studies examining the functions and mechanisms are 
needed to identify new targets for treating GVHD and other diseases affected by 
dysbiosis of the microbiota.  
 
Statement of purpose 
Activation of donor T cells by APCs is critical for the GVT effect following allogeneic 
BMT. However, inappropriate activation of lymphocytes by nonhematopoietic cells 
results in GVHD (Fig. 1.5).  
	 33	
 
Current methods of GVHD prophylaxis are often indiscriminate and kill both disease 
causing and non-disease causing cells. Recent advances have shown that the microbiota 
as well as PTMs, such as acetylation, play a role in regulating GVHD pathogenesis. 
However, the effects that the metabolites that are produced exclusively by the commensal 
 
Fig 1.5 – Antigen presenting cells in GVT: to maximize GVT responses, 
two important factors must be considered: antigen presentation and 
donor T cells. Although both host and donor DCs have been shown to play an 
important role in GVHD, their role in GVT is only beginning to be understood. 
To induce GVT, although donor T cells must recognize both alloantigens and 
tumor specific antigens (TSAs) that presented either directly by the tumor or 
indirectly by the professional APCs, tumor themselves are generally poor 
presenters and activators of T cell effector responses. Therefore, professional 
APCs are required for optimizing GVT. While alloantigen responses are also 
elicited by many APCs including both hematopoietic-derived and non-
hematopoietic-derived APCs cause GVHD, TSAs are exclusively directed to 
tumors and thus considered to GVHD without concomitantly causing GVHD. In 
cases where tumors are poor APCs of TSAs to donor T cells, the TSAs have to 
be efficiently presented by professional APCs, especially DCs, derived from 
either donor or host. This mechanism of presentation includes cross-
presentation.  
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bacteria within the gastrointestinal tract – such as butyrate, an endogenous HDACi – have 
on GVHD are unknown. Furthermore, the role that neddylation (a type of PTM) plays in 
the immune system, and thus immune-mediated diseases such as GVHD, have heretofore 
been unknown. 
Therefore, the goal of my research is to further understand the role of PTMs in immunity 
and their impacts on GVHD pathogenesis. In Chapter II, the PTM neddylation is shown 
to regulate both mouse and human DC function. Mechanistic studies in murine DCs 
showed that inhibiting neddylation prevented the degradation of IκB and thus impeded 
the translocation of NF-κB to nucleus. This resulted in not only decreased inflammatory 
cytokines, but also decreased GVHD and mortality in mice treated with neddylation 
inhibitor, MLN4924. In Chapter III, inhibiting neddylation is shown to have a disparate 
function in regulating macrophages compared with activation of neutrophils. Indeed, 
generation of a novel mouse possessing a conditional macrophage knockout of SAG 
protein exhibited increased LPS-induced mortality even though the neddylation-deficient 
macrophages released less cytokines. Disruption of neddylation in neutrophils was 
demonstrated to increase ROS and also resulted in the increased release of TNFɑ and IL-
6. In Chapter IV, the generation of a different novel mouse that had a T cell-specific 
deletion of SAG revealed that T cell functions may be regulated by the inhibition of 
neddylation, including ameliorating the effects of GVHD. Furthermore, utilization of a 
small molecule inhibitor of neddylation, MLN4924 (currently in phase I/II clinical trials) 
recapitulated the results seen in the knockout mouse, suggesting that carefully designed 
clinical trials may find therapeutic efficacy for MLN4924 and thus may be a new agent 
for regulating GVHD in the clinic. Chapter V describes the findings that the SCFA 
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butyrate (an endogenous HDACi) – produced exclusively by the commensal microbiota – 
is diminished in the intestinal tissue following allo-BMT. This lack of butyrate resulted in 
decreased histone-H4 acetylation in IECs and increased IEC allo-mediated damage, the 
effects of which are reversed by the local intragastric gavage of butyrate. Indeed, 
restoration of histone-H4 acetylation improved junctional integrity and resulted in less 
severe GVHD and improved survival. 
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CHAPTER II 
 
NEDDYLATION PLAYS AN IMPORTANT ROLE IN THE REGULATION 
OF MURINE AND HUMAN DENDRITIC CELL FUNCTION 
 
 
ABSTRACT 
Posttranslational protein modifications (PTMs) are necessary for cells to function 
properly. The role of PTMs in regulating immune responses, specifically those mediated 
by dendritic cells (DCs), which are critical for both innate and adaptive immunity, is not 
well understood. Utilizing multiple but complementary approaches, we determined the 
role of an important but less understood type of PTM, namely, neddylation, in regulating 
DC functions. Inhibition of neddylation suppressed the release of proinflammatory 
cytokines by DCs in response to Toll-like receptor, nucleotide oligomerization domain–
like receptor, and noninfectious CD40L stimulation. These effects were more profound 
than those mediated by the proteasome inhibitor bortezomib or a commonly used 
antiinflammatory agent, dexamethasone. Targeting neddylation also suppressed the 
ability of DCs to stimulate murine allogeneic T cells in vitro and in vivo and human 
allogeneic T-cell responses in vitro. Mechanistic studies demonstrated that inhibition of 
neddylation reduced both canonical and noncanonical nuclear factor-κB (NF-κB) activity. 
Neddylation inhibition prevented the degradation of inhibitor-κB and thus reduced the 
translocation and activation of NF-κB, but without perturbation of the mitogen-activated 
protein kinase/extracellular signal-regulated kinase pathway. Thus, blocking neddylation 
could be a novel strategy for mitigating immune-mediated disease processes. 
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INTRODUCTION 
 
Post-translational protein modifications (PTM) are critical for immunity46. PTMs include, 
but are not limited to, acetylation48, phosphorylation, and ubiquitination.49 These PTMs 
are necessary for the proper function of all cells, including dendritic cells (DCs). DCs are 
critical for both innate and adaptive immunity169,170. Following an encounter with 
inflammatory stimuli or components of microbial or viral origin, DCs upregulate 
costimulatory molecules171 and release proinflammatory cytokines172. Proinflammatory 
cytokines released by DCs play an important role in immunity through an autocrine and 
paracrine fashion on surrounding cells; the molecular processes regulating cytokine 
release from DCs are, however, not completely understood. Proinflammatory cytokines 
have profound impact on causing or exacerbating many diseases states including chronic 
inflammatory diseases, shock, autoimmunity, and alloimmunity92,173-175. 
Pattern recognition receptors (PRRs) such as Toll-like receptor (TLR) and NOD-like 
receptor (NLR) on DCs interact with pathogen-associated molecular patterns (PAMPS) 
allowing selective recognition of microorganisms13,176. A series of signaling events leads 
to the phosphorylation of IKKβ, which in turn phosphorylates inhibitor-κB (IκB) for 
degradation resulting in the activation of the transcription factor NF-κB177. At basal 
conditions, IκB sequesters canonical NF-κB in the cytosol. However, the critical 
molecular regulators of the degradation of phosphorylated IκB are not well understood. 
Activation and translocation of NF-κB results in the transcription of the proinflammatory 
cytokines TNFα and IL-6178. Activation of NF-κB occurs through two distinct, canonical 
and non-canonical NF-κB pathways178. NF-κB is comprised of heterodimers of the Rel 
protein family. The canonical NF-κB is a union of p65 (RelA) and p50 and responds to 
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numerous PRR stimuli resulting in diverse functions. In contrast, the noncanonical 
pathway consists of RelB and p52 constituting NF-κB and responds to a subset of TNFR 
signals such as CD40L179. 
 
Upon PRR stimulation, IκB is phosphorylated and subsequently ubiquitinated resulting in 
its degradation allowing NF-κB to translocate to the nucleus180. Phosphorylation of IκB is 
followed by its ubiquitination and degradation by the E3 ligase complex. This complex 
consists of the proteins Skp1 (S-phase kinase associated protein 1), an F-box protein, 
Cullin1 (Cul1) and a RING box protein (RBX1 or RBX2, also known as SAG), which 
together comprise the Cullin RING Ligase 1 (CRL-1)68,80. The ability of CRL-1 to 
ubiquitinate target proteins, including IκB, is dependent upon the covalent PTM of the 
Cullin1 subunit of the CRL by the attachment of a ubiquitin homolog called Nedd8 
(Neural precursor cell Expressed, Developmentally-Downregulated 8)181. Post-
translational protein modification by the attachment of Nedd8 is known as 
neddylation79,182. Neddylation is an enzymatic process in which Nedd8 is activated in an 
ATP dependent manner by an E1 enzyme known as Nedd8 activating enzyme (NAE) and 
is subsequently transferred to the E2 enzyme, Ubc12183. Nedd8-Ubc12 transfers Nedd8 to 
Cullin displacing CAND1, an inhibitor of Cullin activity183,184. Once activated, CRL-1 
catalyzes the transfer of ubiquitin from the E2 to the substrate183. A small molecule called 
MLN4924 has been recently developed with remarkable specificity and potency for 
inhibiting NAE. MLN4924 forms a Nedd8-AMP mimetic and thereby prevents the initial 
activation of Nedd875. This small molecule is in human clinical trials as an anti-cancer 
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agent, but the role of neddylation in regulating immune cells, specifically DCs, is not 
known.  
 
Utilizing two distinct but complementary approaches (chemical inhibition with the small 
molecule MLN4924 and molecular knockdown of critical CRL proteins), we have 
examined the effect of inactivation of CRL-1 E3 ligase activity on murine and human DC 
function as determined by the release of proinflammatory cytokines and their ability to 
stimulate allogeneic T cells both in vitro and in vivo. We also compared these results to 
the known anti-inflammatory drug, dexamethasone and further determined the 
differential molecular mechanisms that underpin their anti-inflammatory responses. We 
found that inactivation of the CRL-1 E3 ligase resulted in significantly greater 
suppression of proinflammatory cytokine production than dexamethasone or the 
proteasome inhibitor bortezomib and mechanistic studies showed that in contrast to 
dexamethasone, inhibition of neddylation prevented the degradation of IκB as well as the 
translocation and activation of NF-κB without perturbation of the MAPK/ERK pathway.  
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RESULTS 
Inhibition of neddylation attenuates LPS induced proinflammatory cytokine 
production by DCs 
Previous studies have shown that MLN4924 prevents the neddylation of CRLs in several 
cell types81,185. Therefore, we first determined if MLN4924 and/or dexamethasone could 
inhibit neddylation in bone marrow-derived dendritic cells (BMDC). BMDCs pretreated 
with MLN4924 followed by TLR4 stimulation (LPS) exhibited reduced neddylation (Fig. 
2.1). 
 
This inhibition of neddylation was detected using a Nedd8 antibody capable of binding 
Nedd8-conjugated Cullin protein at approximately 90 kDa (Fig. 2.1, top panel)185,186. We 
further confirmed it with an antibody specific for total Cullin-180 (Fig. 2.1, middle panel). 
By contrast, treatment with dexamethasone did not inhibit neddylation in BMDCs (Fig. 
2.1).	 
 
Fig 2.1 – Neddylation inhibition. Protein analysis by western blot of (A, top 
panel) neddylated Cullin proteins and (A, middle panel) Cul1 protein using 
whole cell lysate of BMDC stimulated with LPS in the presence or absence of 
MLN4924 or dexamethasone at the indicated doses. Cells receiving treatment 
were preincubated with MLN4924 or dexamethasone for 2 hours followed by 
concurrent LPS stimulation (0.5 µg/mL) for 4 hours. α-tubulin protein levels 
were analyzed as an equal loading control. 
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Having established that MLN4924 inhibited neddylation, we next determined whether it 
modulated the production of proinflammatory cytokines such as TNFα and IL-6 
following stimulation of BMDCs with LPS187. TNFα (Figure 2.2A) and IL-6 (Figure 
2.2B) cytokine levels in the supernatants were significantly inhibited by MLN4924 in a 
dose dependent manner. Furthermore, MLN4924 suppressed LPS-induced inflammatory 
cytokines significantly more than dexamethasone treatment (Fig. 2.2). 
 
 
Fig. 2.2 - Neddylation inhibition attenuates LPS-induced TNF-α and IL-6 
release and gene expression in BMDC. Quantification via ELISA of cytokines 
TNF-α (A) and IL-6 (B) and qPCR analysis of TNF-α (C) and IL-6 (D) transcripts 
in BMDC stimulated with LPS in the presence or absence of MLN4924 or 
dexamethasone at the indicated doses. Cells receiving treatment were 
preincubated with MLN4924 or dexamethasone for 2 hours followed by 
concurrent LPS stimulation (0.5 µg/mL) for 4 hours. One representative 
experiment of 3 is shown. ***P < .0001. 
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Because LPS increases the expression of TNFα and IL-6 at the transcriptional level188-190 
we next assessed the impact of MLN4924 and dexamethasone on LPS-induced 
transcriptional expression of TNFα and IL-6 mRNA. As shown in Figures 1D and 1E, 
both MLN4924 and dexamethasone inhibited LPS-induced TNFα and IL-6 mRNA levels. 
The impact of MLN4924 on mitigating LPS-induced increases of TNFα and IL-6 mRNA 
was dose-dependent (Figure 2.2C-D).  
These data collectively suggest that MLN4924 and dexamethasone differentially affect 
cullin1 neddylation in DCs and that they may not have interrelated molecular targets. 
More importantly, the data show that inhibition of neddylation results in a more 
significant attenuation of LPS induced TNFα and IL-6 production than dexamethasone in 
BMDC. 
 
Neddylation modulates DC responses to both infectious and non-infectious stimuli 
Next, to determine whether the effects of MLN4924 observed thus far were specific only 
to TLR4 ligation (LPS), we stimulated BMDC with Pam3CSK4 (a TLR1/2 ligand), 
peptidoglycan (PGN, a NOD2 stimulator) and non-infectious CD40L agonist. Treatment 
of DCs in the presence or absence of MLN4924 or dexamethasone, caused a significant 
reduction in the secretion of TNFα by both MLN4924 and dexamethasone, regardless of 
whether they were stimulated with Pam3CSK4 (Figure 2.3A), PGN (Figure 2.3B) or 
CD40L (Figure 2.3C). 
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These data suggest that the effects on suppression of proinflammatory cytokines through 
inactivation of the CRL-1 E3 ligase are not specific to only TLR4, but extend to an array 
of PRR and cellular stimuli such as CD40L. Furthermore, these data also show that 
inhibition of neddylation regulated both canonical (TLR/NLR) and non-canonical 
(CD40L) activated NF-!B pathways. To further compare the effects of neddylation 
 
Fig. 2.3 - Neddylation inhibition in BMDC mitigates release of non-TLR4–
stimulated cytokines in vitro. ELISA quantification of TNF-α release in 
Pam3CSK4 (300 ng/mL) stimulated (A), PGN (5 µg/mL) stimulated (B), and 
CD40L (1 µg/mL) stimulated (C) BMDC in the presence or absence of vehicle, 
MLN4924, or dexamethasone at the indicated doses. (D) Comparison of TNF-α 
release via ELISA of cells treated with vehicle, MLN4924, dexamethasone, or 
bortezomib followed by concurrent stimulation with LPS (0.5 µg/mL). Cells 
receiving treatment were preincubated with vehicle, MLN4924, dexamethasone, 
or bortezomib for 2 hours followed by concurrent stimulation for 4 hours. One 
representative experiment of 3 is shown in cells treated in triplicate. *P < .05; 
**P < .01; ***P < .0001. 
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inhibition to another clinically used inhibitor of the proteasome and NF-κB pathway, we 
next stimulated BMDC with LPS and concurrently treated with either the diluent vehicle, 
MLN4924, dexamethasone, or bortezomib. As shown in Figure 2.3D, blocking 
neddylation inhibited TNFα secretion from the DCs far more potently than the 
proteasome inhibitor bortezomib (Figure 2.3D). 
 
Inhibition of neddylation mitigates the ability of DCs to induce proliferation of 
allogeneic T cells  
To further characterize the effect of inhibition of neddylation on the functions of DCs, we 
determined the impact of treatment of DCs with MLN4924 on their ability to stimulate 
allogeneic T cells169,170 in a mixed lymphocyte reaction (MLR). BALB/C T cells were 
cultured with C57BL/6 irradiated (30Gy) BMDC at 40:1 and 100:1 ratios for 72 (Figure 
2.4A) and 96 (Figure 2.4B) hours. Addition of MLN4924 to the cultures upon plating 
cells significantly reduced the proliferation of T cells (Figure 2.4A-B). To determine 
whether this reduction is due to a direct impact of MLN4924 on DCs, BMDCs were 
preincubated with MLN4924 for 6 hours, washed and then used as stimulators in the 
MLR. Pretreatment of DCs with MLN4924 also reduced proliferation of allo-T cells at 
both 72 (Figure 2.4A) and 96 (Figure 2.4B) hours suggesting that MLN4924 treatment of 
DCs reduced their ability to induce proliferation of allo-T cells. 
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To specifically determine whether inhibition of neddylation can also suppress T cells 
directly, we next stimulated BALB/C CD90.2+ T cells with α-CD3 and α-CD28 
functional Abs for 48 hours following their pre-treatment in the presence or absence of 
MLN4924. MLN4924 significantly reduced the proliferation of T cells (Figure 2.5A) and 
caused a significant decrease in the secretion of IFNγ (Figure 2.5B). 
 
Fig. 2.4 - Neddylation inhibition mitigates allogeneic T-cell proliferation.  
BALB/C T cells were cultured with C57BL/6 irradiated (30 Gy) BMDC at 40:1 
and 100:1 ratios in the presence or absence of MLN4924 for 72 hours (A) and 
96 hours (B). Where indicated, BMDC were preincubated in the presence or 
absence of vehicle or MLN4924 at specified dosage for 6 hours. One 
representative experiment of 3 is shown of groups treated in triplicate. *P < .05; 
**P < .01; ***P < .0001.  
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Inhibition of neddylation regulates DC functions in vivo  
We next investigated the effects of neddylation inhibition on in vivo DC functions. 
Because host antigen presenting cells modulate GVHD, and DCs are the most potent 
APCs, we utilized a clinically relevant, MHC mismatched B6 (H-2b) → BALB/C (H-2d) 
model of allogeneic BMT to test the effect of inhibition of neddylation on induction and 
severity of GVHD. Recipient BALB/C animals were lethally irradiated with 8Gy on day -
1 and transplanted with 0.5 × 106 CD90.2+ T cells and 5 × 106 BM cells from either 
syngeneic BALB/C or allogeneic MHC-mismatched C57BL/6 donors on day 0. The 
recipients also received either MLN4924 (20mg/kg) or vehicle from day -1 to +3 because 
host DCs typically cannot be recovered beyond this time following allo-BMT. All of the 
syngeneic recipients survived with no signs of GVHD demonstrating absence of non-
specific toxicity by MLN4924 (Figure 2.6). The allogeneic recipients receiving only 
vehicle showed signs of severe GVHD and greater mortality than syngeneic animals 
(Figure 2.6A). By contrast, allogeneic recipients receiving MLN4924 exhibited 
 
Fig. 2.5 - T cell proliferation and Th1 lineage cytokines are decreased 
following stimulation with α-CD3 and α-CD28 functional Ab. Balb/c T cells 
were stimulated with α-CD3 and α-CD28 functional Abs in the presence or 
absence of MLN4924. After 42h incubation, 3H (1µCi/well) was added for and 
additional 6 hours followed by (A) determination of proliferating T cells. 
Supernatants were removed prior to 3H stimulation and analyzed for (B) IFNγ 
via ELISA.  
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significantly improved survival compared to vehicle control (Figure 2.6A) suggesting 
that in vivo blockade of neddylation mitigated GVHD.  
 
Because systemic administration of MLN4924 is likely to impact not just DCs but also 
several other cells, particularly donor T cells that are critical for GVHD, the reduction in 
GVHD mortality might be a reflection of its effects on these other cells in vivo. 
Therefore, in order to evaluate the effects of neddylation inhibition only on the in vivo 
function of BM-derived DCs without the confounding effects on other tissues or 
expression of target antigens, we devised a model in which allogeneic CD4+ T cells 
would respond only to MHC class II alloantigens on exogenously administered DCs in an 
acute GVHD model. MHC class II–deficient (Abb (H2-Ab1) C57BL/6 mice (H2b) 
received 10 Gy total body irradiation and were injected with 1 × 107 BMDCs from 
syngeneic WT C57BL/6 (H2b) animals that were incubated overnight with either vehicle 
 
Fig. 2.6 - Neddylation blockade regulates DC-mediated T-cell activation. 
(A) Survival of BALB/C animals lethally irradiated and transplanted with BM and 
CD90.21 T cells from either syngeneic BALB/C or allogeneic C57BL/6 donors. 
Following lethal irradiation (8 Gy) on day 1, MLN4924 (20 mg/kg) was 
administered in 5 daily doses, day 1 to day 3 relative to BMT. Data are 
combined from 2 independent experiments (n 5 10 to 12 animals in the 
allogeneic groups). (B-C) Abb animals were lethally irradiated (10 Gy) on day 1 
and WT B6 BMDC (10 3 106) pretreated with vehicle or MLN4924 overnight 
and subsequently transferred in 2 doses separated by 24 hours (day 1 and day 
0). CD90.21 T cells (2 3 106) from syngeneic WT-C57BL/6 or allogeneic bm12 
animals were transferred on day 0. Following sacrifice on day 6, spleens were 
analyzed for CD69 (B) and Tbet (C).  
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or MLN4924 in 2 doses separated by 24 h. We then injected 2 × 106 CD90.2+ T cells 
from either syngeneic C57BL/6 or allogeneic bm12 donors (see Methods and Figure 2.7), 
which differ from the recipient animals by a single MHC class II antigen. Analysis of 
donor T cells in the spleen at 6 days revealed fewer activated CD69+ (Figure 2.6B) and 
differentiated Tbet+ (Figure 2.6C) CD4+ T cells in animals that received DCs pretreated 
with MLN4924. 
 
 
Blockade of neddylation attenuates the functions of human DCs  
To determine the clinical relevance of our observations we determined whether the 
effects of inhibition of neddylation on DCs was also germane to DCs derived from 
healthy human PBMCs. Human peripheral blood monocyte-derived dendritic cells 
(moDC) were harvested and cultured with and without MLN4924 and stimulated with 
LPS. LPS induces the secretion of both TNFα and IL-6191 from moDCs, but were 
significantly reduced by MLN4924 compared to vehicle control (Figure 2.8A).  Similar 
 
Fig. 2.7 - Description of in vivo transplant scheme. Abb recipient mice, 
which lack expression of MHC II, were lethally irradiated (10 Gy) and 
transplanted with vehicle or MLN4924 treated WT B6 BMDC (10x106) in 2 
doses separated by 24 hours, on d-1 and d0. CD90.2+ T cells (2x106) were 
transferred on d0 to Abb recipients. The spleens of recipient mice were 
analyzed for T cell activation following sacrifice on day 6.  
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to the effect on murine DCs, the reduction of proinflammatory cytokines was also 
significantly greater than dexamethasone (Figure 2.8A). 
 
Next, we determined whether MLN4924 attenuated the ability of human PBMC derived 
DCs to stimulate allogeneic PBMCs. Peripheral blood mononuclear cells (PBMC) and 
moDCs were obtained from two healthy donors and cultured in an MLR at 1:1 and 10:1 
ratios in the presence or absence of MLN4924. Following culture for 96 hours and 120 
hours, a significant decrease in proliferation of PBMCs was observed in cultures 
incubated with MLN4924 (Figure 2.8B), similar to the results observed in murine cells. 
 
Fig. 2.8 – Neddylation modulates human DC function. (A) Quantification via 
ELISA of TNF-a (left) and IL-6 (right) released from human moDCs stimulated 
with LPS in the presence or absence of MLN4924 or dexamethasone at the 
indicated doses. Cells receiving treatment were preincubated with vehicle, 
MLN4924, or dexamethasone for 2 hours followed by concurrent LPS 
stimulation (0.5 mg/mL) for 4 hours. One representative experiment of 3 is 
shown of groups treated in triplicate. (B) Human PBMCs (1 3 105/well) and 
moDCs were obtained from 2 healthy donors and cocultured at 1:1 and 10:1 
ratios in an MLR in the presence or absence of MLN4924 for 96 and 120 hours.  
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Inhibition of neddylation does not increase apoptosis or alter the phenotype of DCs 
Studies have shown previously that MLN4924 reduces the viability of cancer cell lines.81 
Therefore we determined whether the observed effects of inhibition of neddylation 
through inactivation of Cul-1 E3 ligase by MLN4924 was due to reduced BMDC 
viability.  
 
Treatment of BMDCs with MLN4924 for 24 hours at the doses that reduced their 
function did not cause greater apoptosis and thus did not affect cell viability (Figure 
2.9B). We next assessed whether MLN4924 arrested the maturation of DCs as 
determined by the expression of surface co-stimulatory molecules. To determine this, we 
 
Fig. 2.9 – Inhibition of neddylation does not alter phenotype or cell 
viability in BMDC. (A) Flow cytometric analysis of cell surface phenotypic 
markers on BMDC. (B) Cell viability of BMDC cultured in the presence or 
absence of vehicle or MLN4924 for 24 hours. One representative experiment of 
three is shown. ** P<0.01  
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supplemented the culture media during BMDC generation with vehicle or MLN4924 for 
the last 24 hours and then examined cell surface expression of CD80, CD86, MHC II, 
PD-L1, and PD-L2 with flow cytometry. Addition of MLN4924 did not cause phenotypic 
changes (Figure 2.9A). These data taken together suggest that the reduction of DC 
function following treatment with MLN4924 is not due to the result of decreased cell 
viability or phenotypic change, but that these are intrinsic to inhibition of neddylation. 
 
Inhibition of SAG reduces LPS-induced cytokine production in DCs 
The inhibition of LPS-induced cytokine production by MLN4924 suggests that de-
neddylation is critical to this process by inactivation of CRL-1 E3 ligase activity. Next, to 
determine the specificity of the approach and to rule out any potential off-target effects of 
MLN4925, we utilized siRNA mediated knock-down of RBX2/SAG, a critical and 
specific component of the CRL-1 induced neddylation pathway. We next performed 
siRNA-mediated knockdown of RBX1 and RBX2/SAG alone or in combination in 
JAWSII cells. First, we confirmed the efficiency and specificity of knock-down of 
targeting SAG transcripts with siRNA as indicated by reduced levels of SAG (Figure 
2.10A). We next compared TNFα cytokine release following LPS stimulation in JAWSII 
cells transfected with the control scrambled siRNA or SAG specific siRNA. Upon LPS 
stimulation, JAWSII cells transfected with SAG siRNA exhibited a significant reduction 
in expression of TNFα compared with the scrambled siRNA (Figure 2.10B). Interestingly 
double knockdown of Rbx1 and SAG/Rbx2 had little or no effect on cytokine production, 
which could be because Rbx1 may antagonize or cause feedback inhibition of SAG 
(Rbx2). Future studies will address this issue. Nonetheless, collectively, these data 
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suggest that inhibition of neddylation through inactivation of the CRL-1 mediated either 
by siRNA knockdown of SAG or by the small molecule MLN4924, reduced 
proinflammatory cytokine release by DCs. 
 
 
Inhibition of βTrCP but not Cul-5 reduces LPS-induced cytokine expression in DCs 
Inhibition of neddylation via MLN4924 and molecular knockdown of Rbx2 results in 
global CRL inactivation. Therefore, to determine if the observed results are specific to 
CRL-1, we silenced βTrCP as well as Cul-5 using siRNA mediated knockdown in 
 
Fig. 2.10 – siRNA-mediated neddylation inhibition. (A) qPCR analysis of 
SAG expression in JAWSII cells transfected with indicated siRNA (3 mg). 
Scramble transfection performed as control. (B) qPCR analysis of TNF-a 
expression in JAWSII cells transfected with indicated siRNA and stimulated with 
LPS (0.5 mg/mL). Scramble transfection performed as control. One 
representative experiment of 3 is shown. (C-E) JAWSII cells transfected with 
siRNA for βTrCP, Cul5, or scramble as described in Materials and methods. 
Expression of βTrCP (C) and Cul5 (D) mRNA transcripts in JAWSII cells 
receiving indicated siRNA- mediated knockdown. *P < .05; **P < .01; 
***P < .0001 
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JAWSII cells. We first ensured efficient knockdown of both βTrCP (Figure 2.10C) and 
Cul-5 (Figure 2.10D). Next, we examined the expression of TNFα as a functional readout 
from the cells transfected with scramble, βTrCP, or Cul-5 and subsequently stimulated 
with LPS. A significant decrease in TNFα expression was observed in cells receiving 
knockdown of βTrCP, but not in cells with Cul-5 knockdown (Figure 2.11). These data 
suggest that the function of CRL-1 is critical for the underlying mechanism of immune 
suppression following inhibition of neddylation. 
 
 
MLN4924 inhibits translocation and activation of NF-κB  
To determine if inhibition of neddylation prevents transcriptional activity of LPS-induced 
NF-κB, we assessed p65 NF-κB translocation to the nucleus in BMDCs treated with 
MLN4924 or dexamethasone following stimulation with LPS. As anticipated, in cells 
 
Fig. 2.11 – siRNA-mediated neddylation inhibition inhibits LPS-induced 
TNF-a production. Expression of TNF-a mRNA transcripts in cells transfected 
with indicated siRNA and cultured in the presence or absence of LPS (0.5 
mg/mL) for 4 hours. *P < .05  
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cultured in the presence of vehicle and stimulated with LPS for 30 minutes, p65 NF-κB 
was present in the nuclear fraction (Figure 2.12A, top panel). Cells pretreated with 
dexamethasone 500nm and stimulated with LPS, exhibited a similar level of p65 NF-κB 
in the nuclear fraction (Figure 2.12A, top panel). However, pretreating cells with 
MLN4924 prior to LPS stimulation inhibited protein levels of p65 NF-κB in the nuclear 
fraction of BMDCs (Figure 2.12A). Interestingly, these doses of MLN4924 and 
dexamethasone both inhibited LPS-induced release and gene expression of TNFα and IL-
6 (Figure 2.2A-D). These data indicate that LPS-induced nuclear accumulation of p65 
NF-κB in BMDCs is blocked by MLN4924, but not dexamethasone suggesting that 
MLN4924 and dexamethasone have divergent molecular effects. 
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Next, to visualize and demonstrate the translocation of p65, we performed 
immunocytochemistry. BMDC cultured only with vehicle exhibited a diffuse cytoplasmic 
localization of NF-κB (Figure 2.13, top row). By contrast, BMDCs stimulated with LPS 
for 1 hour and treated with vehicle, revealed prominent NF-κB accumulation in the 
nucleus (Figure 2.13, middle row). However, LPS stimulated cells treated with 
MLN4924 showed a dispersed cytoplasmic localization of NF-κB similar to unstimulated 
 
Fig. 2.12 – Neddylation inhibition and dexamethasone differentially affect 
NF-κB translocation in BMDC. (A) Protein analysis by western blot (left) of 
p65 isoform of NF-κB protein using nuclear (N) and cytosolic (C) fractions of 
BMDC in the presence or absence of 500 nm MLN4924 or 500 nm 
dexamethasone and stimulated concurrently with LPS (0.5 mg/mL) for 30 
minutes. Plot (right) shows densitometric and statistical analysis of p65 NF-κB 
presence in the nuclear fraction and cytosolic fraction. Lamin A/C and LDH 
proteins were analyzed to demonstrate the presence of nuclear and cytosolic 
fractions, respectively. One representative experiment of 3 is shown. **P < .01  
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controls (Fig 2.13, bottom row). These complementary methods of examining NF-κB 
translocation showed prevention of translocation of NF-κB to the nuclei in BMDC treated 
with MLN4924. 
 
 
Inhibition of neddylation prevents IκB degradation in BMDC  
Previous studies have shown that IκB is a target of CRLs192. Therefore, we examined the 
effect of MLN4924 on the degradation of IκB in BMDCs when stimulated with LPS. 
Similar to previous studies in BMDCs193 and other APCs194, stimulation with LPS 
 
Fig. 2.13 – Neddylation inhibition affects NF-κB translocation in BMDC. 
Immunocytochemistry analysis of p65 NF-κB (column 3) localization in BMDC 
cultured in the presence or absence of MLN4924 and stimulated with LPS (0.5 
mg/mL) for 1 hour. Cell nuclei were stained using DAPI (column 1). Cytoplasmic 
actin was stained with phalloidin (column 2). Merged images of staining (column 
4). One representative experiment of 3 is shown.  
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resulted in the reduction of IκB protein levels within 30 minutes in vehicle treated 
BMDCs. Levels of IκB were slowly restored over a 6-hour period (Figure 2.14A left, 
middle panel).  
 
The observed decrease in IκB following LPS stimulation coincided with increased 
phosphorylation of IκB at Serine-32 and Serine-36 during the first 30 minutes of 
treatment. The increased p-IκB slowly returned to lower levels during the remaining 5 
hours of treatment (Figure 2.14A left, top panel). Treatment of BMDCs with MLN4924 
500nM inhibited any LPS-mediated decrease in IκB (Figure 21.4B left, middle panel) 
while levels of phosphorylated IκB in the same cells were elevated within 15 minutes 
following LPS treatment (Figure 2.14B left, top panel). Further, the levels of 
phosphorylated IκB remained elevated for the duration of the 6 hour treatment (Figure 
 
Fig. 2.14 – Neddylation inhibition prevents IκB degradation in BMDC. 
Protein analysis via western blot of phosphorylated IκBa protein (A-B, top 
panels) and total IκBa (A-B, middle panels) using whole cell lysate of BMDC 
stimulated with LPS (0.5 mg/mL) for 6 hours in the presence of vehicle (A) or 
500 nm MLN4924 (B). Densitometric and statistical analysis of total IκB (C, top) 
or pIκB (C, bottom) of vehicle or MLN4924-treated cells. ɑ-tubulin protein levels 
were analyzed as an equal loading control. One representative experiment of 3 
is shown. * P < 0.05 
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2.14B). Following densitometric and statistical analysis, the decrease in IκB in vehicle 
treated cells was significantly greater than MLN4924 treated cells (Figure 2.14C, top 
panel). These data indicate that inhibition of neddylation blocks the degradation of 
phosphorylated IκBSer32/Ser36 protein in BMDCs. 
 
Neddylation blockade does not perturb LPS induced activation of MAPK/ERK 
pathway 
Previous studies have shown that LPS stimulation of cells results in activation of the 
MAPK/ERK pathway193. We therefore examined whole cell lysates of BMDC stimulated 
with LPS cultured in the presence of vehicle or MLN4924. Western blot analysis showed 
that ERK protein levels were similar in vehicle treated (Figure 2.15A) and MLN4924 
treated (Fig 2.15B) cells. In addition, levels of pERK increased in a similar manner in 
both vehicle and MLN4924 treated cells (Figure 2.15A-B). These data suggest that 
MLN4924 treatment specifically reduced proinflammatory cytokines through regulation 
of NF-κB pathway without affecting MAPK/ERK pathway. 
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Fig. 2.15 – Neddylation inhibition does not perturb the MAPK/ERK 
pathway. Protein analysis via western blot of phosphorylated ERK protein (A-B, 
top panels) and total ERK (A-B, middle panels) using whole cell lysate of BMDC 
stimulated with LPS for 6 hours in the presence of vehicle (A) or 500 nm 
MLN4924 (B). Densitometric analysis of vehicle-treated cells (A, right) or 500 
nm MLN4924-treated cells (B, right) of phosphorylated ERK and total ERK 
protein. ɑ-tubulin protein levels were analyzed as an equal loading control. One 
representative experiment of 3 is shown.  
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DISCUSSION 
PTMs modulate immunity46. Proteins critical for an effective immune response, such as 
NF-κB, are known to be phosphorylated and acetylated195,196. However, the role that 
neddylation plays in regulating immune cells, such as DCs, through the translocation of 
NF-κB is not clear. Our results demonstrate a novel role for the PTM neddylation in the 
regulation of DC mediated immunity. The mechanism of neddylation characterizes a 
novel molecular target for the inhibition of secretion and transcription of certain LPS-
induced proinflammatory cytokines in dendritic cells. We show that following inhibition 
of neddylation and stimulation via TLR and NLR, release and gene expression of the 
proinflammatory cytokines TNFα and IL-6 are greatly mitigated (Figure 2.2 & 2.3). 
 
Studies have previously shown the ability of MLN4924 to suppress the growth of tumor 
cell lines as well as primary human AML cells79,80,186. Inhibition of NEDD8 pathway by 
MLN4924 has been reported to result in apoptosis75,197. However, our data suggests that 
MLN4924 did not affect BMDC viability (Figure 2.9B) demonstrating that the reduction 
in the production of proinflammatory cytokines was not due to loss of cells, but a 
functional consequence of inhibition of neddylation. Our data also suggest that treatment 
with MLN4924 had significantly greater impact on suppression of the release of 
proinflammatory cytokines than dexamethasone or bortezomib (Figures 2.1 to 2.3) in the 
nanomolar dose range. Moreover inhibition of neddylation with MLN4924 reduced DC 
functions in vivo and attenuated GVHD (Figure 2.6) suggesting that this pathway could 
be targeted to mitigate in vivo inflammatory diseases.  
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Mechanistic studies have uncovered a distinct molecular pathway for MLN4924 
mediated suppression of DC functions when compared with dexamethasone. The primary 
molecular target of dexamethasone is the glucocorticoid receptor (GR)198. Binding of 
steroid results in activation of the receptor and subsequent translocation to the nucleus199 
and is known to interact with transcription factors such as NF-κB and AP-1200. These 
interactions repress the expression of genes coding a number of cytokines that play key 
roles in the immune and inflammatory systems. By contrast MLN4924 specifically 
targets NEDD8 activating enzyme (NAE), a heterodimer of NAE1 and UBA3 subunits75. 
By doing so, MLN4924 inactivates CRLs and impedes the ubiquitination rate of the 
subset of proteins whose degradation is dependent on CRLs75. 
Although dexamethasone significantly inhibited secretion of TNFα and IL-6, which are 
known to be regulated by NF-κB178, it did not directly prevent the translocation of NF-κB 
to the nucleus after LPS stimulation (Figure 2.12), in contrast to MLN4924. The ability 
of MLN4924 to directly prevent the degradation of IκB in LPS stimulated cells (Figure 
2.14B) suggests a specific and distinct mechanism from that of dexamethasone. The role 
of inhibiting neddylation by MLN4924 in suppressing the release of TNFα and IL-6 
through the inactivation of CRL-1 causing IκBα accumulation and subsequent prevention 
of NF-κB activation, is further supported by molecular inactivation of CRL-1 by the 
siRNA knockdown of SAG and βTrCP (Figure 2.10). These data together suggest that 
MLN4924 and dexamethasone block LPS-induced cytokine release through distinct 
mechanisms. 
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Our study is in agreement with previous reports in cell lines demonstrating an effect on 
NF-κB activation201. We extend those observations for the first time in primary cells, 
DCs and their functional immune responses. More importantly we show a similar effect 
on primary human dendritic cells. Furthermore, we uncover the molecular mechanism 
that is dependent on IκB degradation but independent of MAPK/ERK pathway (Figure 
2.14 and 2.15) and show that it is germane to both canonical and non-canonical NF-κB 
signaling mediated release of proinflammatory cytokines. Other studies have shown that 
degradation of IκB and release of proinflammatory cytokines can be altered by 
proteasome inhibitors202. However, these proteasome inhibitors also activate the 
transcription factor AP-1 which is known to contribute to LPS induced cytokines193. Our 
results show that upon treatment of LPS-stimulated BMDC with MLN4924, the 
MAPK/ERK pathway is unperturbed (Figure 2.15) suggesting that AP-1 activity is 
unaltered by inhibition of neddylation. This is likely due to the degradation of IRAK1 
through its association with the E3 ligases TRAF6 and Pellino203. Previous studies have 
shown that Pellino, not CRL, is a likely candidate to serve as the degradation scaffold for 
IRAK1204. Thus inhibition of the neddylation pathway may be a more specific approach 
of inhibiting the degradation of IκB and thereby blocking the increase in proinflammatory 
cytokines as compared to the effects seen by proteasome inhibitors. 
 
Promising preclinical results led to the advancement of MLN4924 to Phase 1 clinical 
trials for both non-hematological and hematological cancers205,206. However, MLN4924s 
immune-modulatory effects have heretofore been largely unrecognized. Our results 
suggest that, at non-cytotoxic doses, drugs such as MLN4924 that specifically target 
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neddylation, may provide novel therapeutic strategies for diseases associated with 
deregulated immune responses such as GVHD, chronic inflammatory disease, shock, 
autoimmunity and allo-transplantation81,92,173-175. 
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MATERIALS AND METHODS 
Cell isolation and cultures: Briefly, bone marrow cells were flushed from the femurs of 
8- to 12-week-old female C57BL/6 mice and cultured in 150 x 15-mm CytoOne petri 
dishes (USA Scientific, Ocala, FL) at 1x107 in 20ml of RPMI supplemented with 10% 
FCS, 4mM L-glutamine, 10 U/ml penicillin, 100 µg/ml streptomycin, 0.5 mM 2-ME, 
20ng/ml GM-CSF. On day 4, 20ml of fresh complete RPMI containing 20ng/ml GM-
CSF was added to each culture. After 7 days of culture, the loosely adherent cells were 
harvested and purified using anti-CD11c magnetic microbeads (Miltenyi Biotec Ltd., 
Auburn, CA) and the autoMACS (Miltenyi Biotec). 
Human peripheral blood mononuclear cells (PBMCs) were isolated from the blood of 
healthy donor volunteers. PBMCs were isolated according to a protocol obtained from 
Current Protocols in Immunology. Briefly, whole heparinized blood was centrifuged 
(2000 rpm, 20ºC, 30 min) using a Ficoll Hypaque density gradient. The mononuclear 
layer was removed from the gradient and washed in complete RPMI and used as either 
responders in human MLR or monocytes were cultured at 1x106 cells/ml in complete 
RPMI containing 800 U/ml human recombinant GM-CSF and 500 U/ml human 
recombinant IL-4. On day 5, fresh complete RPMI containing 100 U/ml TNF-α as well as 
800 U/ml human recombinant GM-CSF and 500 U/ml human recombinant IL-4 was 
added to the culture. Cells were harvested on day 9 to 10 of incubation. All human 
recombinant cytokines were purchased from Peprotech (Rocky Hill, NJ). 
The DC cell line, JAWSII, was established from bone marrow cells of a p53-knockout 
C57BL/6 mouse, and was purchased from the American Type Culture Collection (CRL-
11904; ATCC, Manassas, VA). Cells were grown in a CO2 incubator at 37ºC and 5% 
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CO2 in complete culture medium consisting of α-MEM with 10% FCS, 4mM L-
glutamine, 10U/ml penicillin and 100µg/ml streptomycin, 0.5mM 2-ME, 1mM sodium 
pyruvate, and 5ng/ml murine GM-CSF. Cultures were maintained by transferring 
nonadherent cells to a centrifuge tube and treating attached cells with 0.25% trypsin-
0.03% EDTA (Gibco) at 37ºC for 5 min after rinsing culture flask with pre-warmed PBS. 
The two populations were pooled together, washed once (1000rpm, 10min) and 
distributed into new culture flasks 
Cytokine Detection: Isolated BMDC and human moDCs were seeded on 60mm culture 
dishes at 3x106 cells/well and a 24-well plate at 2x105 cells/well, respectively. Pretreated 
cells were cultured with DMSO (Sigma), MLN4924 (Active Biochem), dexamethasone 
(APP Pharmaceuticals), or bortezomib (Fisher Scientific) at the indicated dosages for 2 
hours. Cells were then stimulated with E. coli-derived LPS (Invivogen), synthetic 
Pam3CSK4 (Invivogen), PGN (Invivogen), or CD40L (Shenandoah Biotechnology) at 
the indicated concentrations for a concurrent 4 hours. Supernatants were subsequently 
collected and stored at -20ºC until analysis. TNFα and IL-6 ELISA kits (mouse and 
human) were purchased from R&D Systems and performed as per the manufacturers’ 
instructions and read at 450nm by a SpectraMax microplate reader (Molecular Devices, 
Sunnyvale, CA). 
Quantitative PCR: Using 1µg of each RNA template, cDNA was synthesized using 
SuperScript VILO (Invitrogen; Carlsbad, CA). qPCR primers for murine GAPDH 
(Forward: CCACAGTCCATGCCATCACTGC; Reverse: 
GCCCAAGATGCCCTTCAGTGGG), TNF   (Forward: 
CGACGTGGAGGCAGAAGAGGC; Reverse: CGTGGGCTACAGGCTTGTCACTC), 
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IL-6 (Forward: CGGAGAGGAGACTTCACAGAGG; Reverse: 
GCAAATTTCCTGATTATATCCAG), Rbx2 (Forward: 
GGACGTTGAGTGCGATACCT; Reverse: TGCCGATTCTTTGGACTACC), βTrCP 
(Forward: TCTGCACCTGCGCTTCAATA; Reverse: 
GAGGGTGATGTCAGTTGGGG), or Cul-5 (Forward: 
CAACGGAACTCCCAGATGCT; Reverse: GCTGCAAGCGTCCAATCAAA).  
Flow Cytometry: To analyze DC surface phenotype, DCs were incubated in the 
presence or absence of MLN4924 or the vehicle (DMSO, Sigma). Cells were then 
harvested and stained with CD11c-conjugated APC (Clone: N418) and one of the 
following per triplicate group: Annexin V (BD Biosciences), CD80 (Clone: 16-10A1), 
CD86 (Clone: GL-1), MHCII-I-Ab (Clone: AF6-120.1), PD-L1 (Clone: MIH5), PD-L2 
(Clone: TY25). All flow cytometry Abs were purchased from eBiosciences. Stained cells 
were then analyzed with an Accuri C6 Flow Cytometer (BD Biosciences). 
Western Blot and Subcellular Fractionation: BMDCs were seeded in 60mm dishes 
with 3x106 cells per dish. Pretreated cells were cultured with DMSO (Sigma), MLN4924 
(Active Biochem), or dexamethasone (APP Pharmaceuticals) at the indicated dosages for 
2 hours followed by concurrent stimulation with E. coli-derived LPS (100ng) for an 
additional 4 hours. Following treatment and stimulation, whole cell lysates where 
obtained and protein concentrations determined with Pierce BCA Protein Assay (Thermo 
Scientific). Equal amounts of protein were separated by SDS-PAGE gel (120V, 1.5h) and 
subsequently transferred to nitrocellulose membrane (20V, 1h). The following antibodies 
were used to analyze the membranes: Nedd8 (19E3), α-tubulin (11H10), NF-!B p65 
(D14E12), Lamin A/C (4C11), pIκBα (5A5), IκBα (L35A5), pERK (D13.14.4E), ERK 
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(137F5) were purchased from Cell Signaling (Danvers, MA). Cullin1 (EPR3103Y) and 
LDH (EP1566Y) were purchased from abcam (Cambridge, MA). Secondary antibodies 
conjugated to HRP (Jackson ImmunoResearch) were used to detect primary antibodies. 
Densitometric analysis performed by ImageJ software. Subcellular fractionation was 
performed on 3x106 BMDC seeded in 60mm dishes. Cells were pretreated in the presence 
or absence of vehicle, MLN4924, or dexamethasone for 2 hours followed by concurrent 
LPS stimulation for 30 minutes. The cytoplasmic and nuclear fractions were isolated 
using the Nuclear Extract Kit (Active Motif) per the manufacturers instructions. The 
extracts where then analyzed via western blot.  
Mixed Lymphoctye Reaction (MLR): Splenic T cells (2x105/well) were magnetically 
separated from WT-B6 or WT-BALB/c mice by autoMACS using CD90.2 microbeads 
and subsequently cultured with irradiated (30 Gy) WT-B6 DC at 40:1 (5x103/well) and 
100:1 (2x103/well) for 72 hours and 96 hours. Human MLRs were performed by co-
culture of PBMCs (1x105/well) and moDCs at 1:1(1x105) and 10:1 (1x104) ratios for 96 
hours and 120 hours. Incorporation of 3H-thymidine (1µCi/well) by proliferating T cells 
or PBMCs during the final 6 hours of culture was measured by a TopCount 
(PerkinElmer). 
Molecular Knockdown: JAWSII cells were seeded into a 24-well plate (2.5x105/well) 
overnight at 37ºC. Cells were transfected with siRNA (3µg) using Oligofectamine 
Reagent (Invitrogen) as per the manufacturers instructions. Cells were incubated with 
transfection medium and siRNA for 24 hours before stimulation with LPS for 4 hours. 
RNA was extracted from cell pellets using RNeasy Mini Kit (Qiagen) and analyzed via 
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qPCR. Rbx1, Rbx2, βTrCP, and Cul-5 siRNA were obtained from Ambion (Carlsbad, 
CA) 
Confocal Microscopy: BMDC were seeded onto Corning glass cover slips (1x105 
cells/slip) (Fisher Scientific) overnight at 37ºC. Pretreated cells were cultured with 
DMSO (Sigma) or MLN4924 (Active Biochem) at the indicated dosages for 2 hours 
followed by concurrent stimulation with E. coli-derived LPS for an additional 1 hour. 
Cover slips were then washed, fixed with 4% paraformaldehyde for 20 minutes, and 
subsequently permeabilized with 0.3% Triton X. Cells were stained with NF-!B p65 
(D14E12) primary (1:500) and Alexa Fluor 488 (Molecular Probes) secondary (1:1000), 
DAPI (Invitrogen), and Alexa Fluor 555 Phalloidin (1:500). Coverslips were then 
mounted using ProLong Gold Antifade Reagent (Molecular Probes) and Z-stack images 
were acquired at room temperature using a Nikon A-1 confocal microscope (Mellville, 
NY) using an oil immersion 60X objective with a numerical aperture = 1.4 and imported 
into NIS-Elements Software (Nikon). Excitation lasers 405nm, 488nm, and 561nm were 
used. Microscope laser exposure and settings were obtained using appropriate isotype 
controls and were retained for each experimental group. 
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CHAPTER III 
 
SAG/RBX2 E3 UBIQUITIN LIGASE DIFFERENTIALLY REGULATES  
INFLAMMATORY RESPONSES OF MYELOID CELL SUBSETS 
 
 
ABSTRACT 
 
Macrophages form an important component of the innate immune system and serve as 
first responders against invading pathogens. While pathways critical for initiation of 
inflammatory responses between macrophages and other LysM+ myeloid cells are largely 
similar, it remains unknown whether a specific pathway has differential effects on 
inflammatory responses mediated between these cells. Sensitive to apoptosis gene (SAG) 
protein has E3 ligase and antioxidant activities. Recent studies demonstrated that SAG 
negatively regulates in vitro inflammatory responses generated by macrophages and 
dendritic cells in response to LPS. However, the in vivo role of SAG on modulation of 
macrophages is not known. We generated novel LysM-Cre/Sagfl/fl mice and observed that 
in contrast to in vitro observations, they showed greater levels of proinflammatory 
cytokines and enhanced mortality in response to LPS. Although Sag-/- macrophages 
released less proinflammatory cytokines, Sag-/- neutrophils exhibited increased 
proinflammatory cytokines suggesting Sag plays a differential role in these cells.
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INTRODUCTION 
The innate immune system consists of several cell types and is the first line of defense in 
the host, functioning as a barrier to infection from invading organisms207. Macrophages 
and neutrophils –two cell types of the innate immune system– derive from the myeloid 
progenitor lineage that are critical for the initiation of inflammation in the context of 
antimicrobial immunity208. Innate immune cells recognize and bind to pathogen 
associated molecular patterns (PAMPs) of pathogens via pattern recognition receptors 
(PRRs). Toll-like receptors (TLRs), a type of PRR, regardless of the innate immune cells 
that express them, utilize similar signal pathways that lead to the activation of the nuclear 
factor-kappa B (NF-κB) pathway178 and initiates the release of proinflammatory 
cytokines209,210. These mutual and complementary features of innate immune cells likely 
favor their interaction and cooperation in generating complimentary innate immune 
responses208. However, whether there are differences in the mechanisms through which 
specific innate immune cells are activated in response to infection remains unknown. In 
this context, specifically, whether the critical LysM-enzyme expressing innate immune 
cells – namely macrophages and neutrophils – utilize the same pathway to produce 
differential inflammatory responses is not known. 
 
SAG –also known as RING box protein 2 (RBX2), Regulator of Cullins 2 
(ROC2), or RING Finger Protein 7 (RNF7)– was originally cloned by differential display 
in our laboratory as a redox-inducible antioxidant protein which scavenges ROS by 
forming intra- and inter- molecular disulfide bonds69,70. As a member of the SCF E3 
ubiquitin ligase complex, SAG binds to ubiquitin-loaded E2 and catalyzes the ubiquitin 
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transfer from the E2 molecule to a substrate for subsequent degradation by the 
proteasome. By promoting the degradation of a variety of substrates through its ligase 
activity, SAG regulates diverse signaling pathways and biological processes, including 
cell apoptosis, embryonic development, vasculogenesis, angiogenesis, and 
tumorigenesis211. This degradative process is known as neddylation and is responsible for 
the regulation of several cellular pathways. SAG was previously reported to maintain 
macrophage survival and to regulate the levels of inflammatory cytokines in response to 
infection by ubiquitinating the pro-apoptotic proteins Bax and SARM201,212. Further, 
inhibitor-κB (IκBα), a classical inhibitor of NF-κB activation, is a direct substrate of the 
SAG-SCFβ-TrCP E3 ubiquitin ligase213 
It is well known that the activation and translocation of NF-κB to the nucleus is 
responsible for the transcription of the proinflammatory cytokines tumor necrosis factor-
alpha (TNFα) and interleukin-6 (IL-6)214,215. The accumulation of IκB upon SAG 
disruption leads to the inhibition of NF-κB activation and thus decreases inflammatory 
responses by dendritic cells (DCs) in vitro50,213. Thus, inhibition of SAG may regulate the 
innate immune response of macrophages in a similar manner as in DCs50. LysM+ cells 
(i.e. macrophages and neutrophils) are keys to the in vivo inflammatory response. In light 
of the regulation of NF-κB by SAG, we tested the hypothesis that Sag deficient LysM+ 
cells would release less proinflammatory cytokines in response to LPS and mitigate LPS 
induced mortality. Surprisingly, we found that loss of Sag protein in these cells resulted 
in a net increase in proinflammatory cytokines and furthermore increased LPS-induced 
mortality. Mechanistic studies showed that disruption of Sag in macrophages, consistent 
with previous reports212, reduced the release of inflammatory cytokines by preventing the 
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degradation of IκBα and thus inhibiting subsequent NF-κB activation. By contrast, Sag 
deficiency in neutrophils up-regulated the release of inflammatory cytokines and ROS 
that likely contributed to the net increase in systemic levels of proinflammatory cytokines 
and increased LPS-induced mortality in response to LPS in vivo. Together, these findings 
suggest that the same molecular pathway – namely Sag – plays a differential role in the 
activation of macrophages and neutrophils.  
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RESULTS 
Characterization of LysM-Cre/Sagfl/fl mice 
To determine the role of SAG in the innate inflammatory response – specifically 
macrophages – we crossed Sagfl/fl mice with LysM-Cre transgenic mice, which express 
Cre recombinase in myeloid cells216. Inactivation of Sag was verified in macrophages of 
the peritoneal cavity by RT-PCR analysis (Fig. 3.1).  
 
The mRNA levels of Sag were significantly decreased in resident peritoneal macrophages 
from LysM-Cre+/Sagfl/fl (KO) mice compared to LysM-Cre-/Sagfl/fl (WT) mice. To 
determine whether hematopoietic deficiency of Sag in LysM+ cells affects their 
development and/or other cells, we performed serial complete blood count (CBC) 
analysis of mice at 4 and 12 weeks of age. Sag-deficiency in the myeloid lineage had no 
significant effect on the total cell numbers of white blood cells, neutrophils, lymphocytes, 
monocytes, eosinophils, basophils, red blood cells, and platelets in the peripheral blood 
(Table 3.1).  
 
Fig. 3.1 – Characterization of LysM-Cre/Sagfl/fl mice. Sag expression is 
significantly decreased in peritoneal macrophages from LysM-Cre/Sagfl/fl mice. 
Residential peritoneal macrophages were flushed from LysM-Cre-/Sagfl/fl wild 
type (WT) and LysM-Cre+/Sagfl/fl knockout (KO) mice, and then subjected to 
mRNA extraction, followed by RT-PCR. 
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Next, we determined whether deficiency of Sag affected the phenotype of macrophages 
by performing immunophenotypical analysis of macrophages isolated from the spleen, 
bone marrow, and peripheral lymph nodes. No differences were observed between WT 
and KO animals in either absolute numbers of macrophages (CD11b+&F4/80+) or 
expression of co-stimulatory molecules (MHCII, CD80, CD86, CD40, PD-L1, PD-L2) 
(Table 3.2). These data indicate that targeted deletion of Sag in the myeloid lineage does 
not result in altered development, total numbers, or phenotype of these cells. 
 
Table 3.1 – Mouse complete blood count (CBC).  
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The in vivo responses of Sag-deficiency in myeloid lineage to LPS  
Previous studies have shown that SAG knockdown in macrophages results in decreased 
release of inflammatory cytokines upon LPS challenge50,212. Therefore we next tested the 
hypothesis whether in vivo LPS stimulation would result in decreased proinflammatory 
cytokines and decreased mortality in KO animals. We injected intraperitoneally (i.p) WT 
and KO mice with a lethal dose of LPS (25 mg/kg). To our surprise, the survival study 
demonstrated significantly increased mortality in KO mice with Sag deficient myeloid 
cells (Fig. 3.2).  
 
Table 3.2 – Mouse naïve phenotype.  
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We next measured LPS-induced production of proinflammatory cytokines and observed 
that the levels of TNFα and IL-6 in the sera of KO mice were significantly higher than 
those of WT mice 18 hours post LPS injection (Fig. 3.3A-B). These surprising data 
suggested that mice with LysM Sag deficiency were hypersensitive to LPS.  
 
 
 
Fig. 3.2 – LysM-Cre+/Sagfl/fl (KO) mice exhibit increased mortality to LPS 
injection. WT and KO mice were injected i.p. with LPS (25 mg/kg body weight), 
and their survival was monitored and plotted every 12 hours up to 72 hours. 
n=23 for WT or KO group. p=0.0006, log-rank test. 
 
Fig. 3.3 – LysM-Cre+/Sagfl/fl (KO) mice exhibit increased LPS-induced 
proinflammatory cytokines in the sera. TNFα and (D) IL-6 in the cardiac sera 
of mice 18 hours after LPS injection; measured by ELISA. * P < 0.05; 
** P < 0.01 
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The in vitro responses of Sag-deficient macrophages to LPS  
Previous studies have demonstrated that SAG regulates other innate immune cell 
responses, such as DCs50 and macrophages during infection212. We next analyzed the 
response of Sag-deficient peritoneal macrophages stimulated with LPS. We observed that 
the release of the proinflammatory cytokines TNFα and IL-6 were significantly reduced 
by Sag-deficient macrophages (Fig. 3.4A-B) with a similar decrease in mRNA transcripts 
for TNFα and IL-6 (Fig. 3.4C-D) from these cells. 
 
 
Studies have shown that inactivation of SAG reduces the viability of tumor 
cells71. However, primary bone marrow derived DCs do not exhibit increased apoptosis 
 
Fig. 3.4 – Sag-deficient macrophages release less TNFɑ and IL-6 in vitro. 
(A-D) Reduced production of proinflammatory cytokines in thioglycollate-elicited 
peritoneal macrophages from LysM-cre/Sagfl/fl mice. Cells were left unstimulated 
or stimulated with 100 ng/ml LPS for 24 hours. TNFα and IL-6 protein 
concentrations were measured in cell culture supernatants by (A&B) ELISA and 
(C&D) mRNA transcript in cells by qPCR.* P < 0.05; ** P < 0.01 
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upon inhibition of SAG E3 ligase complex50 suggesting that inactivation of SAG in 
healthy, non-cancerous cells may not affect cell survival. Thus, we next tested whether 
primary WT and Sag-deficient macrophages stimulated with LPS resulted in altered cell 
viability. Once again, we observed no difference between WT and Sag-deficient 
peritoneal macrophages (Fig. 3.5A). 
 
To ensure that the results observed were not specific to macrophages isolated 
from a particular compartment, we next examined bone marrow derived macrophages 
(BMDMs). Consistent with our results from peritoneal macrophages, no significant 
 
Fig. 3.5 – Sag-deficient macrophage viability and BMDM function. (A&B) 
Sag deficiency has no effect on the (A) apoptosis (Annexin V/PI) of peritoneal 
macrophages or (B) viability of BMDMs in response to LPS. BMDMs derived 
from LysM-cre/Sagfl/fl mice were treated with 100 ng/ml LPS for 72 hours. The 
viability of BMDMs treated with various concentrations of LPS for 72 hours in 
triplicates were normalized to untreated cells and shown as mean ± SEM (n=2) 
(B). (C&D) Reduced production of proinflammatory cytokines in BMDMs 
derived from LysM-cre/Sagfl/fl mice. BMDMs were stimulated with 100 ng/ml 
LPS for 6 and 12 hours. (C) TNFα and (D) IL-6 release were measured in cell 
culture supernatants by ELISA. * p<0.05; ** p<0.01; *** p<0.001. 
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differences in viability of BMDMs from WT or KO mice were observed (Fig. 3.5B). 
Further, the release of TNFα and IL-6 cytokines by BMDMs in response to LPS 
stimulation over a total time period of 12 hours was significantly reduced in the absence 
of Sag (Fig. 3.5C-D). These data together suggest that Sag deficiency in macrophages 
significantly impairs LPS-induced release of proinflammatory cytokines, but had no 
significant effect on the viability of macrophages. 
 
Sag deficient macrophages release less cytokines in vivo 
To further explore why KO mice were hypersensitive to LPS, we next measured LPS-
induced production of proinflammatory cytokines in vivo. We injected LPS i.p. 
(25mg/kg) as before and analyzed macrophages of the peritoneum and spleen by flow 
cytometry 18 hours later.  
 
However, although the total numbers of macrophages were comparable between WT and 
KO mice (Table 3.3), the total number of macrophages isolated from the peritoneum and 
spleen that were producing TNFα and IL-6 were significantly lower (Fig. 3.6A-D) in KO 
animals, compared to WT. Taken together, these data suggest that in the absence of Sag 
in myeloid cells mice show increased LPS-induced mortality and increased 
proinflammatory cytokines in the sera, but the increases were not due to increased 
cytokine release from macrophages. Thus, these data indicated that the increase in 
 
Table 3.3 – Elicited macrophages.  
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proinflammatory cytokines contributing to mortality might be from another type of 
myeloid cell capable of responding to LPS and secreting increased proinflammatory 
cytokines. 
 
 
Impact of Sag deficiency in macrophages: IκB accumulation 
We next pursued the mechanism by which Sag deletion causes reduction of 
proinflammatory cytokines with focus on IκBα/NF-κB, since our previous studies have 
shown that IκBα is a direct substrate of SAG E3 ligase213,and SAG disruption prevents 
the activation and translocation of NF-κB, which contributes to decreased inflammatory 
cytokines from DCs and to the increased radiosensitivity observed in Sag-null murine 
 
Fig. 3.6 – Sag-deficient macrophages release less cytokines in vivo. LysM-
cre/Sagfl/fl (KO) and Sagfl/fl (WT) mice were i.p. injected with PBS or LPS (25 
mg/kg body weight). The cells and the blood samples were harvested 18 hours 
post injection. The total numbers of macrophages producing (A&C) TNFα and 
(B&D) IL-6 in the (A-B) peritoneal cavity and (C-D) spleen were determined by 
flow cytometry. N=4 for PBS elicited; N=6 for LPS elicited. * p<0.05; ** p<0.01; 
*** p<0.001. 
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embryonic stem cells50,213. Upon stimulation of a cell by TLR4, IκBɑ is phosphorylated 
and degraded as a direct substrate of SAG- SCFβ-TrCP E3 ubiquitin ligase. To determine if 
IκBα and NF-κB play a similar role in macrophages as was previously shown in dendritic 
cells50, we examined the protein levels of phosphorylated and total IκB in macrophages 
and found that LPS stimulation resulted in accumulation of phosphorylated IκBα as well 
as total IκBα in Sag-deficient macrophages (Fig. 3.7), indicating that the degradation of 
IκB was impaired in the absence of Sag.  
 
 
Fig. 3.7 – IκB accumulation in Sag-deficient macrophages. BMDMs derived 
from bone marrow cells from WT (n=4) and KO (n=4) mice were pooled by 
group and stimulated with 100 ng/ml LPS for indicated time periods, followed by 
immunoblot with indicated Abs. Densitometric analysis is shown on the right of 
blots after normalization with α-tubulin. 
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Consistent with this notion, we found that nuclear translocation of p65 NF-κB to 
the nucleus was significantly reduced in Sag-deficient macrophages compared to Sag-
competent WT controls (Fig. 3.8). 
 
 
Fig. 3.8 – NF-κB translocation is inhibited in Sag-deficient macrophages. 
Western blot analysis of p65 isoform of NF-κB protein using nuclear [N] and 
cytosolic [C] fractions of peritoneal WT and KO macrophages, stimulated 
concurrently with LPS (100 ng/ml) for 1 hour. Plot on the right of blots shows 
densitometric analysis of p65 level in the nuclear fraction vs. cytosolic fraction. 
Parp and Procaspase-3 serve as biomarkers of nuclear and cytoplasmic 
fractions, respectively. 
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These data suggest that similar to the effects seen in DCs, Sag disruption affects LPS-
induced IκBα degradation, which inhibits NF-κB activation in macrophages, leading to 
reduced levels of proinflammatory cytokines, such as TNFα and IL-6. 
 
Sag deficiency increases proinflammatory responses by neutrophils 
Similar to macrophages, neutrophils are myeloid lineage cells, which also express LysM. 
Thus, to determine the origin of increased LPS-induced cytokine production in the sera of 
mice with Sag deficient myeloid lineage cells, we next analyzed the response of 
neutrophils (CD11b+ & Gr-1+) to LPS stimulation. We stimulated whole splenocyte 
cultures with LPS for 6 hours and 18 hours and observed a significant increase in Sag-
deficient CD11b+ Gr-1+-neutrophils producing TNFα (Fig. 3.9A-B). 
 
As NF-κB is the transcription factor for TNFɑ, we next examined the 
translocation of NF-κB from the cytoplasm to the nucleus in neutrophils. In contrast to 
the results seen in macrophages (Fig. 4B), we did not see a difference in the translocation 
 
Fig. 3.9 – Sag-deficient neutrophils release less TNFɑ and IL-6 in response 
to LPS. Increased TNFα and ROS production in Sag-deficient neutrophils in 
response to LPS. Splenocytes from LysM-Cre-/Sagfl/fl (WT) and LysM-
Cre+/Sagfl/fl (KO) mice (n=5 for each genotype) were stimulated with LPS (100 
ng/ml) and TNFα production was analyzed by flow cytometry (A) 6 hours and 
(B) 18 hours following stimulation. ** P < 0.01; *** P < 0.001 
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of NF-κB in neutrophils (Fig. 3.10). These data suggested that Sag deficiency had a 
differential role in neutrophils as compared with macrophages. 
 
We next explored why Sag deficiency in neutrophils causes an increase in TNFα 
release in contrast to what was observed in macrophages. Given that neutrophils are 
 
Fig. 3.10 – NF-κB translocation is not inhibited in Sag-deficient 
neutrophils. Protein analysis by western blot of p65 isoform of NF-κB protein 
using nuclear [N] and cytosolic [C] fractions of peritoneal WT and KO 
neutrophils, stimulated concurrently with LPS (100 ng/ml) for 1 hour.  Plot at 
right of blots shows densitometric analysis of p65 NF-κB presence in the 
nuclear fraction and cytosolic fraction. Parp and Procaspase-3 serve as 
biomarkers of nuclear and cytoplasmic fractions, respectively. 
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mediators of ROS217 and SAG is known to be an ROS scavenger69,70, we tested the 
hypothesis that increased cytokine release from neutrophils might be due to increased 
ROS in these cells upon Sag deletion. We harvested and stimulated splenocytes with LPS 
(100ng/ml) from WT and KO mice and gated for ROS in neutrophils. We observed a 
significant increase in the production of ROS in neutrophils of KO mice, although the 
basal level of ROS was relatively lower (Fig. 3.11A-B). To determine the mechanism by 
which the ROS level could be induced to a higher degree in Sag-deficient neutrophils, we 
focused on NRF2, an antioxidant transcription factor, which is induced by ROS218,219.  
We stimulated whole splenocyte cultures with hydrogen peroxide (H2O2) and examined 
the percentage of neutrophils expressing NRF2. Following H2O2 stimulation for 3 hrs, we 
observed significantly less NRF2-positive neutrophils in Sag-deficient mice (Fig. 3.11C). 
 
These data together suggest that increased ROS levels in Sag-deficient neutrophils in 
response to stimuli is likely due to lack of Sag-mediated ROS scavenging and reduced 
NRF2 expression with subsequent reduced production of other antioxidants.   
 
Fig. 3.11 – Sag-deficient neutrophils exhibit increased ROS and decrease 
NRF2 transcription factor. (A-B) ROS production upon stimulation with LPS: 
(A) Baseline ROS levels and (B) LPS stimulated levels (100 ng/ml for 1 hour) of 
ROS in WT and KO mice (n=5). (C) Percentage of Nrf2 positive cells in WT and 
KO mice (n=5) analyzed by flow cytometry after 3 hours of stimulation with 
hydrogen peroxide (H2O2). 
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We next ensured that cells that did not express LysM enzyme were unaffected. We, 
therefore, stimulated WT and KO bone marrow derived DCs (BMDCs) with LPS and 
examined the production of TNFɑ and IL-6, and found no difference in either the release 
of TNFa (Fig. 3.12A) and IL-6 (Fig. 3.12B) or in the mRNA expression of these 
proinflammatory cytokines (Fig. 3.12C-D). These data indeed suggested that Sag 
deficiency in LysM+ cells did not affect non-LysM expressing cells. 
 
 
Fig. 3.12 – The function of BMDC from SAG-deficient mice are not 
different from SAG-competent mice. (A) TNFɑ (B) and IL-6 cytokines and (C-
D) corresponding mRNA expression released by bone marrow derived dendritic 
cells (BMDCs) stimulated with LPS (100ng/ml) for 6 hours. * p<0.05; ** p<0.01; 
*** p<0.001. 
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DISCUSSION 
Our data has shown that Sag deficiency in LysM+ mice has no effect on the total 
CBC including myeloid cells of the innate immune system, specifically macrophages and 
PMNs (Table 3.1). However, although the cell number in myeloid lineage was unaltered 
upon Sag deletion, a significant LPS-induced increase in proinflammatory cytokines in 
the sera as well as an increase in mortality were observed in KO mice. Macrophages and 
neutrophils are the first cells of the innate immune system to respond to pathogenic insult 
to the host. Both cell types are known to release proinflammatory cytokines in response 
to PRR ligation, but whether disparate mechanisms exist of inducing inflammatory 
cytokines, remains unknown. Thus, we explored cell-specific responses to LPS and found 
that Sag deficient macrophages release less proinflammatory cytokines with a 
concomitant decrease in IκB degradation and subsequent decrease NF-κB translocation to 
the nucleus, when compared to WT controls. Further, there was no alteration in the KO 
cells viability, similar to our previous examination of DCs50. Despite the decreased 
release of LPS induced proinflammatory cytokines by macrophages both in vitro and in 
vivo, mice with Sag deficient myeloid cells intriguingly exhibited an increased mortality 
rate in response to LPS injection i.p. Hence, we next examined the response of 
neutrophils to LPS stimulation and found a surprising increase in release of TNFα and a 
concurrent increase in ROS with a corresponding decrease in NRF2 transcription factor, 
responsible for the transcription of antioxidant molecules. 
The reasons for the differential response to Sag deficiency in macrophages and 
neutrophils are unclear at the present time. We posit that these responses are likely due to 
differences in cell context in which different Sag substrates are targeted for degradation 
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in cell-type dependent manner. Indeed, the degradation of IκB is inhibited in 
macrophages and dendritic cells50, but this inhibition is not seen in neutrophils upon Sag 
deletion. 
Innate immune signaling is poorly understood. Our finding that Sag protein plays 
a differential role in macrophages and neutrophils is significant and novel as it is the first 
demonstration that Sag function can be determined by targeting – or not targeting – IκBα 
in two types of critical cells of the innate immune system. This observation is consistent 
with our recent finding that Sag plays a tissue specific role during Kras-triggered 
tumorigenesis, in which Sag functions as a Kras-cooperator in the lung220, or Kras-
antagonist in the skin221.  Furthermore, Sag deletion in keratinocytes results in NRF2 
accumulation 221, whereas deletion of Sag in neutrophils causes NRF2 reduction (Fig. 
3.11C).  Future studies will be directed to further dissect the underlying mechanism. 
 
In summary, our findings demonstrate that Sag protein differentially regulates 
inflammatory responses of myeloid cell subsets. In macrophages, disruption of Sag 
reduces the release of inflammatory cytokines by preventing the degradation of IκBɑ, 
which blocks translocation of NF-κB to the nucleus (Fig. 3.13). 
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In neutrophils, disruption of Sag increases the release of inflammatory cytokines by 
increased ROS production, thus contributing to increased mortality in vivo in response to 
LPS (Fig. 3.13). 
  
 
Fig. 3.13 – Model of mechanism. Disruption of Sag in macrophages (left 
arrow) prevents the degradation of IκBα, which blocks NF-κB from translocating 
to the nucleus, thus blocking the transcription of proinflammatory cytokines. In 
neutrophils (right arrow), the depletion of SAG, here acting as a ROS 
scavenger, results in increased ROS production, decreased NRF2, and 
increased ROS-induced TNFα to trigger inflammation 
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MATERIALS AND METHODS 
 
Mouse studies 
The Sagfl/fl mice were generated as previously described222,223. The LysM-cre mice were 
purchased from the Jackson Laboratory (Stock number: 004781). All procedures were 
approved by the University of Michigan Committee on Use and Care of Animals. Animal 
care was provided in accordance with the principles and procedures outlined in the 
National Research Council Guide for the Care and Use of Laboratory Animals. 
 
Macrophage preparation 
For BMDMs preparation, bone marrow cells were flushed from the femurs and tibiae of 
mice and cultured in complete RPMI in the presence of 20% medium conditioned by 
L929 mouse fibroblasts, as described224. On day 7, BMDMs were split and used as 
indicated. To isolate thioglycollate-elicited macrophages, mice were i.p. injected with 1.5 
ml of 5% thioglycollate and peritoneal macrophages were flushed out 3 days post 
injection.  
 
Dendritic cell preparation 
Bone marrow cells were flushed from the femurs of 8- to 12-week- old female C57BL/6 
mice and cultured in 150 x 15-mm CytoOne petri dishes (USA Scientific, Ocala, FL) at 
1x107 in 20ml of RPMI supplemented with 10% FCS, 4mM L-glutamine, 10 U/ml 
penicillin, 100 µg/ml streptomycin, 0.5 mM 2-ME, 20ng/ml GM-CSF. On day 4, 20ml of 
fresh complete RPMI containing 20ng/ml GM-CSF was added to each culture. After 7 
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days of culture, the loosely adherent cells were harvested and purified using anti-CD11c 
magnetic microbeads (Miltenyi Biotec Ltd., Auburn, CA) and the autoMACS (Miltenyi 
Biotec).  
 
LPS administration  
Mice at 2 months old were subjected to i.p. injection of Escherichia coli LPS (0111:B4, 
Sigma, L4391) at 25 mg/kg body weight and were monitored for survival. For short-term 
studies, mice were sacrificed 18 hours post LPS i.p. injection, followed by blood 
collection with cardiac puncture. Peritoneal cavity was then washed with PBS and 
spleens were collected.  
 
Gene expression 
Total RNA was isolated from cells with Trizol reagent (Invitrogen). Complementary 
DNA was made from RNA with Superscript III (Inivitrogen) and subjected to reverse 
transcription PCR or quantitative real-time PCR (qRT-PCR) with a 7500 Real Time PCR 
system (Applied Biosystems).  The cycling program for qRT-PCR was set as follows: 50 
°C 2 min, 95 °C 10 min for the PCR initial activation and 45 cycles of denaturation at 95 
°C for 15 sec, annealing and extension at 60 °C for 1 min.  The sequences of Sag, TNFα, 
IL-1β, IL-6, IL-10, and GAPDH are as follows: SAG-Fwd: 5’- CGC TGA GCC ACC 
GTA CCT -3’, SAG-Rev: 5’- TTA CAC TCT CCC CAG ACC ACA A -3’; TNF-Fwd: 
5’- CCC CAA AGG GAT GAG AAG TT -3’, TNF-Rev: 5’- CTT GGT GGT TTG CTA 
CGA CG -3’; IL6-Fwd: 5’- TCA TAT CTT CAA CCA AGA GGT AAA A -3’, IL6-Rev: 
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5’- CGC ACT AGG TTT GCC GAG TA -3’; GAPDH-Fwd: 5’- GCC GCC TGG AGA 
AAC CTG CC -3’, GAPDH-Rev: 5’- GGT GGA AGA GTG GGA GTT GC - 
3’.  
 
Western blot analysis 
BMDM cells stimulated with LPS for different time periods were harvested, lysed and 
subjected to Western blotting, using various antibodies as follows: Sag monoclonal 
mouse antibody was raised against the RING domain (AA44-113) 225, Roc1 polyclonal 
rabbit antibody 226, pho-IκBα (Cell Signaling), IκBα (Santa Cruz), p65 (Santa Cruz), Parp 
(Cell Signaling), Procaspase-3 (Santa Cruz), and actin (Sigma), as a loading control. 
 
ATPlite assay 
BMDM cells were seeded into 96-well plates with 5,000 cells per well in triplicate and 
treated with various concentrations of LPS for 3 days followed by ATPlite assay using an 
ATPlite kit (Perkin Elmer) according to the manufacturer's instructions. 
 
Cytokine detection 
Isolated peritoneal and BMDC were seeded on 6-well plates at 3x106 cells/well. 
Unstimulated and LPS-stimulated cells were cultured for indicated period. Supernatants 
were subsequently collected and stored at -20°C until analysis. TNFα and IL-6 ELISA 
kits were purchased from R&D Systems and performed as per the manufacturers’ 
instructions and read at 450nm by a SpectraMax microplate reader (Molecular Devices, 
Sunnyvale, CA).  
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Flow cytometry 
To analyze macrophage surface phenotype, peritoneal macrophages were incubated in the 
presence or absence LPS (Sigma). Cells were then harvested and stained with CD11b-
conjugated FITC (Clone: M1/70) and F4.80-conjugated APC with the following per 
triplicate group: Annexin V (BD Biosciences), CD80 (Clone: 16-10A1), CD86 (Clone: 
GL-1), CD40 (Clone: 3/23), MHCII-I-Ab (Clone: AF6-120.1), PD-L1 (Clone: MIH5), 
PD-L2 (Clone: TY25). All flow cytometry Abs were purchased from eBiosciences except 
for NRF2 (Clone: D1Z9C) obtained from Cell Signaling (Beverly, MA). Stained cells 
were then analyzed with an Accuri C6 Flow Cytometer (BD Biosciences).  
 
Statistical analysis 
The two-tailed Student t- test was used for the comparison of parameters between groups. 
Survival analysis was performed by Kaplan-Meier analysis. Statistical significance was 
determined as p<0.05. 
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CHAPTER IV 
 
SAG/RBX2 DEPENDENT NEDDYLATION REGULATES T CELL RESPONSES 
 
 
ABSTRACT 
 
Neddylation is crucial for the degradation of certain proteins. However its role in 
regulating T cells is poorly understood. Neddylation activates the cullin RING ligase 
(CRL) complex, an E3 ligase, responsible for the ubiquitination of a specific subset of 
proteins. An adapter element of the CRL – sensitive to apoptosis gene (SAG) – is critical 
for the function of CRL-mediated ubiquitination and thus deletion of SAG regulates the 
neddylation pathway. We explored the role of SAG and thus neddylation in T cells by 
utilizing two different, but complementary approaches, namely, chemical inhibition with 
small molecule MLN4924 and a novel genetic knockout (KO). We generated T cell-
specific SAG deficient animals by crossing B6 LCK-Cre mice with B6 SAGfl/fl mice. The 
KO animals were viable and splenic and thymic analyses showed no significant 
differences in the numbers of conventional T cells (Tcons) and Tregs between KO and 
WT littermate controls. In vitro functional analysis of Tcons, however, revealed that 
stimulation of SAG-/- T cells with allogeneic irradiated splenocytes, exhibited 
significantly decreased proliferation of allo-T cells. Phenotypic analysis following 
stimulation demonstrated that SAG-/- T cells showed fewer activated cells  (CD69+, 
CD62L-CD44+) and greater expression of naïve (CD62L+CD44-) cells when compared to 
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WT-SAG competent T cells. The SAG deficient T cells also demonstrated reduced 
expression of T effector signature cytokines, IL-17, IFN-γ and IL-4. Similar reduction in 
proliferation, activation marker expression, and release of cytokines was observed when 
the WT-T cells were treated with small molecule inhibitor of neddylation, MLN4924. We 
next determined the in vivo relevance of SAG and neddylation in Tcons by utilizing the 
clinically relevant, major histocompatibility complex (MHC) disparate 
(C57BL/6→BALB/c) model of allogeneic BMT and received T cells from either the WT 
B6 or SAG-/- B6 animals. The allogeneic animals that received SAG-/- T cells 
demonstrated markedly reduced clinical GVHD and significantly increased survival 
when compared to those that received WT-B6 T cells. Similar results were observed in 
B6→B6D2F1 model. To further confirm our results and to determine potential 
translational application, we utilized the small molecule MLN4924, once again in the 
B6→BALB/c system. Mice receiving MLN4924 demonstrated significantly decreased 
clinical GVHD and improved survival. Our studies thus demonstrate that SAG is a novel 
molecular target for regulating T cell responses and mitigating GVHD. Furthermore, the 
clinical availability of the small molecule, MLN4924, suggests that this strategy could be 
tested in carefully designed human clinical trials for attenuating GVHD.   
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INTRODUCTION 
T cell function is critical for a competent immune response19. T cell activation is the 
result of the stimulation of T cell receptor (TCR) and necessary co-stimulatory receptors 
which trigger signaling cascades ultimately resulting in cytokine production, clonal 
proliferation, lineage differentiation, and adaptive immune memory227,228. There are two 
main subsets of T cells that express either CD4+ glycoprotein or CD8+ glycoprotein19. 
CD4+ T cells recognize cognate peptide presented by antigen presenting cells (APCs) 
expressing major histocompatibility complex (MHC) class II molecules and subsequently 
differentiate into several T effector subtypes including TH1, TH2 and TH17 cells that 
express IFNγ, IL-4, and IL-17, respectively20. These lineage ‘signature’ cytokines direct 
the function and response of accessory-immune cell functions, such as macrophages or B 
cells. By contrast, CD8+ T cells recognize viral peptides presented by cells expressing 
MHC class I molecules leading to the release of cytotoxic granules causing the target cell 
to undergo apoptosis229. Thus, CD8+ T cells are known as cytotoxic T lymphocytes 
(CTLs). 
 
T cells are central to the efficacy of allogeneic bone marrow transplantation (allo-BMT) – 
a critical and curative interventional therapy for patients with aggressive hematological 
malignancies230,231. However, 40-50% of allo-BMT recipients experience severe 
transplant related complications known as graft versus host disease (GVHD), leading to 
high transplant related mortality83. Recent advances have indicated that post translational 
protein modifications (PTMs) play an important role in GVHD pathophysiology57,232,233.  
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PTMs modulate cellular processes234. However, the role of T cell PTMs in the initiation 
of GVHD is unknown. Moreover, intracellular protein signaling pathways that are critical 
for T cell functions – and the regulation thereof – are poorly understood. The PTM 
ubiquitination, typically demarcates a protein for degradation thereby regulating the 
proteins location, function, and lifespan – although ubiquitin attachment can activate a 
protein under certain circumstances204. Neddylation, a type of PTM, modulates the 
ubiquitination of a specific subset of proteins68 through the activation of the cullin ring 
ligase (CRL) degradation scaffolding (an E3 ligase) through the attachment of the 
ubiquitin-like molecule, neural precursor cell expressed developmentally downregulated 
protein 8 (NEDD8) to the cullin protein backbone of the CRL complex67. NEDD8 
molecule must be activated by an ATP-dependent specific E1 enzyme known as NEDD8 
activating enzyme (NAE) prior to its transfer to the E2 molecule called NEDD-
conjugating enzyme (Ubc12), which in turn transfers NEDD8 to the cullin E3 ligase 
backbone. NEDD8 attachment to cullin serves as a critical activating step that results in 
the recruitment of the multi-subunit components composing the CRL complex67. There 
are seven known cullin proteins (CUL1, CUL2, CUL3, CUL4A, CUL4B, CUL5, and 
CUL7) that each facilitates the ubiquitination of proteins based upon their own CRL-
complex substrate specificity67. One component of the CRL-5 complex – an adaptor 
molecule known as sensitive to apoptosis gene (SAG) / RING box protein 2 (RBX2) / 
RING finger protein 7 (RNF7) – interfaces with E2-ubiquitin conjugates bringing them 
into close proximity with the target substrate protein and thus leading to mono- or poly-
ubiquitination69-71. Previous studies have shown that silencing SAG by siRNA inhibits 
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the CRL complex, thereby regulating the neddylation pathway50,71-73,211,226. However, 
such molecular knockdown methods are prone to off target effects235-237. 
Another method of regulating the neddylation pathway is through the use of a 
pharmacological small-molecule inhibitor that was recently developed, MLN4924. 
MLN4924 showed remarkable specificity and potency for inhibiting NAE, thus 
preventing the initial activation of NEDD8 molecule and thereby blocking the 
neddylation pathway75. Subsequent studies utilizing MLN4924 have exhibited its ability 
to potently suppress inflammatory responses50,201 and others have shown MLN4924 to be 
a promising agent in the inhibition of cancer cells lines – including human pancreatic 
cells79, breast cancer cells80, and liver cancer cells81. These promising preclinical results 
have led to the advancement of MLN4924 to phase 1 clinical trials for the treatment of 
both hematological and non-hematological cancers205,206. 
 
Neddylation has been shown to be critical for the function of select immune cell 
subsets50,238,239. Furthermore, previous studies have partially examined the role of 
neddylation in T cells, albeit only in the CD4+ T cell subset239. To that end, Jin et. al. 
utilized the primary methodology of shRNA knockdown of Ubc12 (E2) molecule 
(encompassing the possibility of a number of off-target effects) 235-237, which globally 
inhibited all seven CRL complexes. 
 
In this study, we report the generation of a targeted knockout mouse possessing a 
deficiency of T cell-specific SAG protein – thereby selectively inhibiting CRL-2 and -5, 
which is in stark contrast to previous studies utilizing global inhibition of all seven CRL 
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complexes. We found that T cell-specific SAG deficiency resulted in diminished allo-T 
cell proliferation and cytokine release in vitro and decreased GVHD clinical scores, 
improved survival, and decreased inflammatory cytokines in the sera following allo-
BMT, in vivo. These in vivo results corresponded with fewer activated donor T cells 
(CD44hi and CD69+) and increased naïve donor T cells (CD62L+CD44-) in allo-BMT 
recipients of KO T cells, 7 days and 14 day following allo-BMT. Furthermore, 
mechanistic studies suggested that the decreased T cell functions observed were not due 
to inhibition of NF-κB as in other immune cell subsets50,201, but rather through a disparate 
accumulation of the suppressor of cytokine signaling (SOCS) protein. Utilizing a 
different yet complementary approach, we treated recipients of allo-BMT with MLN4924 
that recapitulated the results seen in mice with a targeted deletion of SAG in T cells.  
Our data thus represent a novel in vivo method of targeting specific CRL complexes 
allowing for the discovery of CRL-subtype specific substrates. Furthermore, we report a 
novel molecular mechanism of neddylation in T cells, which was heretofore unknown. 
Additionally, the results of our studies utilizing the small molecule inhibitor of 
neddylation, MLN4924, and its clinical availability suggest that this strategy could be 
tested in carefully designed human clinical trials for attenuating GVHD.   
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RESULTS 
MLN4924 inhibits neddylation but is not cytotoxic to T cells: We have previously 
shown that inhibition of neddylation decreases the function of DCs50. Therefore, we 
hypothesized that deficiency of neddylation will regulate T cell proliferative responses. 
MLN4924 has previously been shown to inhibit neddylation in a variety of cell types, 
including immune cells50,75. Thus, we incubated CD90.2+ T cells in the presence of 
MLN4924 at 100nm and 500nm. We observed only a 25% decrease in neddylation – 
indicated by the presence of the higher molecular weight band of Cul-1 – at the 100nm 
concentration (Fig. 4.1A) over a time period of 6 hours. By contrast, when T cells were 
treated with MLN4924 at 500nm we observed the higher molecular weight band was 
absent within two hours of treatment (Fig. 4.1B) suggesting that MLN4924 indeed 
inhibited neddylation in T cells. 
 
 
 
Fig. 4.1 – MLN4924 inhibits neddylation in T cells. Incubation of MLN4924 
with CD90.2+ T cells at (A) 100nm and (B) 500nm. 100nm resulted in only 
partial inhibition of neddylation over a course of 6 hours. By contrast 500nm 
inhibited neddylation within 2 hours. 
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Although MLN4924 does not affect viability of DCs50, it has been shown to by cytotoxic 
to cancer cells79-81. Thus we next wanted to ensure that MLN4924 was not cytotoxic to T 
cells at doses that deneddylated cullin protein. Therefore, we cultured T cells in the 
presence or absence of the indicated concentrations of MLN4924 and examined the cells 
resulting Annexin V positivity. We saw no difference in the viability of T cells at either 
100nm or 500nm (Fig. 4.2). 
 
 
Inhibiting neddylation decreases T cell functions: We have previously shown that 
culture of DCs with MLN4924 decreases allo-T cell responses and further, that 
MLN4924 has a DC intrinsic effect by decreasing their stimulatory capacity50. However, 
whether inhibition of neddylation in T cells diminishes their proliferative capacity is 
unknown. To test this, we next utilized a mixed lymphocyte reaction (MLR) in which [3]H 
 
Fig. 4.2 – MLN4924 does not alter viability of T cells. Incubation of MLN4924 
with CD90.2+ T cells at 100nm and 500nm does not alter the viability of T cells 
over the course of 16 hours. 
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is taken up and incorporated into proliferating cells. We cultured irradiated C57BL/6 (H-
2b) BMDC with BALB/c (H-2d) CD90.2+ T cells in the following experimental culture 
groups: 1) vehicle treated, 2) MLN4924 was applied to the culture at the time of plating, 
3) T cells that had been pretreated with MLN4924 for 6 hours were co-cultured with DCs 
in the absence of drug, and 4) MLN4924 pretreated T cells were cultured with MLN4924 
present throughout the co-culture. We observed a significant decrease in all groups 
cultured with MLN4924, compared to vehicle treated controls after 72 hours (Fig. 4.3A) 
and 96 hours (Fig. 4.3B) of culture. Interestingly, cultures that contained pretreated T 
cells, but that did not have MLN4924 present during co-culture, still exhibited a 
significant decrease in T cell proliferation suggesting that inhibition of neddylation has a 
T cell-intrinsic effect (Fig. 4.3A). Further, culture of MLN 4924-pretreated T cells with 
drug present throughout co-culture, resulted in an even greater decrease in T cell 
proliferation suggesting that MLN4924 also has an impact on DCs, confirming our 
previous data50 (Fig. 4.3A). 
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In addition to proliferating in response to stimulation, T cells release lineage 
specific cytokines that have many paracrine effects on other immune cell subsets20. Thus, 
we next examined IL-2 (an activation cytokine) and IFNγ, IL-4, and IL-17, which are 
Th1, Th2 and Th17 lineage cytokines, respectively. We saw that all groups treated with 
MLN4924 exhibited decreased cytokine production (Fig. 4.4A-D). When we next utilized 
another method of TCR/co-receptor stimulation, ɑ-CD3 and ɑ-CD28, we observed a 
similar decrease T cell proliferation (Fig. 4.4E). 
 
Fig. 4.3 – Neddylation has intrinsic role in T cell function. Mixed lymphocyte 
reaction of irradiated DC and CD90.2+ T cells for (A) 72 hours and (B) 96 hours 
at 40:1 and 100:1 ratios. * P < 0.05; ** P < 0.01; *** P < 0.001 
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Next, we utilized CFSE and Annexin V staining to measure the proliferation and 
viability dynamics of T cells treated in the presence or absence of vehicle or MLN4924 
and stimulated with ɑ-CD3 and ɑ-CD28 for 48 hours. We saw that proliferation of T cells 
treated with MLN4924 at the time of plating was significantly reduced compared to 
vehicle control without an increase in cell apoptosis (Fig. 4.5A, plot 4). Further, when T 
cells were stimulated and allowed to proliferate for 24 hours prior to the addition of 
MLN4924, we still observed a significant decrease in T cell proliferation (Fig. 4.5A, plot 
3). Indeed, comparison of the T cells that proliferated unimpeded for 24 hours with the T 
cells treated with vehicle alone show a dramatic decrease in proliferation upon inhibition 
of neddylation with MLN4924 (Fig. 4.5B). 
 
Fig. 4.4 – Inhibiting neddylation decreases T cell cytokines. Neddylation 
inhibition of T cells with MLN4924 decreases the realease of (A) IL-2, (B) IFN훾, 
(C) IL-4, and (D) IL-17 after allogeneic stimulation. 
* P < 0.05; ** P < 0.01; *** P < 0.001 
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Phenotype of stimulated T cells following inhibition of neddylation: We next wanted 
to determine if T cells with inhibited neddylation displayed an activated phenotype upon 
stimulation. Following treatment of T cells with MLN4924 and stimulation with ɑ-CD3 
and ɑ-CD28 for 48 hours and 72 hours, we observed decreased activation markers 
(CD44hi, CD69+) and increased naïve T cells (CD44-CD62L+) (Fig. 4.6). Likewise, 
cultures in which T cells were allowed to proliferate for 24 hours prior to the addition of 
MLN4924 contained fewer CD69+ and CD44hi T cells (Fig 4.6). These data suggested 
that inhibition of neddylation in T cells mitigates their proliferation and response 
following stimulation. 
 
Fig. 4.5 – Inhibiting neddylation decreases T cell proliferation without 
increasing apoptosis. (A) Incubating T cells with MLN4924 decreases 
proliferation but does not result in increased Annexin V. (B) Quantification of 
proliferation dynamics in (A). * P < 0.05; *** P < 0.001 
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Generation of novel T cell conditional SAG knockout mouse: The loss of SAG protein 
has previously been shown to regulate the neddylation pathway69-71 and we have shown 
 
Fig. 4.6 – Phenotype of neddylation inhibited T cells. CD90.2+ T cells 
treated with vehicle or MLN4924 and stimulated with ɑ-CD3 & ɑ-CD28 where 
analyzed using flow cytometry for phenotypical markers CD69, CD44, and 
CD62L. 
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knockdown of SAG decreases DC functions50. The results of the previous experiments 
with pharmacological inhibitor of neddylation could be due to off-target effects of 
MLN4924. Thus we next generated knockout mice with a T cell specific deficiency of 
SAG protein by crossing LCK-Cre mice with Sagfl/fl (Fig. 4.7). We then crossed the F1 
heterozygous generations to obtain LCK-Cre-/Sagfl/fl (WT) and LCK-Cre+/Sagfl/fl (KO) 
mice that had deletion of Sag only in T cells. 
 
 
Upon confirming that SAG was indeed deleted in T cells (Fig. 4.8), we examined 
whether the loss of SAG protein affected the development of T cells in the thymus. 
 
Fig. 4.7 – Breeding scheme of T cell conditional SAG knockout mouse. 
Breeding of LCK-Cre mice with SAGfl/fl mice led to novel mice with a deletion of 
Sag only in T cells. 
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We did not observe any difference in the total number of thymocytes nor in the total 
number of double positive T cells (CD4+CD8+) (Fig. 4.9A-B) suggesting thymopoiesis 
functions normally. 
 
 
Fig. 4.8 – SAG protein is knocked out in T cells of mice. Analysis of FACS-
purified T cells (~98% pure) show significantly decreased SAG protein. *** P < 
0.001 
 
Fig. 4.9 – Thymopoiesis is normal in KO mice. Phenotypical analysis of 
naïve mice exhibit no difference in the thymus. 
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Further, phenotypical analysis of the cellular contents of the secondary lymphoid organs 
– spleen and peripheral lymph nodes – revealed no difference in the total number of 
CD3+ T cells (Fig. 4.10A) nor was there a difference in the total number of naïve T cells 
(CD62L+CD44-) suggesting normal T cell development occurs in the conditional 
knockout mouse (Fig. 4.10B-C). 
 
 
Fig. 4.10 – Phenotype is not different in KO mouse. Phenotypical analysis of 
naïve mice exhibit no differences in the peripheral organs. 
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Next, we wanted to examine the allo-proliferative capacity of SAG-deficient T cells. We 
therefore cultured WT or KO T cells with irradiated BALB/c splenocytes for 96 hours. 
Consistent with pharmacological neddylation inhibition, we observed significantly fewer 
SAG-deficient T cells proliferating, when compared with WT-SAG competent controls 
(Fig. 4.11A). To again examine the viability dynamics of proliferating cells, we stained 
KO T cells with CFSE and subjected them to allogeneic stimulation by irradiated 
splenocytes. We observed a similar decrease in prolifeDation without an increase in 
annexin V (Fig. 4.11B) suggesting that although the cells were living, there was a defect 
in their ability to proliferate. 
 
 
 
Fig. 4.11 – Allogeneic stimulation of KO T cells results in less 
proliferation. CD90.2+ purified T cells from KO mice proliferate to a lesser 
degree than WT controls without increased apoptosis. Measured by (A) 3[H] 
uptake and (B) divisions of CFSE stained cells. 
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Mechanism of neddylation in T cells: Inhibition of neddylation – either by MLN4924 
treatment or molecular knockdown of SAG – is known to regulate the degradation of IκB 
thereby preventing the function of the transcription factor NF-κB50,213. T cell receptor 
(TCR) signaling is known to trigger the NF-κB pathway240 thus, we wanted to determine 
if inhibition of NF-κB translocation was responsible for the decrease in SAG-deficient T 
cell functions. To test this, we assessed p65 NF-κB translocation to the nucleus in WT 
and KO T cells following TCR stimulation. Contrary to the aforementioned results in 
DCs50 following inhibition of neddylation, we saw that NF-κB translocation to the 
nucleus was only mildly impacted by deletion of SAG (Fig. 4.12A) after ɑ-CD3 and ɑ-
CD28 stimulation. Likewise, T cells treated with MLN4924 exhibited only a partial 
inhibition of NF-κB translocation following similar stimulation (Fig. 4.12B). 
 
 
 
Fig. 4.12 – Inhibition of neddylation does not impact NF-κB translocation. 
CD90.2+ purified T cells from (A) KO mice (B) MLN treated WT mice were 
stimulated with ɑ-CD3/ɑ-CD28 and examined for NF-κB translocation from the 
[C] cytoplasm to the [N] nucleus. 
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Next, we visualized the dynamics of p65 translocation utilizing a complementary method 
– immunocytochemistry and confocal microscopy analysis. We treated T cells with 
vehicle or MLN4924 and stimulated these cells with ɑ-CD3 and ɑ-CD28. Both vehicle 
and MLN4924 treated cells exhibited similar NF-κB localization (Fig. 4.13). These data 
together suggest that inhibition of neddylation in T cells utilizes a disparate mechanism 
for regulating T cell function, compared to macrophages and DCs. 
 
Because neddylation is a pathway that regulates the degradation of proteins, and proteins 
are known to have positive and negative feedback upon their own, or other protein, 
transcription and translation241,242, we next examined the mRNA transcripts present in 
WT and KO T cells using microarray. Following analysis, we found lower levels of 
 
Fig. 4.13 – Confocal imaging of MLN4924 impact on NF-κB. CD90.2+ 
purified T cells from (A) KO mice (B) MLN treated WT mice were stimulated 
with ɑ-CD3/ɑ-CD28 and examined for NF-κB translocation using 
immunocytochemistry and confocal microscopy. 
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RNF7 / SAG in the KO T cells confirming that SAG was indeed deficient in these cells 
(Fig. 4.14). More importantly, we saw an increased expression of suppressor of cytokine 
signaling (SOCS) proteins in KO T cells (Fig. 4.14). 
 
SOCS proteins are involved in the regulation of intracellular signaling following TCR 
and cytokine-receptor ligation243. Furthermore, SOCS proteins are known to recruit the 
Cul5/SAG complex thereby regulating the ubiquitination of substrate proteins243. Thus, 
based upon the increased expression of SOCS mRNA transcripts in KO T cells, we next 
examined the protein expression of SOCS1 in T cells treated with MLN4924. We saw 
that inhibition of neddylation indeed increased the presence of SOCS1 protein following 
 
Fig. 4.14 – Microarray of mRNA transcripts in WT and KO T cells. mRNA 
was extracted from FACS-purified T cells from WT and KO mice. 
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stimulation (Fig. 4.15A). To determine if the degradation of SOCS proteins were 
regulated by CRL5-specific neddylation, we next stimulated WT and KO T cells with 
irradiated allogeneic whole splenocytes for 96 hours and measured SOCS1 and SOCS 3 
dynamics. We observed that although SOCS proteins were induced in a similar fashion in 
WT and KO T cells, degradation was significantly lower in KO T cells (Fig. 4.16B) 
 
 
Neddylation inhibition decreases GVHD and improves survival: To determine if 
SAG-deficient T cells proliferated to a lesser degree in vivo, we performed a clinically 
 
Fig. 4.15 – SOCS1 is increased when neddylation is blocked in T cells. (A) 
Whole cell lysates were quantified and examined by western blot. Relative 
density was determined based on the ɑ-tubulin loading control. (B) T cells 
(2x106/ml) were stimulated with irradiated allogeneic splenocytes (5x106/ml) for 
indicated times. Presence of SOCS1 and SOCS3 were analyzed by flow 
cytometry. 
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relevant major MHC mismatch allo-BMT in which C57BL/6 (H-2b) cells are transferred 
to BALB/c (H-2d) mice following lethal irradiation of the recipient with 800 cGy, or a 
syngeneic BALB/c to BALB/c transplant as a control. The recipients received 5 x 106 T 
cell depleted (TCD) bone marrow and 0.5 x 106 CD90.2+ T cells from either conditional 
KO SAG-deficient mice or WT SAG-competent mice on day +0. We then analyzed the 
donor-cell immunophenotype in the recipients 7- and 14 days after transplant. On day +7 
after transplant we saw that while there was no significant difference in donor CD4+ or 
CD8+ T cell numbers, there were significantly fewer donor activated T cells 
(CD4+CD44hi and CD8+CD44hi) and significantly greater donor naïve T cells 
(CD4+CD62L+CD44- and CD8+CD62L+CD44-) (Fig. 4.16A). A similar 
immunophenotype was seen on day +14 following transplant (Fig. 4.16B). 
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Fig. 4.16 – Immunophenotype following allogeneic BMT. Cellular analysis of 
the spleen (A) 7 days and (B) 14 days after allogeneic transplant (C57BL/6 [H-
2b] to BALB/c [H-2d]). Recipients received either WT (SAG-competent) or KO 
(SAG-deficient) donor T cells and TCD bone marrow. 
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T cells release cytokines in response to TCR stimulation, which in turn mediate 
GVHD244. Thus, we examined the production of cytokines by donor T cells on day +14. 
We saw that IFNγ, IL-4, and IL-17 were significantly decreased in recipients of donor 
KO T cells (Fig. 4.17). 
 
Next, we scored recipients of syngeneic and allogeneic BMT recipient mice for clinical 
signs of GVHD and observed their survival. The allogeneic recipients that received WT 
donor T cells exhibited signs of severe GVHD (Fig. 4.18A) and greater mortality (Fig. 
4.18B), compared with recipients of syngeneic transplant. By contrast, allo-BMT 
recipients that received donor KO T cells exhibited decreased signs of GVHD and 
significantly improved survival (Fig. 4.18A-B) when compared with recipients of WT 
donor T cells. 
 
Fig. 4.17 – Diminished release of cytokines by KO T cells after allogeneic 
BMT. Whole splenocytes were stimulated with PMA/ionomycin for 6 hours then 
analyzed by flow cytometry. 
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To test if there were any clinical and therapeutic implications of this data, we next wanted 
to determine if MLN4924 could decrease T cell proliferative responses following allo-
BMT. Therefore, we performed a similar major MHC mismatch allo-BMT as above but 
instead transferred WT C57BL/6 T cells (0.5 x 106 CD90.2+) and whole bone barrow (5 x 
106) to BALB/c mice following lethal irradiation of the recipients. We began injecting 
recipient mice with either vehicle or MLN4924 (20mg/kg, sub-q) starting day -1 and 
continued daily administration through day +3, relative to BMT on day 0. All recipients 
of syngeneic BMT survived, indicating MLN4924 did not have non-specific toxicity. 
More importantly, allo-BMT recipients treated with MLN4924 resulted in decreased 
GVHD clinical scores (Fig. 4.19A) and increased survival (Fig. 4.19B) compared with 
allo-BMT recipients of vehicle control.  
Together, these data suggest that inhibition of neddylation in T cells may have possible 
therapeutic relevance and could be used as a novel agent to mitigate GVHD in the clinic. 
 
Fig. 4.18 – Decreased GVHD and increased survival of recipients of KO 
donor T cells. Recipients of KO T cells exhibited less severe clinical signs of 
GVHD and decreased mortality, compared to allogeneic recipients of WT donor 
T cells. 
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Fig. 4.19 – Inhibition of neddylation with MLN4924 decreases GVHD and 
improves survival. Allo-BMT recipients were injected with MLN4924 (20 
mg/kg) for 5 days, starting day -1 relative to BMT on day 0. 
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DISCUSSION 
Previous studies have shown that global inhibition of all CRL complexes inhibit 
neddylation and regulate T cell functions239. Our data utilizing the pharmacological small 
molecule inhibitor of neddylation, MLN4924, confirm and extend these observations of 
neddylation in T cells. More specifically, our use of MLN4924 revealed an intrinsic 
effect of neddylation in T cells, decreased release of T cell-specific cytokines, and a 
defect in T cell proliferation. Furthermore, when T cells were stimulated unimpeded for 
24 hours prior to the addition of MLN4924, proliferation was dramatically halted 
following addition of neddylation inhibitor. These data suggest that T cell responses can 
be mediated through regulation of the neddylation pathway, even after TCR stimulation 
(Fig. 4.3 to 4.5). Additionally, following stimulation we observed fewer activated T cells 
(CD69+, CD44hi) and an increased number of naïve T cells (CD62L+CD44-) in cells 
treated with MLN4924. 
 
However, the impacts that specific CRL complexes have on T cell functions have, thus 
far, been unknown. In contrast to global CRL inhibition, our results provide a novel 
perspective on the role of a particular CRL complex – CRL5 – in T cell proliferative 
responses. Here, we generated a novel knockout mouse with a conditional SAG protein 
deletion in T cells, thus allowing the selective inhibition of specific E3 ligases involved 
in the neddylation pathway. Allogeneic stimulation of SAG-deficient T cells too resulted 
in a decrease in proliferation as well as a diminished release of T cell lineage and 
activation cytokines. 
 
	 121	
Previous studies have shown that the regulation that neddylation confers is through the 
prevention of IκB degradation, thus inhibiting NF-κB translocation to the nucleus50,213. 
However, examination of NF-κB dynamics in T cells, utilizing either MLN4924 or SAG-
deficient T cells, revealed that the NF-κB pathway was only minimally impacted. This 
suggested that a disparate pathway may be responsible for the diminished T cell functions 
observed. We thus profiled the total mRNA expression and found that transcripts for 
SOCS proteins were increased in KO T cells compared with WT SAG-competent 
controls. Therefore, we stimulated T cells and found an increase in SOCS1 protein in 
neddylation-inhibited WT cells treated with MLN4924 and increased SOCS1 and SOC3 
protein in KO T cells after 96 hours of stimulation (Fig. 4.15). These results suggest that 
the increased presence of SOCS protein may be responsible for decreased T cell 
functions following inhibition of neddylation, as SOCS is a known component of the 
CRL5 complex67,243. This disparate mechanism in regulating neddylation is intriguing 
and future studies will serve to further explore the role of SOCS in neddylation-mediated 
regulation of T cell responses. 
 
T cells play a central role in many immune mediated diseases including GVHD83,230. 
Upon transfer of SAG-deficient T cells into MHC mismatched recipients, we observed 
significantly less severe GVHD clinical scores and increased survival. These results 
confirmed our in vitro observations that SAG-deficient T cells have diminutive responses 
following allo-stimulation. Using the same MHC mismatched model, but instead 
transferring WT T cells, we treated recipient mice with MLN4924 and recapitulated the 
results of decreased GVHD and improved survival seen following transfer of KO T cells. 
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In conclusion, our novel finding that the in vivo regulation of a specific neddylation E3 
ligase – CRL5 – plays a specific role in regulating T cells brings new insights to the 
understanding of the neddylation pathway. The data demonstrate an additional heretofore 
unknown mechanism through which neddylation may confer its regulatory effects. Our 
findings may have important clinical implications and suggest that regulation of 
neddylation may mitigate T cell mediated diseases. More specifically, these results 
together suggest that MLN4924 (currently in phase I/II clinical trials) 205,206 may be a 
novel strategy for attenuating GVHD in carefully designed clinical trials. 
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MATERIALS AND METHODS 
Mice: Female C57BL/6 (H-2b; CD45.2+), BALB/c (H-2d) mice were purchased from 
National Cancer Institute and C3H.sw (H-2b) mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME). The age of mice used for experiments ranged between 7 
and 12 weeks. All animals were cared for under regulations reviewed and approved by 
the University Committee on Use and Care of Animals of the University of Michigan, 
based on University Laboratory Animal Medicine guidelines. 
 
Cell isolation and cultures: Briefly, bone marrow cells were flushed from the femurs of 
8- to 12-week-old female C57BL/6 mice and cultured in 150 x 15-mm CytoOne petri 
dishes (USA Scientific, Ocala, FL) at 1x107 in 20ml of RPMI supplemented with 10% 
FCS, 4mM L-glutamine, 10 U/ml penicillin, 100 µg/ml streptomycin, 0.5 mM 2-ME, 
20ng/ml GM-CSF. On day 4, 20ml of fresh complete RPMI containing 20ng/ml GM-
CSF was added to each culture. After 7 days of culture, the loosely adherent cells were 
harvested and purified using anti-CD11c magnetic microbeads (Miltenyi Biotec Ltd., 
Auburn, CA) and the autoMACS (Miltenyi Biotec). 
T cells were isolated from whole splenoctye homogenates, incubated with CD90.2+ 
microbeads and separated using the autoMACS, following the manufacturers 
instructions. 
 
Bone Marrow Transplantation (BMT): BMTs were performed as previously described 
39,245. Briefly, syngeneic (BALB/c  BALC/c or C57BL/6  C57BL/6) and allogeneic 
(C57BL/6  BALB/c or C3H.sw  C57BL/6) recipients received lethal irradiation. On 
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day -1, BALB/c recipients received a total of 800 cGy of irradiation (split dose separated 
by 3 hours) and B6 animals received a single dose of 1000 cGy. Donor splenic CD90.2+ 
T cells were magnetically separated using an autoMACs (Miltenyi Biotec; Bergisch 
Gladbach, Germany) and 0.5 x 106 – 1 x 106 T cells were transferred to BALB/c 
recipients and 2 x 106 T cells were transferred to C57BL/6 recipients. 5 x 106 donor 
whole bone marrow was transferred to all recipients. Survival was monitored daily and 
the recipient body weight and GVHD clinical scores were determined weekly, as 
described previously 39. Histopathologic analysis of the gastrointestinal (GI) tract was 
performed as described 39. Animals received vehicle (sterile water) or butyrate (10mg/kg) 
by flexible 20G-1.5” intragastric gavage needle daily for 1 week, then every other day 
thereafter. 
 
Cytokine Detection: Isolated CD90.2+ T cells were seeded on 60mm culture dishes at 
3x106 cells/well and a 24-well plate at 2x105 cells/well, respectively. Pretreated cells 
were cultured with DMSO (Sigma), MLN4924 (Active Biochem), dexamethasone (APP 
Pharmaceuticals), or bortezomib (Fisher Scientific) at the indicated dosages for 2 hours. 
Cells were then stimulated ɑ-CD3 and ɑ-CD28 at the indicated concentrations for 
indicated time period. Supernatants were subsequently collected and stored at -20ºC until 
analysis. TNFα and IL-6 ELISA kits were purchased from R&D Systems and performed 
as per the manufacturers’ instructions and read at 450nm by a SpectraMax microplate 
reader (Molecular Devices, Sunnyvale, CA). 
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Quantitative PCR: Using 1µg of each RNA template, cDNA was synthesized using 
SuperScript VILO (Invitrogen; Carlsbad, CA). qPCR primers for murine GAPDH 
(Forward: CCACAGTCCATGCCATCACTGC; Reverse: 
GCCCAAGATGCCCTTCAGTGGG), TNF   (Forward: 
CGACGTGGAGGCAGAAGAGGC; Reverse: CGTGGGCTACAGGCTTGTCACTC). 
 
Flow Cytometry: To analyze immunophenotype surface markers, lymphocytes 
contained in the IEC fraction or spleen were harvested, stained and gated on CD4-
conjugated PerCP/Cy5.5 (Clone: GK1.5) or CD8-conjugated APC (Clone: 53-6.7) and 
configurations of the following per mouse in duplicate: CD69-PE (Clone: H1.2F3), 
CD62L-PE (Clone: MEL-14), CD25-PE (Clone: 3C7), CD44-PerCP/Cy5.5 (Clone: IM7), 
CD44-APC (Clone: IM7), FoxP3-APC (Clone: FJK-16s). All flow cytometry Abs were 
purchased from eBiosciences. Stained cells were then analyzed with an Accuri C6 Flow 
Cytometer (BD Biosciences). 
 
Western Blot and Subcellular Fractionation: T cells were seeded in 60mm dishes with 
3x106 cells per dish. Pretreated cells were cultured with DMSO (Sigma), MLN4924 
(Active Biochem), or dexamethasone (APP Pharmaceuticals) at the indicated dosages for 
2 hours followed by concurrent stimulation with ɑ-CD3 and ɑ-CD-28. Following 
treatment and stimulation, whole cell lysates where obtained and protein concentrations 
determined with Pierce BCA Protein Assay (Thermo Scientific). Equal amounts of 
protein were separated by SDS-PAGE gel (120V, 1.5h) and subsequently transferred to 
nitrocellulose membrane (20V, 1h). The following antibodies were used to analyze the 
	 126	
membranes: Nedd8 (19E3), α-tubulin (11H10), NF-κB p65 (D14E12), Lamin A/C 
(4C11), pIκBα (5A5), IκBα (L35A5), pERK (D13.14.4E), ERK (137F5) were purchased 
from Cell Signaling (Danvers, MA). Cullin1 (EPR3103Y) and LDH (EP1566Y) were 
purchased from abcam (Cambridge, MA). Secondary antibodies conjugated to HRP 
(Jackson ImmunoResearch) were used to detect primary antibodies. Densitometric 
analysis performed by ImageJ software. Subcellular fractionation was performed on 
3x106 BMDC seeded in 60mm dishes. Cells were pretreated in the presence or absence of 
vehicle, MLN4924, or dexamethasone for 2 hours followed by concurrent LPS 
stimulation for 30 minutes. The cytoplasmic and nuclear fractions were isolated using the 
Nuclear Extract Kit (Active Motif) per the manufacturers instructions. The extracts where 
then analyzed via western blot.  
 
Mixed Lymphoctye Reaction (MLR): Splenic T cells (2x105/well) were magnetically 
separated from WT-B6 or WT-BALB/c mice by autoMACS using CD90.2 microbeads 
and subsequently cultured with irradiated (30 Gy) WT-B6 DC at 40:1 (5x103/well) and 
100:1 (2x103/well) for 72 hours and 96 hours. Human MLRs were performed by co-
culture of PBMCs (1x105/well) and moDCs at 1:1(1x105) and 10:1 (1x104) ratios for 96 
hours and 120 hours. Incorporation of 3H-thymidine (1µCi/well) by proliferating T cells 
or PBMCs during the final 6 hours of culture was measured by a TopCount 
(PerkinElmer). 
 
Confocal Microscopy: T cells were seeded onto Corning glass cover slips (1x105 
cells/slip) (Fisher Scientific) using cytospin technique. Pretreated cells were cultured with 
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DMSO (Sigma) or MLN4924 (Active Biochem) at the indicated dosages for 2 hours 
followed by concurrent stimulation with ɑ-CD3 and ɑ-CD28 for an additional 24 hours. 
Cover slips were then washed, fixed with 4% paraformaldehyde for 20 minutes, and 
subsequently permeabilized with 0.3% Triton X. Cells were stained with NF-κB p65 
(D14E12) primary (1:500) and Alexa Fluor 488 (Molecular Probes) secondary (1:1000), 
DAPI (Invitrogen), and Alexa Fluor 555 Phalloidin (1:500). Coverslips were then 
mounted using ProLong Gold Antifade Reagent (Molecular Probes) and Z-stack images 
were acquired at room temperature using a Nikon A-1 confocal microscope (Mellville, 
NY) using an oil immersion 60X objective with a numerical aperture = 1.4 and imported 
into NIS-Elements Software (Nikon). Excitation lasers 405nm, 488nm, and 561nm were 
used. Microscope laser exposure and settings were obtained using appropriate isotype 
controls and were retained for each experimental group. 
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CHAPTER V 
 
UNBIASED PROFILING UNCOVERS A CRUCIAL ROLE FOR TARGETED 
GUT MICROBIOME DERIVED METABOLITES IN MODULATING GI 
EPITHELIAL CELL DAMAGE AND MITIGATING GVHD 
 
 
ABSTRACT 
Changes in the community structure of the intestinal microbiota are being progressively 
associated with many diseases, including graft-versus host disease (GVHD). However, 
the impact of these alterations on microbial metabolites and by-products and their impact 
on disease processes, such as GVHD, are not known. Here we utilized unbiased and 
blinded analysis to identify novel alterations in targeted microbial metabolite levels 
including the short chain fatty acids (SCFA) after allogeneic bone marrow transplant 
(allo-BMT). Surprisingly, alterations were observed only in the intestinal tissue but not in 
the luminal contents. The reduced butyrate in CD326+ intestinal epithelial cells (IECs) 
after allo-BMT resulted in decreased histone acetylation, which was restored upon local 
administration of exogenous butyrate. This resulted in improved IEC junctional integrity, 
increased anti-apoptotic proteins, decreased GVHD, and improved survival. Furthermore, 
alteration of the indigenous microbiota with 17 rationally selected strains of high butyrate 
producing Clostridia also decreased GVHD and increased survival following allo-BMT 
in experiments performed at two different institutions. These data demonstrate a 
heretofore unrecognized role of microbial metabolites and suggest that local and specific 
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alteration of microbial metabolites has direct salutary effects on GVHD target tissues and 
can mitigate its severity. 
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INTRODUCTION 
Alterations in the intestinal microbiome are associated with several disease 
processes110,133,134,246,247. However, the effect that changes in the community structure of 
the microbiome have on the production of microbial-derived metabolites is poorly 
explored. Microbial metabolites influence disease severity, but whether these alterations 
in microbial metabolites can impact outcomes after allogeneic bone marrow transplant 
(allo-BMT) are not known. Allo-BMT is a critical interventional therapy for patients with 
aggressive hematological malignancies230,248. Although allo-BMT is a curative and 
widely used treatment, approximately 40-50% of patients experience severe 
gastrointestinal damage from graft-versus-host disease (GVHD), which leads to high 
transplant-related mortality88,230.  
 
Studies have revealed that the intestinal microbiota is significantly altered in patients with 
GVHD and the alterations correlate with GVHD severity and pathogenesis139. 
Nevertheless, the direct causality of the changes in the host microbiota on GVHD 
severity is unclear. More relevantly, whether changes in the microbiota result in 
alterations in levels of microbial metabolites and by-products that have biological impact 
on allogeneic-BMT remain unknown. 
We therefore profiled the levels of microbial metabolites with a specific focus on short 
chain fatty acids (SCFA), which are exclusively derived from the microbiota and are not 
made by the host. Some of these fatty acids (FAs), specifically the histone deacetylase 
inhibitor (HDACi) butyrate, is a preferred energy source for intestinal epithelial cells 
(IECs)60,61,249 and administration of exogenous HDACi regulates GVHD57,245,250. But the 
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impact that host indigenous microbial metabolites that function as HDACi have on 
GVHD remains unknown60,61,249. 
We performed unbiased profiling of the microbial metabolome not just in the bowel 
lumen, but also in the intestinal tissue, serum, spleen, and liver with a specific focus on 
targeted FAs after experimental allo-BMT. We found that only one SCFA, namely 
butyrate was significantly reduced only in the intestinal tissue of allo-BMT recipients 
resulting in decreased histone-H4 acetylation within IECs. Intragastric administration of 
butyrate restored histone-H4 acetylation, improved the junctional integrity of IECs, 
enhanced IEC resistance to apoptosis, decreased the severity of GVHD, and increased 
survival following allo-BMT. Furthermore, rationally altering host GI microbiota to high 
butyrate producers103 mitigated GVHD. 
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RESULTS 
Targeted microbial metabolite profiling: We hypothesized that alterations in the 
composition of the microbiota in the GI lumen would result in an altered microbial 
metabolome after GVHD133,251. We determined the concentration of microbial FA 
metabolites, both short-chain FAs (which are exclusively derived from the microbiome 
and not made by the host) and long-chain FAs up to 18 carbons in length (which are host 
endogenous metabolites), from several sites seven days (day +7) after BMT. Specifically, 
we analyzed the serum, spleen, liver, intestines, and luminal contents (stool) of the 
intestines with gas chromatography mass spectrometry (GC/MS) (Fig. 5.1).  
 
We utilized a well established and clinically relevant model of MHC-mismatched BMT 
with C57BL/6 (H-2b) cells transferred to lethally irradiated Balb/c (H-2d) mice and 
compared it to syngeneic transplant and naïve animals. The animal cages were exchanged 
on day 3 to take any alterations in the microbial environment into account, and analysis 
following GC/MS was performed in a blinded manner. Surprisingly, the concentrations 
 
Fig. 5.1 – GC/MS experimental analysis. Schematic of fatty acid analysis. 
Animal cages of naïve animals and those receiving syngeneic or allogeneic 
BMT were exchanged on day 3 relative to transplant. All groups were sacrificed 
on day 7 and day 21 (Fig. 5.5). Homogenized samples were normalized and 
analyzed via gas chromatography mass spectrometry. 
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of the FAs were not significantly different in the luminal contents of the intestines 
between any of the groups (Fig. 5.2A and Fig. Fig. 5.3A).  
 
They were also not significantly different in the serum or the tissues such as the spleen 
and liver of allogeneic animals (Fig. 5.4) compared with syngeneic animals and naïve 
controls. However, the greatest and the only statistically significant difference –was 
unexpectedly– observed in just one SCFA, butyrate, which was significantly decreased 
only in the intestinal tissue at day 7 (Fig. 5.2B and Fig. 5.3B).  
 
Fig. 5.2 – Fatty acid levels on day +7. (A) Fatty acid levels (short and long 
chain) on day 7 in the intestinal luminal contents (stool) and (B) in the intestinal 
tissue of animals in experimental groups. Only butyrate was different in the 
intestinal tissue of recipients of allogeneic transplant. Representative heatmaps 
are shown of n = 9-10 animals per group. * P < 0.05; ** P < 0.01 
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Fig. 5.3 – Heatmap of fatty acid profiles (short and long chain) of all 
animals combined. All animals were sacrificed 7 days following syngeneic 
(BALB/c  BALB/c) or allogeneic (C57BL/6  BALB/c) transplant in the (A) 
intestinal luminal contents (stool) and (B) in the intestinal tissue. n = 9 – 10 
animals per group. 
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We next determined if the lack of significant change in the FAs from all other sites, and 
the only significant change noted in the intestinal tissue (butyrate) was altered at later 
time points by performing similar analysis on day 21. We once again observed similar 
results on day 21 as on day 7 (Fig. 5.5). 
 
Fig. 5.4 – Butyrate levels in the periphery. Butyrate concentration was not 
different in the serum, spleen, and liver of naïve animals or recipients of 
syngeneic or allogeneic BMT. 
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Functional impact of altered levels of SCFA in the IECs: In light of the reduction of 
butyrate in allogeneic animals only in the intestinal tissue, we next analyzed the potential 
functional impact of reduced butyrate in IECs. Because butyrate is an HDACi60,252,253, we 
examined the level of histone acetylation in purified IECs (CD326+) after transplant. The 
level of acetylated histone-H4 was significantly decreased day 21 (Fig. 5.6A) and day 7 
 
Fig. 5.5 – Fatty acids analysis on day +21. Fatty acid levels (short and long 
chain) 21 days following transplant in the (left) intestinal luminal contents (stool) 
and in the (right) intestinal tissue. Quantifications of the short chain fatty acids 
acetate, propionate, and butyrate are shown below representative heatmaps; 
n= 5 animals per group. 
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(Fig. 5.6B) following allo-BMT demonstrating that reduced butyrate resulted in 
decreased histone acetylation.  
 
Histone acetylation is the result of a balance between the activity of histone acetyl 
transferases (HATs) and histone deacetylases (HDACs). Therefore to confirm if the 
decreased acetylation is secondary to decreased HDAC inhibition from reduction in 
butyrate and not due to potential alterations in HDAC and HAT enzyme levels254 
following transplant, we analyzed the expression of HDACs and HATs in IECs after 
BMT. We observed similar levels of several HDACs (HDAC 1,4,7,9, and 10) (Fig. 5.7A) 
 
Fig. 5.6 – Loss of butyrate decreases levels of acetylated histone H4 in 
IECs. Protein expression of acetyl-histone H4 (top blot) and densitometric 
analysis normalized to presence of ɑ-tubulin (lower blot) (A) 21 days and (B) 7 
days following syngeneic (BALB/c   BALB/c) or allogeneic 
(C57BL/6   BALB/c) BMT. Representative immunoblots; densitometric 
analysis of three similar experiments combined is shown right of blot. 
** P < 0.01 
	 138	
and HATs (p300 and TIP60) (Fig. 5.7C) in the IECs (CD326+) of both syngeneic and 
allogeneic BMT recipients. Furthermore both HDAC (Fig. 5.7B) and HAT (Fig. 5.7D) 
enzyme activity were not different in these animals suggesting that reduction in histone 
acetylation in the IECs after allo-BMT is from reduced levels of butyrate. 
 
 
 
Fig. 5.7 – Loss of butyrate decreases levels of acetylated histone H4 in 
IECs. (A)-(B) Analysis of histone deactylase (HDAC) enzymes and (C)-(D) 
histone acetyltransferase (HAT) enzymes in IECs (CD326+) 21 days following 
syngeneic and allogeneic BMT. (A) Gene expression of representatives of class 
I, II, and IV HDAC enzymes, (B) HDAC activity, (C) histone acetyltransferase 
(HAT) enzyme levels, and (D) HAT activity in syngeneic and allogeneic CD326+ 
IECs. 
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Reduced uptake of butyrate by the IECs: Because butyrate can only be generated by 
luminal microbiota and not by the host tissues, we next explored whether the diminished 
concentration of butyrate observed in the intestinal tissue was from impaired uptake of 
butyrate following allo-BMT. To this end, we examined the expression of the known 
butyrate monocarboxylate transporter (SLC5A8) and the receptor of butyrate (GPR43) in 
IECs following allo-BMT104,252. 
 
Decreased gene expression (Fig. 5.8A) and protein levels (Fig. 5.8B) of both SLC5A8 
and GPR43 (Fig. 5.9A to B) were observed in IECs from allogeneic animals following 
transplant on day +21 and also on day +7 (Fig. Fig. 5.9C) suggesting that reduction in 
butyrate levels in the IECs is due to reduced uptake of the microbiota-derived luminal 
butyrate.  
 
Fig. 5.8 – Loss of butyrate decreases levels of butyrate transporter, 
SLC5A8. (A) Gene expression and (B) protein levels of SLC5A8 
(monocarboxylate transporter of butyrate) in IECs (CD326+) of syngeneic and 
allogeneic transplant recipients 21 days following BMT. Representative 
immunoblots; densitometric analysis of three similar experiments combined is 
shown right of blot. 
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We next analyzed the potential reasons for the reduction in the expression of butyrate 
transporter on IECs after allo-BMT. To this end we cultured primary IECs (CD326+) with 
proinflammatory mediators (IFN! and/or TNFɑ) and analyzed the expression of the 
butyrate transporter SLC5A8. Exposure of IECs to inflammatory cytokines significantly 
decreased the expression of SLC5A8 (Fig. 5.10). These data indicate that the intense 
inflammatory milieu following allo-BMT causes reduced expression of butyrate 
transporters and receptors leading to reduction in butyrate levels and histone acetylation 
in IECs. 
 
Fig. 5.9 – Loss of butyrate decreases level of butyrate receptor and 
transporter. (A) Gene expression and (B) protein level of GPR43 in IECs 
(CD326+) of syngeneic or allogeneic BMT recipients 21 days following 
transplant. (C) Gene expression of SLC5A8 (left) and GPR43 (right) in IECs 
(CD326+) 7 days following syngeneic or allogeneic BMT. Representative 
immunoblots; densitometric analysis of three similar experiments combined, are 
shown below blots. * P < 0.05; ** P < 0.01 
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Rescuing the cellular effects of reduced butyrate: We next determined if the reduced 
levels of butyrate in IECs could be restored in vivo and further, whether this would have a 
functional impact on histone acetylation. In addition to utilizing transporters, butyrate can 
also diffuse across the mucosal barrier into IECs when present in high 
concentrations252,255. Therefore, we hypothesized that administration of high levels of 
butyrate locally would restore histone acetylation of IECs, in vivo. To test this, we again 
utilized the clinical model of MHC-mismatched BMT model in which C57BL/6 (H-2b) 
cells are transferred to Balb/c (H-2d) mice and administered vehicle or butyrate via daily 
intragastric gavage. We found that daily intragastric butyrate administration for 21 days 
significantly restored histone-H4 acetylation when compared with untreated allo-BMT 
recipients (Fig. 5.11A).  
 
Fig. 5.10 – Inflammatory cytokines decrease expression of butyrate 
transporter. Primary IECs (CD326+) cultured in the presence or absence of 
inflammatory cytokines IFN! (40ng/ml) or TNFɑ (500ng/ml) for 6 hours. 
Expression of SLC5A8 is significantly decreased in cells cultured in the 
presence of IFN! or TNFɑ, compared to vehicle control. ** P < 0.01 
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Furthermore, daily intragastric gavage of butyrate resulted in an increase in butyrate 
transporter SLC5A8 (Fig. 5.11B), suggesting that butyrate may have a positive feedback 
mechanism resulting in an increase of its own transporter. To determine whether butyrate 
directly was responsible for induction of its own transporter, we analyzed the level of 
histone acetylation at the promoter of SLC5A8 with chromatin immunoprecipitation 
assay (ChIP). We found an increased association of acetylated histone H4 in the promoter 
region of SLC5A8 in IECs (CD326+) treated with butyrate (Fig. 5.12). 
 
Fig. 5.11 – Local intragastric administration of butyrate increases 
acetylated-H4 and SLC5A8 in IECs. Immunoblot of CD326+ purified intestinal 
epithelial cells from syngeneic (BALB/c  BALB/c) or allogeneic (C57BL/6  
BALB/c) BMT recipients treated daily with intragastric vehicle or butyrate 
(10mg/kg) exhibit restored (A) acetylated histone-H4 and (B) SLC5A8 within 21 
days of BMT with densitometric analysis of three experiments combined, shown 
below blots. Representative immunoblots shown. * P < 0.05; ** P < 0.01 
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Increase in intestinal butyrate mitigated GVHD severity: Systemic administration of 
HDACi decreases inflammation, enhances Tregs, and reduces in vivo biological 
responses such as acute GVHD48,245,250. We therefore determined if increasing local 
levels of endogenous HDACi, butyrate, would impact in vivo biological responses such 
as GVHD. Again using the C57BL/6 into Balb/c model, we administered vehicle control 
or butyrate via daily intragastric gavage for one week, followed by administration every 
other day for the remainder of the experiment.  
Local intragastric administration of butyrate resulted in decreased weight loss (Fig. 
5.13A) and GVHD clinical scores (Fig. 5.13B) culminating in increased survival (Fig. 
5.13C) of allo-BMT recipients compared with vehicle control recipients. 
 
Fig. 5.12 – Butyrate increases association of acetyl-H4 with SLC5A8. 
Chromatin immunoprecipitation (ChIP) of butyrate treated IECs (CD326+) 
exhibit increased acetylated histone H4 in the promoter region of SLC5A8. 
** P < 0.01 
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We found similar improved survival using a second clinical model of BMT utilizing a 
MHC-matched, minor antigen mismatched model in which C3H.SW (H-2b) cells are 
transferred to C57BL/6 (H-2b) mice, thus demonstrating strain-independent results (Fig. 
5.14). Furthermore, histopathological analysis 21 days following BMT revealed that 
recipients of butyrate intragastric gavage exhibited decreased histological scores in the 
intestines (Fig. 5.13D). 
 
Fig. 5.13 – Intragastric gavage of butyrate decreases GVHD and improves 
survival. (A) Decreased weight loss on day 21 with (B) decreased, GVHD 
clinical score, (C) improved survival, and (D) decreased 21 day post- BMT 
intestinal histopathology of recipients of syngeneic or allogeneic BMT treated 
with intragastric butyrate or vehicle. * P < 0.05; ** P < 0.01; *** P < 0.001 
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Increase in intracellular butyrate protects GI epithelium: We next determined if the 
decreased GI GVHD resulted in reduced translocation of luminal contents and improved 
epithelial integrity. Because allogeneic targeting of IECs disrupts cellular tight 
junctions256-258, we utilized transmission electron microscopy (TEM) to examine the 
ability of butyrate to preserve cellular junctions following allo-BMT. Significantly, 
intense leakage of the electron dense stain ruthenium red257 was found in the cell-cell 
interstitial space of allo-BMT recipients treated with vehicle alone (Fig. 5.15A, middle 
panel). However, the integrity of the IEC junction was preserved at both day 7 (Fig. 
5.15A, right panel) and day 21 (Fig. 5.15B) in allo-BMT recipients that received local 
intragastric administration of butyrate. 
 
Fig. 5.14 – Intragastric gavage of butyrate improves survival of mMHC- 
mismatch BMT. Improved survival was observed using a second model of 
syngeneic (C57BL/6  C57BL/6) and allogeneic (C3H.sw  C57BL/6) BMT 
indicating strain independent effects. Each recipient received 2 x 106 T cells 
and 5 x 106 bone marrow cells following lethal irradiation (1000 cGy) on day -1.  
** P < 0.01 
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Utilizing a complementary methodology, we further assessed the intestinal permeability 
after allo-BMT by intragastric administration of FITC-dextran, a non-metabolized 
carbohydrate259. Butyrate-treated allo-BMT recipients exhibited significantly less 
detectable FITC-dextran in the serum at 21 days (Fig. 5.16) following transplant. 
 
Fig. 5.15 – Butyrate improves IEC junctions. Transmission electron 
microscopy (TEM) of intestines, isolated from recipients of syngeneic (BALB/c 
  BALB/c) or allogeneic (C57BL/6   BALB/c) transplant with or without 
intragastric gavage of butyrate for duration of experiment; all samples were 
isolated (A) 7 and (B) 21 days following BMT and stained with ruthenium red 
(0.1%). Intense ruthenium red leakage observed in recipients of allogeneic 
transplant treated with vehicle compared to butyrate treatment or syngeneic 
BMT; arrows indicate cell interface.  
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Reduction in GVHD is independent of donor Tregs: We next explored the potential 
mechanisms of butyrate-induced protection in GI GVHD and examined several 
possibilities. First, T regulatory cells (Tregs) mitigate GVHD and butyrate has been 
shown to increase intestinal Tregs103,260 in certain model systems. We therefore analyzed 
the cellular contents of the intestine 21 days after allo-BMT to determine whether 
butyrate had an impact on local Tregs. The total numbers of recovered cells from the 
intestine were not different between vehicle- and butyrate-treated allo-BMT recipients 
(Fig. 5.17A). By contrast, immunophenotypical analysis following allo-BMT revealed 
that intestinal infiltration of donor CD4+ and CD8+ T cells and activated T cells (CD69+ 
and CD44hi) was decreased in animals that received local intragastric butyrate 
administration (Fig. 5.17B).  
 
Fig. 5.16 – Less FITC-dextran traverses IEC barrier in butyrate treated allo-
BMT recipients. Decreased level of FITC-dextran translocation across the GI-
barrier into blood serum in butyrate treated allogeneic BMT recipients, 
compared to vehicle control 21 days post BMT. * P < 0.05 
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However, the ratio of donor Tregs to effector T cells was not different in the intestine of 
these animals (Fig. 5.18A). Microbiota derived butyrate has been shown to increase 
immune-regulatory macrophages in the GI tract which increased Tregs261. Therefore we 
next determined whether administration of butyrate altered donor macrophage recovery 
from the intestinal tract. However we observed no difference in the total number of donor 
macrophages in the intestine of allogenenic recipients that were treated with either 
vehicle or butyrate (Fig. 5.18B). 
 
Fig. 5.17 – Fewer activated T cells in butyrate treated allo-BMT recipients. 
Intestinal immunophenotypical analysis of recipients 21 days following 
allogeneic (C57BL/6  BALB/c) BMT treated with either butyrate or vehicle via 
intragastric gavage. (A) Total intestinal cell numbers harvested were not 
different between recipients of allogeneic BMT treated with butyrate or vehicle. 
(B) Total cell numbers of intestinal CD4+ & CD8+ T cells (left column) and 
activated T cells: CD69+ T cells (middle column) & CD44hi T cells (right column). 
* P < 0.05; ** P < 0.01 
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To further determine whether the salutary effects of local treatment with butyrate on GI 
GVHD were dependent on donor Tregs, we next performed a BMT, utilizing the same 
MHC-mismatched BMT model in which C57BL/6 (H-2b) cells are transferred to Balb/c 
(H-2d) mice. We transferred T cell-depleted (TCD) bone marrow and purified CD4+ 
CD25- T cells from donors and administered vehicle or butyrate to the recipients daily for 
1 week, then every other day thereafter as above. We still observed decreased GVHD 
clinical scores (Fig. 5.19A) and improved survival (Fig. 5.19B) in the animals that 
received butyrate despite the absence of donor Tregs.  
 
Fig. 5.18 – Intragastric gavage of butyrate does not alter Treg ratio or 
number of donor macrophages in the intestine. (A) Ratio of intestinal Tregs 
(CD4+CD25+FoxP3+) to effector cells (CD4+FoxP3-) and (B) total cell number of 
intestinal donor macrophages (CD11b+F4.80+) in recipients of allo-BMT treated 
with vehicle or butyrate. 
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To further examine whether the local administration of butyrate impacted donor T cells 
directly, we determined the HDAC and HAT enzymatic activity in donor T cells 
harvested from the recipient animals. Both the HDAC activity (Fig. 5.20A) or HAT 
activity (Fig. 5.20B) in the donor T cells harvested from the recipient spleen were similar 
between butyrate and vehicle treated allogeneic animals. These results suggest that the 
reduction in GI GVHD upon intragastric administration of butyrate is independent of its 
potential effects from donor Tregs. 
 
Fig. 5.19 – Improved GVHD score and increased survival were still 
observed in the absence of Tregs. Syngeneic (BALB/c  BALB/c) and 
allogeneic (C57BL/6  BALB/c) BMT and butyrate treatment in recipients that 
received CD4+CD25- (Treg depleted) donor T cells and T cell depleted (TCD) 
bone marrow resulting in (A) decreased GVHD score and (B) improved survival 
in animals treated with butyrate (10mg/kg). 
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Microbial metabolite, butyrate protects IECs from conditioning and allo-T cell 
mediated damage: We next sought to explore the potential mechanisms that contribute 
to butyrate-induced protection from severe GVHD. Because (a) butyrate is decreased in 
IECs, (b) administration of butyrate mitigated GI GVHD independent of Tregs, but (c) 
improved junction integrity, we therefore explored whether butyrate had direct effects on 
protecting IECs from allo-T cell mediated damage and conditioning. We hypothesized 
that the absence of butyrate would result in increased irradiation-induced apoptosis and 
allogeneic-mediated damage of IECs. To test this we treated IECs ex vivo with vehicle or 
butyrate for 24 hours and withheld or subjected the cells to irradiation (6 Gy), followed 
by 24 hours of additional incubation with butyrate. We observed that butyrate was not 
toxic to IECs (Fig. 5.21A, left) and more importantly conferred protection from 
irradiation-induced apoptosis (Fig. 5.21A, right).  
 
Fig. 5.20 – No difference in splenic T cell HDAC or HAT activity. (A) HDAC 
activity and (B) HAT activity was not altered in T cells of the spleen 21 days 
following syngeneic or allogeneic BMT. 
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Furthermore, to determine if butyrate protected IECs from allogeneic T cell-mediated 
damage, we next determined the ability of butyrate-treated IECs to withstand damage 
mediated by alloreactive T cells. We isolated and cultured primary IECs with butyrate or 
vehicle control, overnight. The pre-treated IECs were next co-cultured with primed 
allogeneic CD8+ T cells, in the absence of butyrate. Fewer butyrate pre-treated IECs 
succumbed to CD8+ T cell killing within 6 hours (Fig. 5.21B, left) and 16 hours (Fig. 
5.21B, right) following co-culture, compared with control. 
 
 
Because butyrate is a primary energy source for IECs60,61,249, we next determined whether 
butyrate enhances survival and growth of IECs in vitro. To this end, we cultured 
intestinal organoids in the presence or absence of butyrate. We observed that culture in 
the presence of butyrate significantly increased organoid size (Fig. 5.22A). Next we 
 
Fig. 5.21 – Butyrate protects from irradiation- and allo-induced apoptosis. 
(A) CD326+ purified intestinal epithelial cells (IECs) cultured in the presence or 
absence of butyrate and withheld (left panel) or subjected to (right panel) 
irradiation (6 Gy). Butyrate did not effect the viability of IECs but protected these 
cells from irradiation induced apoptosis. (B) Allogeneic CD8+ T cell killing 
assay. CD326+ IECs incubated with or without butyrate overnight followed by 
co-culture with allo-primed CD8+ T cells resulted in less allo-induced apoptosis 
in butyrate pretreated IECs. * P < 0.05; ** P < 0.01 
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confirmed the impact of butyrate on IEC junctional function in the organoid cultures by 
determining the expression levels of claudins (Fig. 5.22B). We further observed that 
culture of organoids with butyrate significantly increased the expression of several 
junctional proteins such as claudins (1, 5, 6, 10, 11, 13, 14, 17, and 18). 
 
 
Molecular mechanisms of IEC protection: To determine the potential molecular 
mechanism for enhanced protection from irradiation- and allogeneic T cell-mediated 
 
Fig. 5.22 – Butyrate increases organoid size and improves organoid 
junctions. (A) Butyrate treatment (0.5mM and 1mM) resulted in increased size 
(area, µm2) of cultured primary intestinal organoids, compared to control. (B) 
Butyrate treatment (1mM) resulted in increased expression of junctional 
claudins (1, 5, 6, 10, 11, 13, 14, 17, and 18) in cultured primary intestinal 
organoids, compared to control.  * P < 0.05; *** P < 0.001 
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apoptosis, we hypothesized that butyrate would increase anti-apoptotic genes by 
modulation of histone acetylation. We analyzed pro- and anti-apoptotic gene expression 
levels262 and found that BAK and BAX were significantly decreased (Fig. 5.23A), 
whereas transcripts of the anti-apoptotic protein BCL-B were significantly increased (Fig. 
5.23B) in butyrate treated IECs (CD326+). 
 
Next we determined whether butyrate had direct impact on the improved junctional 
integrity of IECs. We therefore examined expression levels of junctional proteins such as 
occludin and JAM (Fig. 5.24) in IECs (CD326+) following butyrate treatment, which 
significantly increased their expression.  
 
Fig. 5.23 – Butyrate treatment of IECs decreases pro-apoptotic proteins 
and increases anti-apoptotic proteins. (A) Decreased gene expression of the 
pro-apoptotic proteins BAK (left) and BAX (right) and (B) increased expression 
of the anti-apoptotic protein BCL-B ** P < 0.01; *** P < 0.001 
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We also determined if the restored levels of histone-H4 acetylation observed in butyrate-
treated allo-BMT recipients was responsible for increased BCL-B and JAM expression 
via ChIP. We found that acetylated histone-H4 was indeed associated with the promoter 
region of BCL-B (Fig. 5.25A) and JAM (Fig. 5.25B) in butyrate treated IECs (CD326+). 
 
 
Fig. 5.24 – Butyrate treatment of IECs increases mRNA expression of 
junctional proteins. Gene expression level junctional proteins occludin and 
JAM in primary CD326+ IECs is increased when cultured in the presence of 
butyrate 1mM.  * P < 0.05; *** P < 0.001 
 
Fig. 5.25 – Butyrate treatment of IECs increases acetyl-H4 association 
with BCL-B and JAM. Butyrate has direct effects on BCL-B and JAM as 
chromatin immunoprecipitation assay (ChIP) of butyrate treated IECs (CD326+) 
exhibit increased acetylated histone H4 in the promoter region of (A) BCL-B 
and (B) JAM. * P < 0.05; ** P < 0.01 
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These data thus collectively suggest butyrate has several salutary effects on IECs that 
may or may not be mutually exclusive, such as regulating the expression of genes 
involved in decreased IEC apoptosis and increased junctional proteins in IECs. To 
determine if these are involved in in vivo protection from GVHD, we determined the 
expression of pro- and anti-apoptotic proteins as well as junctional proteins in IECs 
(CD326+) isolated 21 days following allo-BMT. 
 
We once again observed similar results as seen in vitro with pro-apoptotic proteins BAK 
and BAX significantly decreased in allo-BMT recipients that received intragastric 
butyrate treatment (Fig. 5.26) and significantly increased transcripts of the anti-apoptotic 
protein BCL-B (Fig. 5.26). Further, gene expression of junctional proteins were, again, 
 
Fig. 5.26 – Intragastric gavage of butyrate increases anti-apoptotic gene 
expression, in vivo. Analysis of IECs (CD326+) isolated from recipients of 
syngeneic (BALB/c  BALB/c) and allogeneic (C57BL/6  BALB/c) BMT 
treated with butyrate or vehicle daily via intragastric gavage for 21 days. 
Butyrate treatment of allogeneic recipients decreased gene expression level of 
pro-apoptotic proteins BAK (left) and BAX (middle), increased the anti-apoptotic 
protein BCL-B (right) * P < 0.05; *** P < 0.001 
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similarly increased in butyrate treated animals (Fig. 5J). Overall, our results identify 
several ways in which butyrate can directly enhance epithelial cell function ranging from 
protection from irradiation and allo-T cell mediated apoptosis to proliferation and 
junctional protein expression, both in vitro and in vivo. 
 
 
Increasing butyrate levels by administration of rationally designed microbiota 
mitigates GVHD:  The endogenous HDACi butyrate is a by-product of microbial 
fermentation163 and our data suggested that increased local butyrate decreases GVHD. 
Therefore, we next tested the hypothesis that altering the composition of indigenous GI 
microbiota in hosts to those that can produce high levels of butyrate will mitigate GVHD. 
To test this hypothesis, we utilized 17 rationally selected strains of Clostridia that have 
been shown to increase butyrate both in vitro and in vivo103,263. We administered these 17 
 
Fig. 5.27 – Intragastric gavage of butyrate increases junctional protein 
gene expression, in vivo. Increased junctional protein gene expression in 
CD326+ purified IECs isolated 21 days following allo-BMT. * P < 0.05 
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strains via intragastric gavage every other day to naïve mice starting 14 days prior to allo-
BMT and continued administration of the 17-strain cocktail for 21 days post-BMT. Prior 
to BMT, we wanted to determine whether these strains could establish colonization 
despite the presence of an indigenous host microbiota. Therefore, we characterized the 
microbiota in feces collected from animals that received vehicle and 17-strain 
administration by 16S rRNA-encoding gene sequencing. In animals that received the 17 
Clostridial strains, 16S analysis264-266 revealed an important biologically significant shift 
in the microbiota indicating that these organisms could be detected as part of the gut 
microbiota with increased colonization of the 17 strains in naïve mice within 14 days 
(day -1 relative to BMT) of commencing administration (Fig. 5.28A and Fig. 5.28B). 
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Fig. 5.28 – Intragastric gavage of 17 strains of Clostridia take hold 
amongst indigenous microbiota. (A) 16S rRNA-encoding gene sequencing of 
stool for percent of 17 Clostridal strains in total GI community on day -1 and day 
+35, relative to allogeneic (C57BL/6  BALB/c) BMT on day 0.  Vehicle or 17-
strain cocktail were administered to recipients every other day via intragastric 
gavage beginning day -14 and continued through day +21, relative to BMT. (B) 
Detailed presence of bacterial strains found in animals colonized with 17-strain 
cocktail. nd – not detected.  * P < 0.05; *** P < 0.001 
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Furthermore, GC/MS analysis 21 days following allo-BMT revealed an increased trend 
of butyrate in the luminal contents (Fig. 5.29A) and a significantly increased level of 
butyrate in the intestinal tissues (Fig. 5.29B) of animals that received intragastric gavage 
of the 17 Clostridial strains. 
 
Importantly, the recipients of intragastric gavage of the 17 strains and allo-BMT 
exhibited significantly decreased GVHD (Fig. 5.30A) and increased survival (Fig. 
5.30B). Detectable levels of the 17 Clostridial strains were diminished within 2 weeks 
(day +35) of ceasing intragastric administration (Fig. 5.28).  
 
Fig. 5.29 – Intragastric gavage of 17 strains of Clostridia increase butyrate 
in the intestinal tissue. Recipients of allogeneic BMT gavaged with vehicle or 
colonized with 17-strain cocktail were sacrificed 21 days following BMT. 
Intestinal luminal contents (stool) and intestinal tissue were harvested and 
analyzed via GC/MS. (A) Allo-BMT recipients colonized with 17 Clostridial 
strains exhibited butyrate levels that trended higher in the intestinal lumen and 
(B) butyrate levels that were significantly higher in the intestinal tissue. 
** P < 0.01 
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Because microbiota variations are known to occur in different colonies of mice, we also 
determined whether mice housed at another institution (Memorial Sloan Kettering Cancer 
Center) and treated with the same 17 Clostridial strains would also mitigate GVHD. 
Additionally, because clinical BMT patients are often treated with antibiotics, as an 
alternative approach to colonizing the indigenous microbiota, we treated C57BL/6 (H-2b) 
mice with an antibiotic cocktail (ampicillin 5mg, metronidazole 4mg, clindamycin 5mg, 
vancomycin 5mg) daily by intragastric gavage for 6 days to target obligate anaerobes. 
The mice were then colonized 4 and 6 days later with either human E. faecalis or the 
same cocktail of 17 strains of human Clostridia103 by intragastric gavage. Once again, we 
characterized the fecal microbiota by 16S gene sequence analysis on day -1, relative to 
BMT. Upon analysis, we observed increased presence of the Clostridial strains in 
recipients that received the cocktail of Clostridia (Fig. 5.31A), compared to recipients of 
 
Fig. 5.30 – Intragastric gavage of 17 strains of Clostridia decreases GVHD 
and improves survival. (A) Decreased GVHD clinical score and (B) increased 
survival following syngeneic (BALB/c  BALB/c) and allogeneic BMT 
(C57BL/6  BALB/c) with vehicle or 17-strain administration. 
* P < 0.05; ** P < 0.01; ** P < 0.01 
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E. faecalis. The animals were next used as recipients of a MHC-mismatched B10.BR (H-
2k) BMT and followed for survival. Once again, we observed significantly increased 
survival in the animals treated with the cocktail of 17 Clostridial strains (Fig. 5.31B). 
 
 
These results suggest that altering the indigenous microbiota with rationally selected 
strains of Clostridia, known to produce high levels of butyrate103,263, can decrease the 
severity of GVHD and improve survival across multiple institutions with strain 
independent results. 
 
Fig. 5.31 – Intragastric gavage of 17 strains of Clostridia decreases GVHD 
and improves survival - MSKCC. (A) Decreased GVHD clinical score and (B) 
increased survival following syngeneic (BALB/c  BALB/c) and allogeneic BMT 
(C57BL/6  BALB/c) with vehicle or 17-strain administration. 
* P < 0.05; ** P < 0.01; ** P < 0.01 
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DISCUSSION 
Previous studies have shown that the community structure of the microbiota is altered 
following allo-BMT133,134. The impacts that these alterations in microbial diversity have 
on the GI metabolome have thus far been unknown. Our results provide a novel 
perspective on microbial metabolites and their impact on GVHD. Here, we use an 
unbiased, blinded method to analyze targeted by-products of microbial fermentation. Our 
FA profiling revealed that the greatest and only significantly decreased SCFA, butyrate, 
is diminished in the intestinal tissue after allogeneic transplant (Fig. 5.2B). Reduction of 
butyrate in allo-BMT IECs decreased histone-H4 acetylation while increasing butyrate 
via intragastric gavage restored acetylated histone-H4 levels, protected epithelial 
integrity, decreased the severity of GVHD, and increased survival following allogeneic 
BMT. An important and surprising observation was the lack of changes in luminal (stool) 
butyrate, despite a documented shift in the microbiome species that produce less butyrate 
after allo-BMT133. While it remains to be formally tested, we posit that this may be 
because of reduced uptake into IECs due to decreased butyrate transporter, thus leaving 
overall butyrate levels not significantly reduced in the lumen because less is being taken 
into the IECs despite a decreased production by the shift in the microbiota after allo-
BMT.  
 
While at high concentrations, some amount of butyrate can passively diffuse across 
epithelial cell membranes252. At low concentrations, the effects of butyrate on IECs are 
dependent upon the sodium-coupled monocarboxylate transporter SLC5A8 and the G-
protein coupled signaling receptor (GPCR) GPR43252. By contrast the reasons for 
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decreased transporter proteins after allo-BMT are intriguing. Previous reports observed a 
decrease in SLC5A8 following alterations in the microbiota267. Thus, our findings that 
SLC5A8 and GPR43 are decreased in IECs (CD326+) following allo-BMT are consistent 
with this report and other studies revealing taxonomic changes in the microbiota occur 
after allo-BMT133,134. Furthermore we demonstrate for the first time to our knowledge 
that exposure of IECs to inflammatory cytokines leads to reduction in the expression of 
butyrate transporters. Moreover our data suggest that butyrate appears to have a positive 
feedback effect on its own transporter expression. These data suggest that the 
inflammatory milieu early after allo-BMT reduces the levels of butyrate transporter 
SLC5A8 leading to its reduction in the IECs and further reducing transporter expression 
and butyrate intake in a feedback mechanism. These insights will need to be formally 
tested further in future studies. Nonetheless, our data suggest increased local butyrate, 
either by exogenous source or by increased microbiota-derived butyrate, could increase 
IEC butyrate by passive diffusion and enhance expression of SLC5A8, break the 
feedback loop, and mitigate GI damage and decrease GVHD252. 
 
Previous studies have shown that 17 rationally selected strains of Clostridia, which 
produce high levels of butyrate, increase Tregs in the intestines103. Although we did not 
observe an increase in Treg cells in the intestine following butyrate treatment of allo-
BMT recipients, we cannot formally rule out the contribution of butyrate-mediated 
effects on Tregs (directly or indirectly via macrophages) for decreased GVHD when they 
are present in the donor inoculum. Nonetheless our data do suggest that butyrate 
administration could mitigate GVHD despite stringent depletion of mature donor Tregs. 
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Our data do however suggest that butyrate has direct salutary effects on the intestinal 
epithelial target tissue in GVHD. Thus, the effect of butyrate on GVHD target cells, 
namely GI epithelium, likely contributes to protection from GVHD. Our data does not 
directly address the impact of butyrate on various other cells that make up GI epithelium 
besides IECs. Clearly, butyrate and HDACi also have a multitude of effects on immune 
cells and our data cannot directly measure their impact on GVHD protection. However, a 
growing body of evidence indicates that GVHD pathophysiology can be regulated by 
manipulation of the host response to injury, and not just by suppressing the donor 
immune system259,268,269. Our results extend these observations and suggest that direct 
modulation of target tissues could be an additional important strategy to decrease GVHD 
without resorting to further global immunosuppression. 
 
In conclusion, our novel finding that alterations in microbial diversity after allo-BMT 
change the microbial metabolic profile, specifically that of butyrate, is a paradigm shift in 
our understanding of the mechanisms through which the microbiota confer their effects 
on host homeostasis. The data demonstrate a complex nexus between microbiota, 
metabolism and epigenetic regulation of target tissues in determining the severity of 
GVHD. Our findings may have important clinical implications and suggest that 
increasing local levels of butyrate in the GI tract may mitigate GVHD severity without 
causing global immunosuppression. Thus, increasing the endogenous local levels of the 
HDACi butyrate by enhancing the microbiota with 17 high butyrate-producing rationally 
selected Clostridia strains103,263, reduces the severity of GVHD in clinical models and 
thus may be a novel therapeutic strategy for management of clinical GVHD. 
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MATERIALS AND METHODS 
 
Reagents: RPMI, penicillin and streptomycin, and sodium pyruvate were purchased from 
Gibco (Grand Island, NY); FCS from GemCell (Sacramento, CA); 2-ME from Sigma (St. 
Louis, MO); murine GM-CSF from Peprotech (Rocky Hill, NJ). All antibodies (Abs) 
used for FACS were purchased from eBioscience (San Diego, CA). DMSO and butyrate 
were obtained from Sigma (St. Louis, MO), and lipopolysaccharide (LPS) from 
InvivoGen (San Diego, CA). 
 
Mice: Female C57BL/6 (H-2b; CD45.2+), BALB/c (H-2d) mice were purchased from 
National Cancer Institute and C3H.sw (H-2b) mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME). The age of mice used for experiments ranged between 7 
and 12 weeks. All animals were cared for under regulations reviewed and approved by 
the University Committee on Use and Care of Animals of the University of Michigan, 
based on University Laboratory Animal Medicine guidelines. 
 
Cell isolation and cultures: Primary intestinal epithelial cells (IECs) were obtained from 
C57BL/6 mice as described previously 270. Briefly, luminal contents of intestine were 
flushed with CMF solution. Intestine was then minced into 0.5cm pieces, washed with 
CMF four times, transferred to CMF/FBS/EDTA, and incubated at 37 °C for 60 minutes 
(shaking tubes every 10 minutes). Supernatant containing IECs was then transferred 
through 100 µM cell filter followed by incubation on ice for 10 minutes to allow 
sedimentation. Supernatant was again transferred through a 75 µM cell filter. CD326+ 
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IECs were next purified utilizing either FACS or anti-APC magnetic microbeads 
(Miltenyi Biotec Ltd., Auburn, CA) and an autoMACs (Miltenyi Biotec).  
For viability assay, CD326+ IECs were seeded on gelatin coated 100mm culture dishes 
and treated in the presence of absence of indicated butyrate concentrations overnight. 
Cells were then subjected to or withheld from irradiation (6 Gy) and cultured for another 
24 hours. 
 
Bone Marrow Transplantation (BMT): BMTs were performed as previously described 
39,245. Briefly, syngeneic (BALB/c → BALC/c or C57BL/6 → C57BL/6) and allogeneic 
(C57BL/6 → BALB/c or C3H.sw → C57BL/6) recipients received lethal irradiation. On 
day -1, BALB/c recipients received a total of 800 cGy of irradiation (split dose separated 
by 3 hours) and B6 animals received a single dose of 1000 cGy. Donor splenic CD90.2+ 
T cells were magnetically separated using an autoMACs (Miltenyi Biotec; Bergisch 
Gladbach, Germany) and 0.5 x 106 – 1 x 106 T cells were transferred to BALB/c 
recipients and 2 x 106 T cells were transferred to C57BL/6 recipients. 5 x 106 donor 
whole bone marrow was transferred to all recipients. Survival was monitored daily and 
the recipient body weight and GVHD clinical scores were determined weekly, as 
described previously 39. Histopathologic analysis of the gastrointestinal (GI) tract was 
performed as described 39. Animals received vehicle (sterile water) or butyrate (10mg/kg) 
by flexible 20G-1.5” intragastric gavage needle daily for 1 week, then every other day 
thereafter. 
For BMTs performed at MSKCC, C57BL/6 mice were treated with an antibiotic cocktail 
to target obligate anaerobes (ampicillin 5 mg, metronidazole 4 mg, clindamycin 5 mg, 
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and vancomycin 5 mg) gavaged daily for 6 days (BMT days -18 to -13) followed 4 and 6 
days later by oral gavage with indicated bacteria (BMT days -9 and -7) or PBS. 
Clostridial bacteria were cultured individually on plates and resuspended in anaerobic 
PBS at a final OD (600nm) of 0.02 to 0.06. One week later, mice were irradiated (12 Gy 
single dose) and transplanted with B10.BR BM (5 x 106) and T cells (0.5 x 106 CD5 
MACS), and followed for development of clinical GVHD.  
 
Gas chromatography mass spectrometry (GC/MS): To determine targeted fatty acid 
quantitation, samples (plasma, spleen, liver, intestine, and intestinal fecal content) from 
mice 7d and 21d post-transplant were harvested, homogenized, and snap-frozen in liquid 
N2. Equal volumes of plasma and homogenized tissue were utilized, while fecal content 
was weighed at necropsy. Samples were dispersed in acidified water spiked with stable 
isotope-labeled SCFA standards and extracted with diethyl ether. The ether layer was 
immediately analyzed by gas chromatography/mass spectroscopy using a Phenomenex 
ZB-WAX column on an Agilent 6890 GC with a 5973MS detector. Quantitation was 
performed by calibration to internal standards. The tissue levels were normalized by 
protein concentration of the homogenized tissue. Heatmap data was generated using 
GenePattern software from the Broad Institute (Cambridge, MA). Metabolomic data, 
mass spectral analytical parameters and spectral raw data from the study and meta data 
will be deposited in the National Institutes of Health Metabolomics Data Repository 
Coordinating Center (DRCC) at the University of California San Diego 
(http://www.metabolomicsworkbench.org/data/index.php). 
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16S deep sequencing: On indicated days, fecal pellets were collected from mice and 
stored at -80°C. DNA was extracted and purified with phenol-chloroform following 
bead-based lysis. Sequencing and analysis was performed as described 271. Briefly, the 
V4 region of the 16S rRNA gene was sequenced using Ilumina MiSeq technology. 
Sequencers were trimmed and analyzed using Mothur 264. The 16S rRNA gene sequence 
from each strain in the 17 strain cocktail was added to the version 9 trainset sequences 
from the Ribosomal Database Project 272. The resulting sequences were classified by 
comparing to described trainset with the requirement that the confidence score is 100%.  
MSKK 16S experiment were analyzed using the Illumina MiSeq platform to sequence the 
V4-V5 region of the 16S rRNA gene. Sequence data were compiled and processed using 
mothur version 1.34 264, screened and filtered for quality 265, then classified to the species 
level 273 using the Greengenes reference database 266. 
 
17 strain mixture: The 17 strain mix was prepared as described 103. Briefly all strains 
were grown in 5 ml of EG media for 24 hours at 37°C under anaerobic conditions. Each 
strain was grown to confluence, with the exception of St 3,8,13,26, and 29. Cells were 
scraped from EG agar plates and added to the 5 ml culture to obtain the same 
approximate optical density as the other strains. All cultures were then mixed and 
glycerol was added to a final concentration of 20%. Aliqouts (1 ml) were individually 
frozen and stored at -80°C. 
 
Transmission Electron Microscopy (TEM): Samples were stained as previously 
described 257. Briefly, the intestines from mice that received butyrate or vehicle treatment 
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were harvested 7 days and 21 days following syngeneic and allogeneic BMT and flushed 
with 0.1 M Sorensen’s phosphate buffer (pH 7.4) to remove luminal contents using a 20G 
needle. The intestines were next gently flushed with 0.1% ruthenium red (RR) containing 
2.5% glutaraldehyde fixative in Sorensen’s buffer and immediately placed in a dish 
containing the stain/fixative. Cross sections were immediately sliced (2mm wide) from 
the duodenum, jejunum, and illium. The tissue was then rinsed three times with 
Sorensen’s buffer, containing 0.1 percent RR and post-fixed for one hour in one percent 
osmium tetroxide in the same buffer containing RR.  The samples were again rinsed with 
Sorensen’s buffer containing RR. Next, the tissue was dehydrated in ascending 
concentrations of ethanol, treated with propylene oxide, and embedded in Epon epoxy 
resin. Semi-thin sections were stained with toluidine blue for tissue identification. 
Selected regions of interest were ultra-thin sectioned (70 nm thick) mounted on copper 
grids, and post stained with uranyl acetate and lead citrate. The samples were examined 
using a Philips CM100 electron microscope at 60 kV.  Images were recorded digitally 
using a Hamamatsu ORCA-HR digital camera system operated using AMT software 
(Advanced Microscopy Techniques Corp., Danvers, MA). 
 
FITC-dextran assay: Food and water was withheld from all mice for four hours on day 
21 post bone marrow transplant. FITC-dextran (Sigma-Aldrich; St. Louis, MO) was 
administered by 20G-1.5” flexible intragastric gavage needle (Braintree Scientific; 
Braintree, MA) at a concentration of 50mg/ml in PBS. BMT recipients received 
800mg/kg (~16mg/mouse). Four hours later, serum was collected from peripheral blood, 
diluted 1:1 with PBS, and analyzed on a plate reader at excitation/emission wavelength of 
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485nm/535nm. Concentrations of FITC-dextran experimental samples were determined 
based on a standard curve. 
 
Western Blot: CD326+ purified IECs were harvested from animals that received 
syngeneic (BALB/c  BALB/c) or allogeneic (C57BL/6  BALB/c) BMT. Whole cell 
lysates were next obtained and protein concentrations determined with Pierce BCA 
Protein Assay (Thermo Scientific). Equal amounts of protein (20 µg) were separated by 
SDS-PAGE gel electrophoresis (120V, 1.5h) and subsequently transferred to 
polyvinylidene difluoride (PVDF) membrane using a Bio-Rad semi-dry transfer cell 
(Hercules, CA) (20V, 1h). The following antibodies were used to analyze the 
membranes: ɑ-tubulin (Cell Signaling, clone 11H10) and Acetyl histone H4 
(Lys5/8/12/16) (EMD Millipore, clone 3HH-4C10). Secondary antibodies conjugated to 
HRP (Jackson ImmunoResearch) were used to detect primary antibodies, where needed. 
Densitometric analysis was performed using ImageJ software (National Institutes of 
Health; Bethesda, MA). 
 
Quantitative PCR: mRNA was isolated from samples using RNeasy kit following 
manufacturers instructions (Qiagen; Venlo, Netherlands). Using 1µg of each mRNA 
template, cDNA was synthesized using SuperScript VILO (Invitrogen; Carlsbad, CA). 
qPCR primers were designed for murine targets: 
 
qPCR Probe Forward Reverse 
GAPDH CCACAGTCCATGCCATCACTGC GCCCAAGATGCCCTTCAGTGGG 
SLC5A8 GCTGGATTTGCATCCGTAAT TGGGACTGGTTGACACCATA 
GPR43 CACGGCCTACATCCTCATCT TTGGTAGGTACCAGCGGAAG 
p300 TGCCTCCCATTGTTGATCCT ACTCGTTGCAGGTGTAGACA 
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TIP60 TGGACGGAAGCGGAAATCTA CGGCCAAGCTCAATACACTC 
BAK CAGATGGATCGCACAGAGAG TCTGTGTACCACGAATTGGC 
BAX ACTAAAGTGCCCGAGCTGAT ATGGTCACTGTCTGCCATGT 
BCL-B 
(Bcl2l10) TCATAGTGACCCGAGACTGC TGTTGCAAAGAAGCCTGACA 
JAM ACTGCTCAATCTGACGTCCA ATAGGGAGCTGTGATCTGGC 
Occludin CTCTCAGCCAGCGTACTCTT CTCCATAGCCACCTCCGTAG 
E-Cadherin CCTGTCTTCAACCCAAGCAC CAACAACGAACTGCTGGTCA 
HDAC1 TGGGGCTGGCAAAGGCAAGT GACCACTGCACTAGGCTGGAACA 
HDAC4 AGCTCTGGCAACGTCAGCACT AAGTGGGGCGACTGAGCCTTCT 
HDAC7 GCTCAGCATGTGCATGTGGAACAC TGAGAGCCTGGTGTGTCTGGCT 
HDAC9 TGCACCTTTGCCTCAGAGCACG TGGCTGCCTGGTTGCTTCAGT 
HDAC10 TAGCAGCCAAACATGCCAAGCAGA ATGCTCATAGCGGTGCCAAGAGAAA 
 
All primers were verified for the production of a single specific PCR product using a 
melting curve program. 
 
Chromatin Immunoprecipitation: Primary CD326+ IECs were seeded on gelatin (Cell 
Biologics; Chicago, IL) coated cell culture dishes (100mm) overnight followed by 
treatment with butyrate 1mM for 24 hours. Cells were harvested and used for ChIP 
analysis using EZ-Magna ChIP kit from EMD Millipore (Billerica, MA) following the 
manufacturers instructions. Briefly, cells were cross-linked with 1% formaldehyde and 
extracted chromatin was sonicated using a Bioruptor Pico by Diagenode (Denville, NJ) to 
yield DNA fragments predominately in the range of 200 – 1000bp. Sonicated lysates 
were immunoprecipitated (IP) utilizing either ChIP grade specific antibodies purchased 
from EMD Millipore for acetylated histone-H4 and RNA Pol II or IgG control antibody. 
De-crosslinked DNA was next examined by qPCR using primers designed in the 
promoter region of the target gene BCL-B (Forward: CCTACTCTGCCTGGCTCTTT; 
Reverse: ACCCTTCTGAGTCCCTGAGA), SLC5A8 (Forward: 
CACAGCACAGCCTTCTTTGT; Reverse: TCCAGTTCACAGTCCAGGTC), and JAM 
(Forward: TGCCGGGATTAAAAGCATGG; Reverse: 
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ACAGGGACAGCAGGATTAGG). IP efficiency of all samples was verified by qPCR 
analysis of the promoter region of GAPDH (Forward: CTGCAGTACTGTGGGGAGGT; 
Reverse: CAAAGGCGGAGTTACCAGAG). Data analysis was determined as percent of 
input utilizing the equations: ∆Ct[normalized ChIP] = (Ct[ChIP] - (Ct[Input] - Log2 (6.644))) and % 
Input = 2(-∆Ct [normalized ChIP]). 
 
Flow Cytometry: To analyze immunophenotype surface markers, lymphocytes 
contained in the IEC fraction or spleen were harvested, stained and gated on CD4-
conjugated PerCP/Cy5.5 (Clone: GK1.5) or CD8-conjugated APC (Clone: 53-6.7) and 
configurations of the following per mouse in duplicate: CD69-PE (Clone: H1.2F3), 
CD62L-PE (Clone: MEL-14), CD25-PE (Clone: 3C7), CD44-PerCP/Cy5.5 (Clone: IM7), 
CD44-APC (Clone: IM7), FoxP3-APC (Clone: FJK-16s). All flow cytometry Abs were 
purchased from eBiosciences. Stained cells were then analyzed with an Accuri C6 Flow 
Cytometer (BD Biosciences). 
IECs were stained with CD326-conjugated APC (Clone: G8.8) and DAPI and sorted to 
98% purity using a FACSAria III (BD Biosciences) gating on live cells. 
 
CTL Assay: CD8+ T cells were isolated from Balb/c (H-2d) mice using anti-CD8 
microbeads and LS columns (Miltenyi Biotec) following the manufacturers instructions. 
CD8+ T cells were primed in the presence of irradiated (30 Gy) C57BL/6 (H-2b) 
splenocytes for 6 days prior to culture with primary IECs for 6h and 16h. Primary 
C57BL/6 IECs were harvested and incubated overnight in the presence or absence of 
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butyrate 1 mM in gelatin coated (Cell Biologics Inc.; Chicago, IL) 100 mm-culture dishes 
(Fisher Scientific). 
 
Statistics: Bars and error bars represent the means and standard errors of the mean, 
respectively. Non-survival analysis was performed using students unpaired t test between 
two groups. ANOVA was used for comparisons with more than two groups. Survival 
data analysis was performed using a Mantel-Cox log-rank test. 
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CHAPTER VI 
 
CONCLUSION 
 
 
Collectively, the data presented in this thesis demonstrate a novel role for the PTM 
neddylation in the function of the immune system. Specifically, inhibition of neddylation 
in both murine and human DCs decreases the release of the inflammatory cytokines 
TNFɑ and IL-6. Mechanistic studies in DCs of mice showed that blockade of the 
neddylation pathway prevented the loss of IκB, a protein that binds to and sequesters the 
transcription factor for TNFa and IL-6 in the cytoplasm, NF-κB, thus preventing its 
translocation to and function in the nucleus50,51. Not only did neddylation inhibition 
confer an anti-inflammatory effect on DCs, but it also decreased the DCs ability to 
stimulate allogeneic T cells both in vitro and in in vivo clinical models of allo-BMT. The 
diminished DC functions resulted in decreased GVHD pathogenesis and improved 
mortality. Future studies will address the mechanism of how inhibiting neddylation 
decreases the allo-stimulatory capacity of DCs. Although GVHD is a complex syndrome 
in which there are many mediators of disease, it is possible that the diminutive NF-κB 
pathway seen in neddylation-inhibited DCs, plays a role274,275. Our data suggest that 
MHCII expression was not impacted on DCs treated with MLN4924, but these results 
remain to be formally tested. Furthermore, the decreased inflammatory cytokine 
environment may also serve to decrease autocrine signaling in DCs and paracrine 
signaling in accessory cells that are known to modulate GVHD91,244.
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The generation of a novel conditional knockout mouse that is SAG-deficient only in 
LysM expressing cells uncovered a disparate role of neddylation in myeloid cells, 
specifically macrophages and neutrophils. Injection of these KO mice with LPS resulted 
in increased mortality and inflammatory cytokines in the sera. However, cellular analysis 
revealed that KO macrophages released less inflammatory cytokines (TNFɑ and IL-6) in 
response to LPS stimulation in vitro and in vivo. By contrast, examination of SAG 
deficient neutrophils interestingly revealed a significant increase in the expression of 
TNFɑ. Concomitantly, ROS expression was increased in KO neutrophils corresponding 
with decreased NRF2, a transcription factor with anti-oxidative functions. Future in-depth 
studies will examine why NRF2 is diminished in KO neutrophils. SAG protein has 
multiple roles in quotidian cell activity 1) it serves as an adaptor protein for CRL2/5 
complexes and 2) it is a redox-inducible antioxidant protein which scavenges ROS by 
forming intra- and inter-molecular disulfide bonds67,69,70. Thus we hypothesize that 
disruption of SAG protein results in increased ROS activity due to diminutive ROS-
scavenger functions. 
 
Through the generation of a novel conditional T cell knockout mouse that too, lacked 
SAG protein, led to the discovery that inhibition of neddylation in T cells decreases their 
proliferative capacity in vitro and in vivo. Indeed, KO T cells stimulated by allogeneic 
APCs exhibit less proliferation without an increase in apoptosis. Surprisingly, when 
neddylation is inhibited in T cells, NF-κB translocation is only mildly impacted – 
suggesting that a disparate mechanism from that of DCs and macrophages is responsible 
for the effects of neddylation blockade. To that end, mechanistic studies found that 
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inhibition of neddylation resulted in the increase of SOCS1 protein, a known suppressor 
of T cell functions. Furthermore, utilization of the small molecule inhibitor, MLN4924, 
too resulted in decreased allo-responses (fewer activated T cells following allo-BMT and 
decreased GVHD translating to improved survival) suggesting that carefully designed 
clinical trials may find MLN4924 to be a possible therapeutic agent for the treatment of 
GVHD pathogenesis in patients. Future studies will serve to address the mechanism of 
why more SOCS1 protein is present following stimulation of neddylation-inhibited T 
cells. SOCS proteins are known to recruit CRL2 and CRL5 – that use SAG as an adaptor 
molecule – to degrade signaling proteins within cells243. Furthermore, SOCS proteins are 
known to be putative targets of neddylation68. It is thus our hypothesis that due to the 
inhibition of neddylation, SOCS proteins are not degraded and thus accumulate, enabling 
increased suppression of T cell signaling. 
 
Furthermore, the data in this thesis present a heretofore unknown role for the SCFA 
microbial metabolite, butyrate. Butyrate is an endogenous HDAC inhibitor that is made 
exclusively by the microbiota60,61. Unbiased and blinded profiling of several target sites 
of GVHD revealed that butyrate was diminished only in the intestinal tissue following 
allogeneic BMT, but not after syngeneic BMT. Surprisingly, butyrate was not decreased 
in the lumen (stool) of the intestine suggesting that there was a defect in butyrate uptake. 
Indeed, examination of CD326-purified IECs revealed that the transporter of butyrate, 
SLC5A8, was decreased both at the transcriptional and protein level. Loss of butyrate 
within IECs resulted in a decrease in acetylated histone-H4 and increased junctional 
permeability of IECs. Intragastric gavage of butyrate resulted in restoration of these 
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functions, protected mice from GVHD, and improved their survival after allo-BMT. 
Butyrate has been shown to increase intestinal Tregs103, but our data show that the 
improved results were still observed even in the absence of donor Tregs – suggesting that 
butyrate treatment had a salutary effect on the IECs. Indeed, treatment of purified IECs 
with butyrate conferred protection from irradiation- and allo-induced apoptosis. Future 
studies will further dissect why the expression of SLC5A8 (the transporter of butyrate) is 
decreased following allo-BMT. Our data show that when IECs are cultured with TNFɑ or 
IFN!, SLC5A8 expression is decreased. However, further studies are needed to formally 
test this. Furthermore, whether the signaling receptor of butyrate, GPR43 – that too is 
decreased after allo-BMT – plays a role in conferring protection from GVHD will be 
formally tested utilizing GPR43-/- mice. Ongoing experiments in the lab are examining 
the severity of GVHD in GPR43 chimeric recipients. We hypothesize that GPR43-/- into 
WT mice (thus having no GPR43 on hematopoietic cells, but GPR43 on IECs) will 
exhibit protection from GVHD. By contrast, WT into GPR43-/- animals (thus no GPR43 
on IECs) will exhibit decreased protection from GVHD. 
 
Together, the data presented in this thesis highlight the – heretofore unknown – important 
roles of neddylation and acetylation in the immune system. 
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CHAPTER VII 
 
FUTURE DIRECTIONS 
 
 
The data presented in this thesis further our understanding of the roles of PTMs in the 
immune system and answer important questions regarding the regulation of immune cell 
function, activation, and proliferation. However, these novel studies reveal new gaps in 
our knowledge of the roles of PTMs in immunity. Thus, this chapter will discuss future 
studies to highlight specific approaches that build upon the novel data. 
Chapter II revealed an important role for neddylation in murine and human DC function 
through the utilization of a specific small molecule inhibitor of neddylation, MLN4924. 
Future studies will further validate the findings revealed by pharmacological inhibitor 
with a genetic model of neddylation inhibition by crossing SAG-floxed mice with 
CD11c-Cre mice. In addition to validating the small molecule results, these novel mice 
with a DC-specific deletion of SAG protein will allow us to further understand the role of 
SAG in DC ontogeny. Furthermore, we will characterize the biochemical and molecular 
mechanisms through which neddylation regulates IκB degradation in further detail. 
Chapter III described a novel disparate mechanism of macrophage and neutrophil 
regulation. Indeed, deletion of SAG in Lys-M specific myeloid cells revealed a positive 
regulation of NF-κB in macrophages but a negative regulation of NF-κB in neutrophils. 
Further analysis of SAG-deficient neutrophils revealed that the loss of SAG resulted in 
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increased ROS release upon stimulation with these cells exhibiting a concomitant 
decrease in a transcription factor for antioxidant mediators, NRF2. Future studies will 
explore the role of the compensatory mechanism observed in the genetic knockout system 
by utilizing other complimentary approaches such as small molecule inhibition of 
neddylation (MLN4924) and molecular knockdown of SAG protein. The reasons that 
macrophage and neutrophils are regulated differently by neddylation are intriguing, yet 
unknown. Thus future studies will determine the practical mechanisms for the differential 
effects in macrophages and neutrophils. 
Chapter IV highlighted an important role for neddylation in the function and proliferation 
of T cells. We utilized two complementary methods of regulating neddylation – 
utilization of MLN4924 and the generation of a novel mouse that is genetically deficient 
in SAG, only in T cells. In depth examination, revealed that inhibition of neddylation 
either pharmacologically or by genetic knockout of SAG confers a deficiency in the 
function, activation, and proliferation of T cells by preventing the degradation of SOCS1 
and SOCS3 proteins. Thus, in future studies we will further characterize the molecular 
mechanisms with gain and loss of function experiments of SOCS in WT and KO cells, by 
either knocking down or overexpressing SOCS proteins. Furthermore, the results 
presented in this chapter suggest that MLN4924 – which is currently in phase I/II clinical 
trials) may represent a novel strategy to mitigate clinical GVHD. 
Chapter V presented novel data examining the role of acetylation in GVHD target tissue 
pathology (non-immune cells). To that end, we found that the endogenous HDACi 
butyrate is decreased in the intestinal tissue following allo-BMT, but not syngeneic BMT, 
compared with naïve controls. The diminutive levels of butyrate in the allo-intestinal 
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tissues lead to a decrease in acetylation of histone-H4, increased junctional permeability, 
and increased allo-mediated damage – the effects of which were restored upon local 
intragastric gavage of exogenous butyrate resulting in mitigated GVHD severity and 
improved mortality. Although we show that levels of the transporter of butyrate 
(SLC5A8) are decreased following allo-BMT, butyrate also enters IECs through passive 
diffusion. Thus, future studies will evaluate the key molecular pathway for butyrate 
uptake. In addition, we will probe the molecular pathways of IEC resistance to allo-
damage, such as tissue bioenergetics.  
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